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History of cardiovascular disease 
Atherosclerosis is a pathophysiological process in the arteries leading to accumulation of 
inflammatory cells, lipid and calcium in arterial walls. Atherosclerosis ultimately results in 
stenosis of arteries and cardiovascular disease (CVD). Leonardo Da Vinci (1452–1519) already 
described in his finding on the autopsy on a centenarian that ‘vessels in the elderly restrict the 
transit of blood through thickening of the tunics’ (1). In 1799 Caleb Hillier Parry, a British 
physician (1755–1822), was the first to describe atherosclerosis in the autopsy of a patients 
suffering from chest pains. Upon examination of the heart he concluded that the coronaries 
had become bony canals. These observations were the basis for his subsequent book ‘Inquiry 
into the symptoms and causes of ‘syncope anginosa’, commonly called angina pectoris’.  
 
Traditional assessment of cardiovascular risk 
At present, CVD, and specifically ischemic heart disease and stroke, have become leading 
causes of death worldwide (2). The most common underlying pathophysiological process for 
CVD is atherosclerosis, which may ultimately result in vascular occlusion with myocardial 
infarction or stroke as a result. The detection of an increased risk for CVD in a specific 
individual up till now is mainly based on the presence of major cardiovascular risk factors: 
male sex, dyslipoproteinemia, hypertension, smoking and diabetes mellitus, which were 
found previously in a large population-based study, the Framingham study (3). In subjects with 
obesity a number of these risk factors, namely hypertension, dyslipiproteinemia, 
hyperglycemia and abdominal obesity cluster and are called the ‘metabolic syndrome’. This is 
associated with a twofold higher risk for CVD (4). Further research was performed to identify 
additional factors that contribute to the pathophysiology of atherosclerosis. 
A few decades ago, atherosclerosis was generally considered a bland arterial wall collection 
of cholesterol with smooth muscle accumulation, although already in 1856 Virchow et al. had 
hypothesized that immune cells might be involved in the pathogenesis of atherosclerosis. It 
took however more than 125 years to test this hypothesis (5). A research group from the 
Göteborg University was the first to identify immune cells in atherosclerotic plaques (6). 
Although these findings were initially met with skepticism (7), inflammation has now been 
recognized as a key regulatory process in the pathogenesis of atherosclerosis.  
 
Whereas the detrimental roles of systemic chronic low-grade inflammation have been studied 
intensively during the past 30 years, the primary cause of proinflammatory changes in patients 
at increased risk of CVD has not been elucidated. Individuals with obesity that develop CVD 
are often characterized by a status of chronic low-grade inflammatory (8, 9). It has been 
hypothesized that differences in inflammatory status might explain the individual differences 
in cardiovascular risk among subjects with overweight and obesity. 
 
Low-grade inflammation in atherosclerosis 
The immune system is a host defense mechanism that involves a complex cellular and humoral 
network and helps the body fight against infections. It consists of an innate part, which 
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embody non-specific defense mechanisms that act within hours after the presence of certain 
antigens; and of an adaptive part, which is antigen-specific and performed by the B- and T-
cells. Cells from both the innate and specific immune system have been shown to contribute 
to the initiation, progression and destabilization of atherosclerotic plaques (10). Triggers such 
as hypertension and hyperglycemia can initiate the expression of adhesion molecules such as 
vascular adhesion molecule-1 (VCAM-1) by endothelial cells. This process is stimulated by 
oxidized lipids and pro-inflammatory cytokines. The intima layer will subsequently be 
infiltrated by various immune cells such as monocytes and lymphocytes. Monocytes have 
shown to play a pivotal role in atherosclerosis development. Monocytes mature into 
macrophages and engulf modified lipoproteins, becoming foam cells. This induces a pro-
inflammatory state in the atherosclerotic plaque which attracts other immune cells that  
further exacerbate the inflammation. As foam cells accumulate, a process of necrosis is 
initiated in the core of the plaque. Due to accumulation of lipid coalescences and death of 
macrophages and smooth muscle cells, a necrotic core is created, which provokes 
inflammation further. Fibrous tissue is added to form a fibrous cap between this necrotic core 
and the endothelium. As inflammation blocks the creation of new collagen fibers and 
stimulates the destruction of existing collagen, partly by stimulating the production of matrix 
metalloproteinases by macrophages, the fibrous cap becomes thin and ruptures. This event 
in the atherosclerotic plaque is the cause of the majority of acute coronary syndromes (11).  
 
Low-grade inflammation in obesity 
Since the discovery that tumor necrosis factor (TNF)-α is overexpressed in the adipose tissue 
of mice with obesity, numerous studies have focused on the role of adipose tissue in the 
development of inflammation (12). One of the current hypotheses linking obesity to increased 
inflammation suggests that fat mass expands due to a positive energy balance, which leads to 
local hypoxia at adipocyte level and cell death. Cell death results in the release of danger-
associated molecular patterns (DAMPs) that can induce an inflammatory reaction of both 
adipocytes and surrounding tissue macrophages. While initially considered to be of little 
relevance for metabolic dysregulation and cardiovascular risk in obesity, the modest increases 
in circulating inflammatory mediators have in recent years been found to be strongly 
associated with the development of NAFLD, type 2 diabetes mellitus and atherosclerosis (13, 
14).  
 
One of the most commonly used biomarker of low-grade inflammation is C-reactive protein 
(CRP). In 2010 in a meta-analyse of 160 000 asymptomatic individuals, CRP levels were 
associated with risk of coronary heart disease, ischaemic stroke and cardiovascular mortality 
(15). The increased CVD risk imposed by CRP was comparable to that of hypertension and 
dyslipoproteinemia. Another important observation came from a large study by Ridker et al 
(16). They randomized healthy individuals with an LDL-cholesterol of < 3.4 mmol/L but an 
increased hsCRP levels of > 2.0 mg/L to 20 mg rosuvastatin or placebo and followed for 
occurrence of CVD. In these ‘healthy’ individuals with increased hsCRP levels, rosuvastatin 
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significantly reduced the incidence of major cardiovascular events, proving again the 
importance of low-grade inflammation in CVD. Most mechanistic studies suggest that CRP 
itself is unlikely the underlying to be pathogenic, but its precursor IL-6 and probably even more 
important the members of the IL-1 family are the causative factors(17). The inflammasome 
has been shown to play a pivotal role in the production of IL-1 family cytokines. 
 
The inflammasome 
The inflammatory process that leads to the low-grade inflammation state in individuals with 
obesity is not initiated by an infection, but by metabolic factors and is therefore also called 
‘metaflammation’ (18). This metaflammation is present in the adipocytes, but also in other 
metabolically active organs like the liver, pancreas and the central nerve system(19). A key 
player in this process is the inflammasome, which consists of intracellular sensor molecules, 
of which the NOD-like receptor family pyrin domain containing-3 (NLRP3) is probably one of 
the most important ones. Activation of this inflammasome is mediated via recognition of 
sterile danger ligands (danger associated molecular pattern, DAMP) or pathogen-derived 
ligands (pathogen associated molecular pattern, PAMP) by pattern recognition receptors 
(PRRs). Activation depends on two signals. Glucose, oxidized LDL-cholesterol, and uric acid, all 
Figure 1 – Activation of the NLRP3 inflammasome by different danger associated 
molecular patterns (DAMPs) ©Inge van den Munckhof 
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increased in obesity, have been demonstrated to activate the NLPRP3 (20, 21). After activation 
of the inflammasome an intracellular cascade starts leading to activation of caspase-1. 
Caspase-1 cleaves multiple proteins, including pro-interleukin(IL)-1β and pro-IL-18, which 
then become biologically active (22). Individuals with an increase in BMI but who are 
metabolically healthy are characterized by less NLRP3 inflammasome activation compared to 
individuals with the metabolic syndrome (23).  
 
The role of IL-1, IL-6 and IL-18 
Multiple lines of evidence have shown a causal role for the IL-1 family in atherosclerosis. The 
strongest evidence was found in the CANTOS trial investigating the effect of canakinumab, a 
human monoclonal antibody that inhibits the pro-inflammatory cytokine IL-1β in subjects with 
a previous myocardial infarction. Treatment with canakinumab reduced the incidence of 
cardiovascular death, non-fatal myocardial infarction and non-fatal stroke during their 3.5 
year follow-up (24). Next to IL-1β, IL-18 is another important cytokine from the IL-1 family 
(25). Besides IL-1β and IL-18, several modulators have been found to influence IL-1 related 
pathways, including IL-18 binding protein (IL-18BP) (26), alpha-1-anti-trypsin (AAT), and 
adipokines.  
However not only this inflammatory pathway is important in the pathogenesis of 
atherosclerosis, as very recently, the anti-inflammatory drug colchicine has also shown to 
reduce the risk of cardiovascular events in individuals with chronic coronary disease (27). 
Colchicine has broad cellular effects that include inhibition of tubulin polymerization and 
alteration of leukocyte responsiveness. 
 
Adipokines 
Cytokines produced by the adipocyte, adipokines, represent another way by which the 
adipose tissue could contribute to the inflammatory process during metabolic dysregulation 
and obesity. Adipokines mediate the crosstalk between adipose tissue and the other 
metabolic organs. Leptin and adiponectin are the best known adipocytokines. Leptin regulates 
body weight by signaling nutritional status to other organs, especially the hypothalamus that 
then produces neuropeptides which modulate food intake and energy expenditure (28). The 
leptin level is closely related to the adipose tissue mass. Recombinant leptin however cannot 
be used as weight losing drug in the general population, as individuals with obesity are 
resistant to leptin due to hyperleptinemia. Leptin acts pro-inflammatory via macrophages, T 
cells, and other immune cells to stimulate the production of a wide spectrum of cytokines (28, 
29). Adiponectin has been shown to have various anti-inflammatory actions: it suppresses 
TNF-α production in obese mice; it can enhance the clearance of apoptotic cells by facilitating 
their opsonization and uptake by macrophages and has been shown to NFκB activity leading 
to reduced monocyte adhesion to endothelial cells(28). The adiponectin levels are negatively 
associated with adiposity and fasting glucose (30). Circulating levels of adiponectin and leptin 
are generally higher in women than in men. This is at least partly caused by a higher 
percentage of adipose tissue in women (31). 
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Systemic and adipose tissue inflammation measurement 
Low-grade inflammation is usually assessed by measurement of circulating cytokines and 
related peptides such as high sensitivity C-reactive protein (hsCRP). As mentioned above, the 
adipokines can also easily be measured in the blood. The immune cell count and 
differentiation reflect another way of measuring low-grade inflammation. In addition to 
systemic inflammation, there is accumulating evidence that also the phenotype of circulating 
immune cells impact on the development of atherosclerosis. Circulating monocytes have an 
enhanced cytokine production capacity in patients with risk factors for atherosclerosis, 
including familial hypercholesterolemia and elevated lipoprotein (a) (32, 33), and in patients 
with established coronary atherosclerosis (34, 35). The capacity to produce cytokines can be 
assessed through ex vivo stimulation experiments of immune cells, this represents another 
way to investigate and detect low-grade inflammation.  
 
Next to measurement of low-grade inflammation markers in the blood, direct analysis of the 
metabolically active tissues could provide new insights. Especially, the subcutaneous adipose 
tissue compartment can be relatively easily reached by biopsy. During obesity different 
processes are histologically visible in the adipose tissue. Firstly, the adipocyte cell size 
increases to store additional energy. Secondly, immune cells are 
attracted. The presence of these macrophages in the adipose 
tissue has been mainly related to obesity-associated 
complications such as diabetes mellitus (36). The presence of 
three or more macrophages around one adipocyte is called a 
crown-like structure. These structures were found to be 
increased 30-fold in obese diabetic mice compared to 
lean mice (37). The number of crown- like structure is 
associated with a more pro-inflammatory phenotype 
via activation of the inflammasome. As the phenotype by which inflammation in the adipose 
tissue presents is quite heterogenous (20,21), several parameters can be combined into an 
adipose tissue inflammation score. 
 
Role of obesity in cardiovascular disease 
The prevalence of obesity has dramatically increased over the last decades. In 2018 almost 
half of the Dutch population was overweight and 15.4% were obese (38). These numbers are 
even higher in other countries such as the USA with an obesity rate above 40%. The 
worldwide pandemic of obesity has led to an increased prevalence of cardiovascular risk 
factors (diabetes mellitus, hypertension and dyslipidemia). As mentioned, the cluster of 
these obesity related cardiovascular risk factors is called the ‘metabolic syndrome’. 
Interestingly however, not all individuals with obesity develop the metabolic syndrome and 
resulting CVD. Approximately 20-30% of these individuals are metabolically healthy and their 
risk for CVD is substantially lower than in individuals with metabolically unhealthy obesity 
Figure 2 – Crown-like structure 
indicated by arrow 
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As the volumes of the different fat compartments are not easily measurable, indirect 
measures are usually used to assess adiposity. Calculation of body mass index (BMI), which is 
the sum of the weight (kg) divided by the square of the length (m2), is the most commonly 
used method to diagnose overweight and obesity. A BMI between 25 and 30 kg/m2 is defined 
as overweight and a BMI > 30 kg/m2 is defined as obesity.  
There is a strong correlation between 
BMI and CVD, however this is not a 
linear relationship. This is mainly due to 
the fact that the body composition itself 
is not taken into account. Not only does 
the amount of muscles influence the 
cardiovascular risk, also does the 
distribution of fat within the body. 
Especially the fat around the abdominal 
organs, the visceral adipose tissue 
(VAT) is associated with diabetes 
mellitus and CVD (41). The results of 
studies investigating the atherogenic 
risk of subcutaneous adipose tissue 
(SAT) have been conflicting. Once regarded as a single entity, the abdominal SAT can actually 
further be divided by the scarpa fascia into the deep (dSAT) and superficial adipose tissues 
(sSAT). The adipocytes from dSAT have higher lipolytic activity than superficial SAT adipocytes 
and contribute substantially to free fatty acid (FFA) levels in the circulation (42). However, the 
separate role of the distinct subcutaneous adipose tissue compartments with regard to 
cardiovascular risk is not clear.  
Fat can also be stored in the liver. Hepatic steatosis is defined by a hepatic fat content above 
5.6% and is seen as the hepatic equivalent of the metabolic syndrome. Hepatic steatosis is the 
first stage of non-alcohol fatty liver disease (NAFLD) and is usually benign (43). However, in 
10-20% of these individuals, NAFLD progresses to non-alcohol steatohepatitis (NASH) which 
can result in cirrhosis. The cardiovascular risk in both NAFLD and NASH is substantially higher 
(44, 45). The relation between SAT and hepatic steatosis is not clear, because the separate 
layers of the SAT have not been taken into account in this relationship. 
 
If fat is mainly distributed abdominally, known as the ‘apple shape’ in men, this will increase 
the waist circumference, which is associated to a higher cardiovascular risk. On the other 
hand, fat that is mainly distributed around the hip region, the ‘pear shape’ in women has been 
related to a lower CVD risk (46). The anthropometric marker waist-hip-ratio has been 
Figure 3 – Different fat compartments that can be 
divided on an MRI image – VAT Visceral adipose 
tissue; dSAT deep subcutaneous adipose tissue; 
sSAT superficial subcutaneous adipose tissue 
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developed to take the effect on risk of both fat compartments into account. Mainly in men, 
the waist circumference and waist-hip-ratio have been shown to be superior to BMI in its 
relation to non-invasive markers of atherosclerosis. However, in women, the data on the 
relation of these anthropometric markers with metabolic and cardiovascular risk factors are 
conflicting. This suggest a sex-specific role of the adipose tissue compartments in metabolic 
dysregulation and atherosclerosis.  
 
Sex differences 
Although women develop CVD approximately eight years later than men (47, 48), the annual 
CVD mortality rate is about the same for women as for men (49, 50). In most historical 
cardiovascular research studies women were excluded. The knowledge about CVD in women 
has largely been extrapolated from studies investigating these relations in men. However, 
differences are already present in the anatomy of (atherosclerotic) arteries. Women generally 
have smaller arteries, with less plaque volume, but a higher stenosis grade (51). It is known 
that the microvasculature is more important in the pathophysiology of CVD in women than in 
men (52). Another important contribution to the prognosis of CVD in women is a delay in 
diagnosis and treatment, partly because of a different set of symptoms (53). Next to these 
factors, a difference in the fat distribution, as discussed above, could contribute to sex-specific 
differences in the atherosclerotic process. Besides, these differences in chronic low-grade 
inflammatory state and it’s metabolic and vascular consequences could also contribute to 
atherosclerosis. 
 
Sex-specific differences in inflammation have been described before. In general , both the 
innate and the adaptive immune responses to pathogens are higher in women than in men 
(54). Also circulating cytokine levels differ between women and men. In healthy individuals IL-
1Ra levels were higher in women compared to men, whereas IL-18BP levels were lower in 
women compared to men (55). Colleagues have shown that in stimulation experiments in 
healthy individuals the production of pro-inflammatory cytokines from monocytes was higher 
in men after stimulation with several agents (55). The exact aetiology behind these differences 
is not yet fully known.  
 
Role of gut microbiota in obesity and cardiovascular disease 
Several studies suggest that obesity-related metabolic dysregulation and systemic 
inflammation is at least partly driven by an altered gut microbial composition and function 
(56). The human gut microbiota consists of approximately 1013-1014 microbes, including 
bacteria, viruses, fungi and protozoa. The gene content of the gut microbiota (metagenome) 
in the human gut may exceed that of the host by at least 100-fold (57). Besides their function 
in intestinal epithelial homeostasis, development of the immune system, protection against 
pathogens and energy homeostasis (58-61), the gut microbiota also plays a role in 




Role of gut microbiota in cardiovascular disease 
Karlsson et al. was the first to demonstrate several associations between the gut microbiota 
and carotid atherosclerosis. In patients with symptomatic atherosclerosis the genus Collinsella 
was enriched, whereas Roseburia and Eubacterium were enriched in healthy controls. In 
coronary atherosclerosis patients, the phylum Bacteroidetes was significantly decreased, 
while the order Lactobacillus was significantly increased in these patients (63).  
 
Role of gut microbiota in obesity 
The relationship between obesity and the gut microbiome composition was first reported in 
2005. Genetically induced obese mice appeared to have less phylum Bacteroidetes and more 
Firmicutes compared to lean phenotypes (64). A further major observation came from 
Turnbaugh et al. who reported that the core gut microbiome of individuals affected by obesity 
has an increased capacity for energy harvesting (65). A low gut microbial diversity has 
previously been reported in individuals with obesity compared to lean individuals (66). 
However, not just the diversity of gut microbiota, but also the presence of specific species has 
been related to metabolic dysregulation and chronic low-grade inflammation markers 
 
Many potential underlying mechanisms have been proposed. Possible ways by which the gut 
microbiome could influence inflammatory mechanisms have been reviewed extensively (67), 
which is part of this thesis. Besides the impact on inflammatory pathways, it is also known that 
the gut microbiota is related to metabolites, which are small molecules essential in particular 
metabolic processes. Previous studies have shown that the gut microbiota explain a 
substantial amount of lipoprotein variance (68). Next to these indirect pathways, it has been 
suggested that trimethylamine N-oxide (TMAO), a gut microbial-derived metabolite, could 
directly influence the atherosclerotic process. In 2013 increased TMAO levels were found to 
be associated with an increased risk of incident major adverse cardiovascular events (69).  
 
So far, the effect of the above-mentioned factors influencing obesity-associated low-grade 
inflammation in atherosclerosis is not fully known, and clearly more detailed information 
regarding these effects is needed. In this thesis I propose that fat distribution, sex differences, 
the IL-1 family and the gut microbiome play an important role in the pro-inflammatory state 
in individuals affected by obesity.  
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Aim and outline of the thesis  
As described in the previous paragraphs, obesity is importantly linked to the development of 
metabolic disorders and CVD. However, some of the individuals with obesity are metabolically 
healthy and their risk for CVD is substantially lower. The central hypothesis in our studies is 
that differences in inflammatory status partly explain the individual differences in 
cardiovascular risk among subjects with overweight and obesity. The overall aim of this thesis 
is to gain more insight into factors influencing obesity-associated low-grade inflammation in 
atherosclerosis. A better understanding of these factors and the role of low-grade 
inflammation in atherosclerosis might offer novel diagnostic tools and eventually new 
treatment strategies to prevent or treat CVD. This thesis therefore provides several studies in 
women and men with overweight and obesity on: 
- The impact of fat distribution and its relation to metabolic dysregulation. 
- The contribution of fat distribution on low-grade inflammation. 
- The impact of sex on the relation between low-grade inflammation markers and the 
presence of the metabolic syndrome. 
- The relation of circulating low-grade inflammation markers with non-invasive 
measurements of atherosclerosis. 
- The relation between the gut microbiota, plasma metabolome and non-invasive 
measurements of atherosclerosis.  
 
Research population 
Much of the work presented in this thesis has been established in the 300-OB study, in which 
in total 302 individuals aged between 55 and 82 were enrolled in the period between 2014 
and 2016 in the Radboud university medical center. All individuals were overweight or obese 
and half had the metabolic syndrome. Most of these individuals (n = 227) had also participated 
in the Nijmegen Biomedical Study – Non-Invasive Measurements of Atherosclerosis 1 (NBS-
NIMA1) study, a population-based survey of Nijmegen residents (70). Additionally, we 
recruited 75 participants, acquaintances of earlier included subjects, fulfilling the inclusion 
criteria (age > 55 years and BMI > 27 kg/m2). Exclusion criteria were: a recent cardiovascular 
event (myocardial infarction, transient ischemic attack, or stroke less than six months before), 
history of bariatric surgery or bowel resection, inflammatory bowel disease, renal dysfunction, 
increased bleeding tendency, use of oral or subcutaneous anti-coagulant therapy, use of 
thrombocyte aggregation inhibitors other than acetylsalicylic acid and carbasalate calcium or 
a contra-indication for MRI. Participants who used lipid-lowering therapy, temporarily 
discontinued this medication four weeks prior to the measurements. All women were 






Part of the findings were validated in the 500 Functional Genomics (500FG) cohort, consisting 
of healthy individuals with a mean age 29 years and mean BMI 22.7 kg/m2. The analysis on the 
gut microbiome were also performed in a part of the LifeLines Deep study, we included 978 
subjects (567 women and 411 men) with an average BMI of 25 kg/m2. 
 
Methods 
All individuals filled out an extensive questionnaire about life style, medication use, and 
previous medical history. Blood sampling was performed in the morning after an overnight 
fast to measure blood glucose, triglycerides, total cholesterol and high-density lipoprotein 
cholesterol. The inflammatory status was phenotyped extensively by measurement of 
circulating cytokines, cell counts, stimulation experiments of PBMCs and whole blood and 
analysis of subcutaneous adipose tissue. We used a high-throughput targeted Nuclear 
Magnetic Resonance (NMR) metabolomics platform (Nightingale's Biomarker Analysis 
Platform) to generate spectra for the quantification of 231 lipid and metabolite measures.  
Fecal samples were collected within one-two days after blood samples were taken. 
Metagenomic shotgun sequencing was performed using the Illumina HiSeq platform (Illumina, 
San Diego, California). The profile of microbial composition was determined using MetaPhlan 
2.2 and the abundance of metabolic pathways was determined using HUMAnN2. 
All individuals underwent comprehensive cardiovascular assessment, including the 
measurement of carotid intima-medial thickness (cIMT), plaque presence and maximum 
plaque thickness. Abdominal and thigh fat distribution and liver fat content were determined 
by magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (MRS), 
respectively.  
 




The overall aim of this thesis is to obtain more insight in factors influencing obesity-associated 
low-grade inflammation in atherosclerosis. In this thesis we therefore investigated the 
following research questions: 
- Are sex-specific differences present in the distribution of fat within the subcutaneous 
adipose tissue layer? Does the amount of sSAT and dSAT relate to hepatic steatosis, 
the metabolic syndrome and its individual traits?  
- Are sex-specific differences in fat distribution associated with different inflammatory 
profiles? And how does the fat distribution relate to adipose tissue inflammation?  
- Does sex impact the relation between inflammation and metabolic syndrome in 
individuals with overweight and obesity. What is the role of circulating metabolites 
and hormones on this relation? 
- How do systemic inflammatory mediators, especially from the IL-1 family, relate to 
non-invasive markers of atherosclerosis? Is there a circulating cytokine that is 
associated with adipose tissue inflammation? 
- Does the gut microbiota impact on the plasma metabolome? And is this related to 
cardiometabolic phenotypes and individual metabolic risk of cardiovascular disease? 
- How is the gut microbiota related to markers of low-grade inflammation in humans 
(systemic review)? What are the possible mechanisms by which the gut microbiota 
can influence chronic low-grade inflammation and thereby contribute to the 
development and progression of ACVD? 
 
Outline of the thesis 
To address the research questions, this thesis continues with chapter 2, in which we evaluated 
the sex-specific associations of the deep and superficial SAT and the VAT with hepatic steatosis 
and the metabolic syndrome traits.  
We investigated this in 285 individuals with overweight and obesity from the 300-OB study of 
whom MRI and MRS measurements were present.  
 
In chapter 3, we investigated the relation between adipose tissue distribution and markers of 
systemic and adipose tissue inflammation in a sex-specific manner. This study was performed 
in the 300-OB cohort. MRI measurements were performed to assess the fat distribution in 
detail. Systemic low-grade inflammation was assessed via three groups of inflammatory 
parameters: plasma adipokine and cytokine concentrations, immune cell subpopulations in 
the blood, and the ex-vivo cytokine production capacity of circulating immune cells (such as 
monocytes and T cells). Subcutaneous fat biopsies were taken to analyze the adipose tissue 
inflammation. The different adipose tissue compartment volumes were related to all these 
inflammatory markers to see whether sex-specific differences in fat distribution were 




Recently, the importance of anti-inflammatory therapies has been shown in CVD. However, 
these anti-inflammatory therapies in CVD are being developed under the assumption that 
inflammatory pathways are identical in women and men, but it is not known if this is indeed 
the case. In chapter 4, we investigated the impact of sex on the relation between inflammation 
and metabolic syndrome in overweight women and men. All individuals from the 300-OB 
cohort were included. The three groups of inflammation markers were related to the presence 
of the metabolic syndrome and the different metabolic traits in women and men. We also 
investigated the role of circulating metabolites, which were analyzed via Nuclear Magnetic 
Resonance metabolomics platform, and sex hormones on this relation.  
 
In chapter 5, our aim was to investigate the impact of systemic inflammatory mediators, 
especially from the IL-1 family of cytokines, on atherosclerosis in individuals with overweight 
and obesity. We therefore performed ultrasound measurements of the carotid artery in all 
300-OB participants to assess the intima-medial thickness, plaque presence and maximum 
plaque thickness. These cardiovascular parameters were related to circulating cytokines. We 
also assessed whether these inflammatory mediators were related to adipose tissue 
inflammation. Part of the findings were validated in the 500FG cohort, consisting of healthy 
individuals with a mean age 29 years and mean BMI 22.7 kg/m2. 
 
Another factor which relates to obesity and cardiovascular risk is the gut microbiome. 
However, it is not fully known by which (patho)physiological process the gut microbiota 
influences the cardiovascular risk. Therefore, we related the microbial species and pathways 
in two different human studies to the plasma metabolome, which mainly included lipoprotein 
composition, but also inflammatory markers, and related it to atherosclerotic manifestations. 
Next to the 300-OB cohort, 978 individuals from the LifeLines Deep study, taken from a general 
Dutch population, were included in these analyses. The gut microbiota was analyzed via 
metagenomic shotgun sequencing. Plasma metabolites were analyzed using nuclear magnetic 
resonance (NMR) and the Nightingale's Biomarker Analysis Platform. The results of this study 
can be found in chapter 6.  
 
Up till now, many gut microbiome studies have been carried out in mice. As the composition 
of the gut microbiota in mice differs significantly from humans, the relation with obesity-
associated low-grade inflammation could also be affected in a different way. In chapter 7, we 
therefore performed a systematic review of all articles on the relation between the gut 
microbiome and markers of low-grade inflammation in humans. Next to that, we speculated 
on possible mechanisms through which the gut microbiota can affect low-grade inflammation 
and thereby CVD. 
 
Finally, chapter 8 discusses the findings described in the previous chapters by comparing them 
to the literature. We discuss the strengths and limitations of our research and provide 









1. Boon B. Leonardo da Vinci on atherosclerosis and the function of the sinuses of Valsalva. Neth Heart J. 
2009;17(12):496-9. 
2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 
235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease 
Study 2010. Lancet. 2012;380(9859):2095-128. 
3. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J, 3rd. Factors of risk in the development of 
coronary heart disease--six year follow-up experience. The Framingham Study. Annals of internal medicine. 
1961;55:33-50. 
4. Meigs JB, Wilson PW, Fox CS, Vasan RS, Nathan DM, Sullivan LM, et al. Body mass index, metabolic  
syndrome, and risk of type 2 diabetes or cardiovascular disease. The Journal of clinical endocrinology and 
metabolism. 2006;91(8):2906-12. 
5. Virchow R. Cellular Pathology. 1858. 
6. Jonasson L, Holm J, Skalli O, Gabbiani G, Hansson GK. Expression of class II transplantation antigen on 
vascular smooth muscle cells in human atherosclerosis. The Journal of clinical investigation. 1985;76(1):125 -31. 
7. Hansson GK, Jonasson L. The discovery of cellular immunity in the atherosclerotic plaque. 
Arteriosclerosis, thrombosis, and vascular biology. 2009;29(11):1714-7. 
8. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860 -7. 
9. Stienstra R, Stefan N. Tipping the inflammatory balance: inflammasome activation distinguishe s 
metabolically unhealthy from healthy obesity. Diabetologia. 2013;56(11):2343-6. 
10. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83(2):456S-60S. 
11. Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, et al. Pathologic assessment of the 
vulnerable human coronary plaque. Heart. 2004;90(12):1385-91. 
12. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor -alpha: direct 
role in obesity-linked insulin resistance. Science (New York, NY). 1993;259(5091):87 -91. 
13. Ferrante AW, Jr. Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. 
Journal of internal medicine. 2007;262(4):408-14. 
14. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear 
receptors. Nature. 2008;454(7203):470-7. 
15. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein 
concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. 
Lancet. 2010;375(9709):132-40. 
16. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Rosuvastatin to prevent 
vascular events in men and women with elevated C-reactive protein. The New England journal of medicine. 
2008;359(21):2195-207. 
17. Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify 
Novel Targets for Atheroprotection. Circulation research. 2016;118(1):145-56. 
18. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415 -45. 
19. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 
2017;542(7640):177-85. 
20. Tack CJ, Stienstra R, Joosten LA, Netea MG. Inflammation links excess fat to insulin resistance: the role 
of the interleukin-1 family. Immunological reviews. 2012;249(1):239-52. 
21. Grebe A, Hoss F, Latz E. NLRP3 Inflammasome and the IL -1 Pathway in Atherosclerosis. Circulation 
research. 2018;122(12):1722-40. 
22. Stienstra R, Tack CJ, Kanneganti TD, Joosten LA, Netea MG. The inflammasome puts obesity in the 
danger zone. Cell metabolism. 2012;15(1):10-8. 
23. Esser N, L'Homme L, De Roover A, Kohnen L, Scheen AJ, Moutschen M, et al. Obesity phenotype is 
related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue. Diabetologia. 
2013;56(11):2487-97. 
24. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory 
Therapy with Canakinumab for Atherosclerotic Disease. The New England journal of medicine. 2017.  
25. Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 
2013;4:289. 
26. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: a 
novel modulator of the Th1 cytokine response. Immunity. 1999;10(1):127 -36. 
24 
 
27. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in Patients with 
Chronic Coronary Disease. The New England journal of medicine. 2020. 
28. Cao H. Adipocytokines in obesity and metabolic disease. The Journal of endocrinology. 2014;220(2):T47-
59. 
29. La Cava A, Matarese G. The weight of leptin in immunity. Nature reviews Immunology. 2004;4(5):371-9. 
30. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of 
the metabolic syndrome. Circulation journal : official journal of the Japanese Circulation Society. 
2004;68(11):975-81. 
31. Hellstrom L, Wahrenberg H, Hruska K, Reynisdottir S, Arner P. Mechanisms behind gender differences 
in circulating leptin levels. Journal of internal medicine. 2000;247(4):457-62. 
32. Bekkering S, Stiekema LCA, Bernelot Moens S, Verweij SL, Novakovic B, Prange K, et al. Treatment with 
Statins Does Not Revert Trained Immunity in Patients with Familial Hypercholesterolemia. Cell metabolism. 
2019;30(1):1-2. 
33. van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, et al. Oxidized 
Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in 
Humans. Circulation. 2016;134(8):611-24. 
34. Bekkering S, van den Munckhof I, Nielen T, Lamfers E, Dinarello C, Rutten J, et al. Innate immune cell 
activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. 
Atherosclerosis. 2016;254:228-36. 
35. Shirai T, Nazarewicz RR, Wallis BB, Yanes RE, Watanabe R, Hilhorst M, et al. The glycolytic enzyme PKM2 
bridges metabolic and inflammatory dysfunction in coronary artery disease. The Journal of experimental 
medicine. 2016;213(3):337-54. 
36. Apovian CM, Bigornia S, Mott M, Meyers MR, Ulloor J, Gagua M, et al. Adipose macrophage infiltration 
is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arteriosclerosis, 
thrombosis, and vascular biology. 2008;28(9):1654-9. 
37. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage  
localization and function in adipose tissue of obese mice and humans. Journal of lipid research. 
2005;46(11):2347-55. 
38. CBS-Statline. Gezondheid, leefstijl, zorggebruik en -aanbod, doodsoorzaken; vanaf 1900: CBS; 2019 
[Available from: https://opendata.cbs.nl/statline/#/CBS/nl/dataset/37852/table?ts=1571126265494 . 
39. Rasouli N, Molavi B, Elbein SC, Kern PA. Ectopic fat accumulation and metabolic syndrome. Diabetes, 
obesity & metabolism. 2007;9(1):1-10. 
40. Karelis AD. Metabolically healthy but obese individuals. Lancet. 2008;372(9646):1281-3. 
41. Neeland IJ, Ross R, Despres JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, 
atherosclerosis, and cardiometabolic disease: a position statement. The lancet Diabetes & endocrinology. 
2019;7(9):715-25. 
42. Monzon JR, Basile R, Heneghan S, Udupi V, Green A. Lipolysis in adipocytes isolated from deep and 
superficial subcutaneous adipose tissue. Obesity research. 2002;10(4):266 -9. 
43. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. 
Clinics in liver disease. 2004;8(3):521-33, viii. 
44. Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, et al. Progression of carotid 
vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general 
population during 10 years of follow-up. Atherosclerosis. 2016;246:208-13. 
45. Boutari C, Lefkos P, Athyros VG, Karagiannis A, Tziomalos K. Nonalcoholic Fatty Liver Disease vs. 
Nonalcoholic Steatohepatitis: Pathological and Clinical Implications. Current vascular pharmacology. 
2018;16(3):214-8. 
46. Schorr M, Dichtel LE, Gerweck AV, Valera RD, Torriani M, Miller KK, et al. Sex differences in body 
composition and association with cardiometabolic risk. Biology of sex differences. 2018;9(1):28.  
47. Sans S, Puigdefabregas A, Paluzie G, Monterde D, Balaguer-Vintro I. Increasing trends of acute 
myocardial infarction in Spain: the MONICA-Catalonia Study. European heart journal. 2005;26(5):505-15. 
48. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk 
factors associated with myocardial infarction in 52 countries (the INTERHEART study): case -control study. Lancet. 
2004;364(9438):937-52. 
49. Albrektsen G, Heuch I, Løchen M-L, Thelle DS, Wilsgaard T, Njølstad I, et al. Lifelong Gender Gap in Risk 
of Incident Myocardial Infarction: The Tromsø Study. JAMA Internal Medicine. 2016;176(11):1673-9. 
25 
 
50. Leening MJG, Ferket BS, Steyerberg EW, Kavousi M, Deckers JW, Nieboer D, et al. Sex differences in 
lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. BMJ : 
British Medical Journal. 2014;349:g5992. 
51. Schulz UG, Rothwell PM. Sex differences in carotid bifurcation anatomy and the distribution of 
atherosclerotic plaque. Stroke. 2001;32(7):1525-31. 
52. Kothawade K, Bairey Merz CN. Microvascular coronary dysfunction in women: pathophysiology, 
diagnosis, and management. Curr Probl Cardiol. 2011;36(8):291-318. 
53. McSweeney JC, Cody M, O'Sullivan P, Elberson K, Moser DK, Garvin BJ. Women's early warning 
symptoms of acute myocardial infarction. Circulation. 2003;108(21):2619-23. 
54. Klein SL, Flanagan KL. Sex differences in immune responses. Nature reviews Immunology. 
2016;16(10):626-38. 
55. Ter Horst R, Jaeger M, Smeekens SP, Oosting M, Swertz MA, Li Y, et al. Host and Environmental Factors 
Influencing Individual Human Cytokine Responses. Cell. 2016;167(4):1111 -24 e13. 
56. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, et al. The gut microbiota as an environmental 
factor that regulates fat storage. Proceedings of the National Academy of Sciences of the United States of 
America. 2004;101(44):15718-23. 
57. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue  
established by metagenomic sequencing. Nature. 2010;464(7285):59-65. 
58. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. 
Science (New York, NY). 2012;336(6086):1268-73. 
59. Mazmanian SK, Kasper DL. The love-hate relationship between bacterial polysaccharides and the host 
immune system. Nature reviews Immunology. 2006;6(11):849-58. 
60. Jia W, Li H, Zhao L, Nicholson JK. Gut microbiota: a potential new te rritory for drug targeting. Nat Rev 
Drug Discov. 2008;7(2):123-9. 
61. Holmes E, Kinross J, Gibson GR, Burcelin R, Jia W, Pettersson S, et al. Therapeutic modulation of 
microbiota-host metabolic interactions. Science translational medicine. 2012;4(137):137rv6. 
62. Buford TW. (Dis)Trust your gut: the gut microbiome in age-related inflammation, health, and disease. 
Microbiome. 2017;5(1):80. 
63. Yamashita T, Emoto T, Sasaki N, Hirata KI. Gut Microbiota and Coronary Artery Disease. International 
heart journal. 2016;57(6):663-71. 
64. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. 
Proceedings of the National Academy of Sciences of the United States of America. 2005;102(31):11070 -5. 
65. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut 
microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027 -31. 
66. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome  
correlates with metabolic markers. Nature. 2013;500(7464):541-6. 
67. van den Munckhof ICL, Kurilshikov A, Ter Horst R, Riksen NP, Joosten LAB, Zhernakova A, et al. Role of 
gut microbiota in chronic low-grade inflammation as potential driver for atherosclerotic cardiovascular disease: 
a systematic review of human studies. Obesity reviews : an official journal of the International Association for 
the Study of Obesity. 2018;19(12):1719-34. 
68. Fu J, Bonder MJ, Cenit MC, Tigchelaar EF, Maatman A, Dekens JA, et al. The Gut Microbiome Contributes 
to a Substantial Proportion of the Variation in Blood Lipids. Circulation research. 2015;117(9):817 -24. 
69. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of 
phosphatidylcholine and cardiovascular risk. The New England journal of medicine. 2013;368(17):1575 -84. 
70. Holewijn S, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. The metabolic syndrome and its traits 












Superficial versus deep subcutaneous adipose tissue: 













Tessa Brand, Inge C.L. van den Munckhof, Marinette van der Graaf, Kiki Schraa, Helena M. 











Subcutaneous adipose tissue (SAT) is not homogeneous, as the fascia scarpa separates the 
deep SAT (dSAT) from the superficial SAT (sSAT). The aim of this study was to evaluate the sex-
specific associations of sSAT and dSAT with hepatic steatosis and the metabolic syndrome in 
individuals with overweight.  
 
Methods 
We recruited 285 individuals with a BMI≥27 kg/m2, aged 55-81 years. Abdominal magnetic 
resonance imaging was performed around level L4-L5 to measure VAT, dSAT and sSAT volumes. 
The amount of hepatic fat was quantified by MR spectroscopy.  
 
Results  
Men had significantly higher volumes of VAT (122.6 cm3 versus 98.7 cm3, p < 0.001) and had 
only half of the volume of sSAT compared to women adjusted for BMI (50.3 cm3 in men versus 
97.0 cm3 in women, p < 0.001). However, just a small difference in the volume of dSAT was 
observed between sexes. In men, dSAT correlated significantly with hepatic fat content in 
univariate analysis (stand. β = 0.190, p < 0.05), while VAT correlated significantly with hepatic 
steatosis in a multivariate model, adjusted for age, alcohol use and other abdominal fat 
compartments (stand. β = 0.184, p = 0.037). Moreover, dSAT in men correlated negatively with 
HDL-c (stand. β = -0.165, p = 0.038) in multivariate analyses. In women with a BMI between 
30-40 kg/m2 (but not a lower BMI), in a multivariate model adjusted for age, alcohol use and 
other abdominal fat compartments, VAT correlated positively (stand. β = -0.404, p = 0.003), 
and sSAT negatively (stand. β = -0.300, p = 0.04) with hepatic fat content. 
 
Conclusions 
In men, dSAT is associated with hepatic steatosis and adverse metabolic traits, such as lower 
HDL-cholesterol levels; while in women with obesity sSAT shows a beneficial relation with 






The prevalence of obesity has nearly doubled worldwide since 1980 (1). This increase has led 
to a pandemic increase in obesity-related disorders such as hypertension, dyslipidaemia and 
diabetes mellitus, which are all components of the metabolic syndrome. Especially the 
expansion of the visceral adipose tissue stores is related to the metabolic dysregulation, and 
subsequently leads to an increased risk for cardiovascular morbidity and mortality (2, 3). 
Visceral adipose tissue (VAT) is an important factor in the development of non-alcoholic fatty 
liver disease (NAFLD), also seen as the hepatic equivalent of the metabolic syndrome, both in 
women and men. Approximately 75% of individuals with obesity have increased hepatic fat, 
defined as a hepatic fat fraction above 5.6% as measured by magnetic resonance spectroscopy 
(4-6). Hepatic steatosis is the first stage of NAFLD and is usually benign and reversible (7). 
However, this condition can progress to non-alcoholic steatohepatitis (NASH), resulting in 
cirrhosis in 1-2% of patients (8). Both NAFLD and NASH are related to a higher risk for 
cardiovascular disease (9, 10).  
Previous studies have reported that VAT is an important factor in the development of NAFLD 
and contributes to an increased cardiovascular risk (2, 3, 11). However, a relative increase in 
subcutaneous adipose tissue (SAT) compared to VAT is related to decreased severity of NAFLD 
(12). Currently, there are two hypotheses to explain the difference between VAT and SAT in 
the pathogenesis of NAFLD. The “portal theory” proposes that the liver is exposed to excessive 
free fatty acids (FFA) and pro-inflammatory factors released from the visceral fat into the 
portal vein of patients with obesity, which promotes the development of hepatic insulin 
resistance and hepatic steatosis (13). However, only 5-30% of the delivered FFA to the liver 
originates from visceral fat (14, 15), while at least 50-60% of the FFA comes from the systemic 
circulation and thus from subcutaneous fat (16). The second hypothesis is the “ectopic fat 
hypothesis”(17), which proposes an indirect mechanism whereby increased energy storage in 
peripheral subcutaneous fat exerts a protective effect by decreasing fat deposition in the liver, 
muscle and heart. However, although subcutaneous fat seems to be related to a more 
beneficial metabolic profile than visceral fat, it is important to realize that subcutaneous fat is 
not a homogeneous compartment, and we now hypothesize that there is a differential 
contribution to fatty liver disease of the two different subcutaneous fat compartments. 
Once regarded to be a single entity, the abdominal SAT is divided by the scarpa fascia into the 
superficial (sSAT) and the deep subcutaneous adipose tissue (dSAT). The adipocytes from dSAT 
have higher lipolytic activity than superficial SAT adipocytes and contribute substantially to 
FFA levels in the circulation (18). It has been suggested that abdominal dSAT exhibits an 
intermediate phenotype between VAT and abdominal sSAT (19). Moreover, in patients with 
type 2 diabetes mellitus, a higher relative distribution of abdominal fat in sSAT was associated 
with a lower cardiovascular risk, whereas dSAT was related to a higher blood pressure and 
lower heart rate variability (20).  
Although different studies have shown that dSAT and sSAT are evidently distinct abdominal 
adipose tissue depots, in the majority of the studies investigating the association between 




distinction is made between dSAT and sSAT. As adipocytes from dSAT and sSAT have a 
different metabolic and inflammatory profile (21), we hypothesized that dSAT, but not sSAT, 
is associated with hepatic steatosis. We also investigated the associations between the 
different components of the metabolic syndrome and the various adipose tissue  
compartments (VAT, dSAT, sSAT), taking into account the sex differences in adipose tissue 
distribution.  
 
RESEARCH DESIGN AND METHODS 
Study population 
We enrolled 302 individuals with overweight (BMI above 27 kg/m2), aged 55-80 years, in the 
period between 2014 and 2016 (300-OB study). The majority of the individuals (n = 227) also 
participated in the NBS-NIMA1 study, a population-based survey of Nijmegen residents (22). 
We recruited another 75 participants, acquaintances of previously included individuals, who 
fulfilled the inclusion criteria of age > 55 years and BMI > 27 kg/m2. Exclusion criteria were: a 
recent cardiovascular event (myocardial infarction, transient ischemic attack, or stroke less 
than six months before), history of bariatric surgery or bowel resection, inflammatory bowel 
disease, renal dysfunction, increased bleeding tendency, use of oral or subcutaneous anti-
coagulant therapy, use of thrombocyte aggregation inhibitors other than acetylsalicylic acid 
and carbasalate calcium or a contra-indication for MRI. Participants who used lipid-lowering 
therapy, temporarily discontinued this medication four weeks prior to the measurements. 
All women were postmenopausal and did not use hormonal replacement therapy. All 
participants received detailed written and oral information and provided written informed 
consent. The Arnhem-Nijmegen Medical Ethics Committee approved the study protocol (in 
accordance with the Declaration of Helsinki). 
 
Clinical parameters 
Individuals filled out an extensive questionnaire about life style, medication use, and previous 
medical history. Blood sampling was performed in the morning after an overnight fast. Blood 
glucose, triglycerides (TG), total cholesterol (TC) and high-density lipoprotein cholesterol 
(HDL-c) were measured by standard laboratory procedures. Weight and height were 
measured and body mass index was calculated as body weight (kg) divided by the square of 
height (m). Waist circumference (WC) was measured at the level of the umbilicus to the 
nearest 0.1 cm. Hip circumference was measured at the level of the trochanter major. 
Waist/hip ratio (WHR) was calculated by dividing the waist circumference by the hip 
circumference. The diagnosis of metabolic syndrome was made using the clinical criteria of 
the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) (23).  
 
MRI and MRS data acquisition 
Abdominal fat distribution and liver fat content were determined by magnetic resonance 




combined MR examinations were performed on a 3.0 T Magnetom Skyra or Trio MR system 
(Siemens, Erlangen, Germany). Individuals were examined in the supine position with their 
arms positioned parallel to the lateral sides of the body. For the determination of visceral and 
subcutaneous fat distribution a series of T1-weighted FLASH 2D axial MR images were 
acquired from a region extending from 4 cm above to 4 cm below the fourth and fifth lumbar 
interspace (16 slices, matrix size 192/256, field of view 300-353 / 400-470 mm2, slice thickness 
5 mm, breath-hold, TR/TE 80 ms/2.46 ms). Breathing commands were used to avoid motion-
induced artifacts. 
For the MRS measurement, a single voxel of 27 cm3 was positioned in the right lobe of the 
liver, avoiding the biliary tree and large blood vessels. A STEAM (24) localization sequence 
without water suppression was used for data acquisition. To minimize relaxation effects on 
signal intensity long repetition time (TR = 3 s) and short echo time (TE = 20 ms) were used. Six 
scans were averaged during breath holding for 15 seconds. No pre-scans were used. 
 
VAT, SAT, sSAT and dSAT analysis 
The images acquired were retrieved from the MR scanner and analyzed with software 
developed in the IDL 6.0 environment, called HIPPO FAT (version 1.3, V. Positano) (25). Due to 
the T1-weighting, fatty tissues are represented with signal intensity in these images. 
VAT, SAT, dSAT and sSAT volumes were measured on 8 separate slices, with an interslice 
distance of 5 mm, around the L4-L5 intervertebrate level. HIPPO FAT automatically generates 
three contour lines at each image provided by an active fuzzy clustering algorithm (26) that 
allowed the separation of SAT from VAT: (1) along the outer margin of the SAT, (2) along the 
inner margin of the SAT and (3) around the smallest possible region in the visceral region that 
included all VAT. A histogram of signal intensities in the VAT region was provided, in which a 
Gaussian curve automatically fitted the high-intensity peak, which identified the visceral fat.  
After automatic segmentation, the analyst (TB), if necessary, manually adjusted both the 
contour lines and the shape of Gaussian curve by eyeballing. The MRI scan allows visualization 
of the scarpa fascia as a fine black line. To divide sSAT from dSAT, a line was drawn manually 
over the scarpa fascia. Adipose tissue pixels between this line and the outer margin of the SAT 
were defined as sSAT. dSAT was calculated by the total subcutaneous adipose tissue pixels 
minus the superficial subcutaneous adipose tissue pixels (dSAT = SAT – sSAT). Interclass 
correlation coefficients for inter-observer comparisons were 0.799 for VAT, 0.999 for SAT, 
0.998 for dSAT and 0.999 for sSAT based on n = 11. 
 
Quantification of hepatic fat content 
All MR spectra were post-processed using the jMRUI software v3.0 package and the AMARES 
algorithm (27) to determine water (4.7 ppm) and methylene (1.3 ppm) resonance areas. 
Intrahepatic TG content was expressed as the fraction of the methylene signal in the combined 
signal of methylene and water (%). No correction for relaxation differences was applied. Based 
on the European guidelines(28) we considered NAFLD to be present when the ratio methylene 






Quantitative variables are shown as the mean ± standard deviation. As hepatic fat content is 
not normally distributed, the univariate analyses on the relations to hepatic fat content 
content are performed by non-parametric tests (spearman correlation), while all other 
univariate analyses are performed by pearson correlations (Table 2 and 3). The association 
between the various abdominal adipose tissue compartments and the characteristics of the 
metabolic syndrome were investigated using linear regression analysis, adjusted for sex, age, 
alcohol intake and medication use (antidiabetic, antihypertensive drugs and statins). The 
statistical analysis was performed using SPSS version 22 (Armonk, NY: IBM Corp). A p-value 




In seven individuals MRI was not performed because of claustrophobia. In ten individuals it 
was not possible to calculate any abdominal adipose tissue volume due to insufficient MRI 
data (mostly movement artefacts). Our study cohort thereby consisted of 285 individuals (126 
women and 159 men). In seven individuals it was not possible to calculate the VAT volumes 
due to low quality images and eighteen individuals could not be classified due to missing data 
for liver fat as MR spectroscopy could not be performed in these individuals due to technical 
difficulties. 
Subjects with missing data on VAT or liver fat were excluded from analyses including these 
variables. The mean age was 67.1 ± 5.3 years and mean BMI was 30.6 ± 3.3 kg/m². 44.6% of 
the study population was treated for hypertension (54 women and 73 men), 25.3% were on 
lipid lowering medication (26 women and 46 men), 7.4% used oral antidiabetic medication (6 
women and 15 men), and 1.8% used insulin. There was no significant correlation between the 
units of alcohol per day and the amount of hepatic steatosis. The baseline characteristics of 
the study population are shown in Table 1. A total of 153 individuals met the NCEP ATP III 
criteria for metabolic syndrome with no significant difference in the prevalence between 
women and men. The prevalence of a hepatic fat content ≥5.6% as measured by magnetic 












Table 1 - Baseline characteristics of the study population (n = 285).  
 
Abdominal adipose tissue distribution 
Men had a higher weight (95.7 kg versus 83.3 kg), larger WC (109.2 cm versus 102.3 cm), and 
higher WHR (0.99 versus 0.91) than women, all p < 0.001. There was a clear sex difference in 
the abdominal adipose tissue distribution. On the eight 5 mm MRI slices as described before, 
men had a significantly higher volume of VAT (122.6 cm3 versus 98.7 cm3, p < 0.001) and a 
lower volume of SAT (137.1 cm3 versus 193.8 cm3, p < 0.001) compared to women, despite no 
difference in BMI. This resulted in a higher VAT/SAT ratio in men compared to women (0.97 
versus 0.54). When adjusted for height, the difference between women and men of VAT and 
SAT remained significant. In particular, there was a profound difference in the volume of sSAT 
(50.3 cm3 in men versus 97.0 cm3 in women, p < 0.001), whereas the difference in dSAT volume 
was much smaller, but still significant (86.9 cm3 in men versus 96.8 cm3 in women, p = 0.007). 





cohort (n = 
285) 
Subjects with metabolic 
syndrome 
Subjects without metabolic 
syndrome 
  
Mean ± SD 
Women (n = 69) 
Mean ± SD 
Men (n = 84) 
Mean ± SD 
Women (n = 69) 
Mean ± SD 
Men (n = 75) 
Mean ± SD 
Age (yr) 67.1 ± 5.3 67.8 ± 5.5 67.1 ± 5.6 67.5 ± 5.0 66.0 ± 5.0 
Weight (kg) 90.2 ± 12.8 85.0 ± 11.0* 97.7 ± 12.1* 81.2 ± 9.4 93.4 ± 11.0 
BMI (kg/m²) 30.6 ± 3.3 31.4 ± 3.9* 31.2 ± 3.4** 29.9 ± 2.8 29.6 ± 2.7 
WC (cm) 106.1 ± 9.6 104.9 ± 9.7*** 112.3 ± 8.3*** 99.2 ± 7.9 105.7 ± 7.8 
Hip circumference (cm) 111.2 ± 7.4 113.9 ± 9.7 110.7 ± 6.7 111.6 ± 7.2 109.0 ± 5.0 
Waist/hip ratio 1.0 ± 0.1 0.9 ± 0.1* 1.0 ± 0.0*** 0.9 ± 0.1 1.0 ± 0.1 
Glucose 5.7 ± 1.3 6.2 ± 1.5*** 6.1 ± 1.6*** 5.0 ± 0.5 5.2 ± 0.7 
Triglycerides 1.8 ± 1.0 2.2 ± 0.8*** 2.3 ± 1.4*** 1.3 ± 0.4 1.3 ± 0.4 
HDL-c 1.3 ± 0.3 1.3 ± 0.3*** 1.1 ± 0.3*** 1.6 ± 0.2 1.3 ± 0.3 
Systolic BP (mmHg) 129.5 ± 13.8 131.7 ± 15.2 131.3 ± 13.9* 127.3 ± 13.3 127.1 ± 12.3 
Diastolic BP (mmHg) 80.0 ± 8.9 78.2 ± 9.3 81.1 ± 9.9 77.2 ± 7.2 82.5 ± 7.9 
VAT (cm3) 112.0 ± 39.0 107.1 ± 34.2** 138.1 ± 
39.4*** 
88.7 ± 27.7 106.1 ± 35.0 
SAT (cm3) 162.2 ± 55.3 195.7 ± 53.8 145.6 ± 45.4** 191.6 ± 52.5 127.7 ± 38.2 
sSAT (cm3) 70.9 ± 33.0 98.7 ± 31.6 51.6 ± 17.7 95.0 ± 28.7 48.8 ± 14.1 
dSAT (cm3) 91.3 ± 30.9 97.0 ± 30.4 94.0 ± 31.0** 96.7 ± 31.7 78.9 ± 27.7 
VAT/SAT ratio 0.8 ± 0.4 0.6 ± 0.2** 1.0 ± 0.4** 0.5 ± 0.2 0.9 ± 0.4 




Abdominal adipose tissue distribution in relation to metabolic syndrome  
We next assessed whether the volume of the separate adipose tissue compartments and the 
hepatic fat content correlated with the metabolic parameters. In all individuals with metabolic 
syndrome, VAT and VAT/SAT ratio were significantly higher compared to individuals without 
the metabolic syndrome, both in women and in men. The hepatic fat content was twice as 
high in men with the metabolic syndrome (12.9% vs 6.6%, P < 0.001), and this was also 
significantly higher in women with metabolic syndrome (12.1% vs 6.6%, P = 0.016). 
Furthermore, in men with metabolic syndrome dSAT was significantly higher than in men 
without metabolic syndrome (94.0 cm3 vs 78.9 cm3, p = 0.001), whereas no difference was 
found for sSAT.  
In univariate analysis, both VAT and hepatic fat content showed a strong association with the 
separate components of the metabolic syndrome. In men, dSAT was associated negatively 
with HDL-c (Table 2). After adjustment for age, alcohol, and medication use, only in men dSAT 
was associated negatively with HDL-c in the plasma (Fig. 1). In contrast, we found no 
association between these markers and sSAT both in women women. As expected, VAT 
associated positively both in women and men with glucose and TG levels and was negatively 
associated with HDL-c. Hepatic fat content was associated in women with glucose and 
triglycerides and inversely with HDL-c, in men only glucose and TG correlated with hepatic 
liver fat (Fig. 1). 
 
 
Volume VAT Volume sSAT Volume dSAT Hepatic fat content 
 
Wome










n (n = 
126) 
Men (n 
= 159)  
Wome
n (n = 
120) 
Men (n = 
147) 
WC .448*** .513*** .400*** .558*** .527*** .721*** .300** .249** 
Triglycerides .335*** .255** -.010 -.096 -.021 .014 .392*** .241** 
HDL-c -.257** -.229** -.075 -.013 .021 -.192* -.361*** -.114 
Systolic BP .168 .105 .128 .080 .200* .092 .138 .057 
Glucose  .383*** .213** .106 -.027 .057 .023 .389*** .344*** 
 
Table 2 – Univariate correlations of hepatic fat content and the different abdominal fat 
compartments with the metabolic syndrome traits. Relation with hepatic fat content is based 
on spearman correlations, relation with abdominal fat compartment volumes are based on 
pearson correlation. VAT Visceral Adipose Tissue; sSAT superficial Subcutaneous Adipose 
Tissue; dSAT deep Subcutaneous Adipose Tissue. HDL-c High-Density Lipoprotein cholesterol; 







Figure 1 – Associations of metabolic parameters with the different abdominal adipose tissue 
compartments, adjusted for age, alcohol intake, medication use and stratified for sex.  
On the Y-axis the standardized β coefficients are reported. Blue bars represent women and 
white bars represent women. Every metabolic parameter is adjusted for specific medication 
use (A for antidiabetic medication, B and C for lipid lowering medication).  
VAT Visceral Adipose Tissue; dSAT deep Subcutaneous Adipose Tissue; sSAT superficial  





















































































Abdominal adipose tissue distribution in relation to hepatic fat content  
In all individuals, there was a significant correlation between VAT and hepatic fat content. This 
association remained significant, also after adjustment for  age, alcohol intake and other 
abdominal fat compartment volumes (sSAT and dSAT in this case), with a standardized beta 
of 0.184 for men (p = 0.037) and a standardized beta of 0.304 for women (p = 0.001). Only in 
men however, dSAT was positively associated with both VAT and hepatic fat content in a 
bivariate analysis (Table 3).  
 
  Hepatic fat content Volume dSAT Volume sSAT 
 
Women 
(n = 120) 
Men (n = 
147) 
Women 




(n = 126) 
Men (n 
= 159)  
Volume VAT .390*** .322*** .148 .198* .191* .055 
Volume sSAT -.009 -.001 .498*** .679***   
Volume dSAT .113 .190*     
 
Table 3 – Univariate correlations between hepatic fat content and between different 
abdominal fat compartments. Relation with hepatic fat content is based on spearman 
correlations, relation with abdominal fat compartment volumes are based on pearson 
correlation. 
VAT Visceral Adipose Tissue; sSAT superficial Subcutaneous Adipose Tissue; dSAT deep 
Subcutaneous Adipose Tissue. *P < 0.05, **P < 0.01, ***P < 0.001. 
 
As the amount of total adipose tissue could influence the relation between the different 
adipose tissue compartments and hepatic steatosis, we investigated the associations with VAT, 
dSAT and sSAT for different BMI categories (BMI 27 – 30 kg/m2 and BMI 30 – 40 kg/m2; data 
not shown) after correction for age, alcohol intake and other abdominal fat compartment 
volumes. In men, the association between different adipose tissue compartments and hepatic 
steatosis was not significant anymore. However, large differences were observed between 
women with overweight and obesity. VAT was strongly positively associated with hepatic fat 
content, whereas sSAT was significantly negatively associated with hepatic fat content in 
women with a BMI between 30 and 40 kg/m2 with a standardized beta of -0.300, p = 0.04. In 
women with overweight (BMI between 27 and 30 kg/m2) however, no associations were seen 
between the abdominal fat compartments and hepatic fat content. 
 
DISCUSSION 
In this study, we observed profound sex differences in the abdominal fat distribution and its 
correlations with hepatic steatosis and components of the metabolic syndrome. Although 
women and men had similar BMI, men had significantly higher volumes of VAT and relatively 
more dSAT compared to women. Within the SAT compartment, women had a much higher 
ratio of superficial to deep SAT compared to men. Importantly, only in men, dSAT was 




in women, dSAT did not show any associations with these parameters. In contrast, only in 
women with obesity, sSAT was negatively associated with hepatic fat content.  
 
A sex difference in SAT distribution has been reported by Golan et al. (20), who investigated 
VAT, total SAT and sSAT measurements by MRI. In line with our results, they observed that 
men had a higher VAT/SAT ratio and women had a higher proportion of abdominal sSAT. 
Furthermore, our results confirm the results of another study, who suggested that in men 
adiposity is characterized by disproportionate expansion of dSAT compared with sSAT, 
whereas in women both dSAT and sSAT expand similarly in obesity (29). A greater proportion 
of dSAT in men at any level of subcutaneous or total body fat compared with women was 
previously observed, in contrast with our results (30). However, in that study, single slice 
computed tomography was used to evaluate abdominal adipose tissue compartments, which 
may explain the differences with our findings. A possible explanation for the higher VAT 
content and lower dSAT and sSAT content in men could be the difference in hormonal status. 
Hyperandrogenism in normal weight PCOS women was associated with preferential visceral 
fat deposition and moreover an increased proportion of small subcutaneous abdominal 
adipocytes, which could limit subcutaneous fat storage (31). Moreover, six months of 
testosterone therapy in aging men with a low normal bioavailable testosterone decreased 
subcutaneous fat on the abdomen and lower extremities, while visceral fat remained 
unchanged (32). 
 
In all individuals, VAT correlated significantly with hepatic fat content. As previous studies 
have shown that fat volumes could be influenced by medication use (33-35), we also adjusted 
the analysis of VAT and hepatic fat content for antidiabetic, antihypertensive and lipid 
lowering medication, however, VAT still remained positively associated with hepatic fat 
content in all individuals. It would be interesting to investigate whether the duration of 
medical therapy would influence this relation. Importantly, in men, dSAT also correlated 
positively with hepatic fat content, while in women with obesity sSAT correlated negatively 
with hepatic fat content. Yaskolka Meir et al. found in a group of 275 individuals selected on 
a high waist circumference or dyslipidemia, only a significant positive association for VAT with 
hepatic fat content, while sSAT was inversely associated with hepatic fat content in an age, 
sex and waist circumference adjusted model (36). However they did not perform analysis 
stratified by sex, which could explain the differences with our results. Another study related 
abdominal adipose tissue volumes in a small group of type 2 DM patients with peripheral and 
hepatic insulin resistance. They found that dSAT was only in men associated with peripheral 
and hepatic insulin resistance (37). An explanation for the clear difference in women with 
obesity between dSAT and sSAT in its association with hepatic steatosis and metabolic 
syndrome may be the contrasting morphological cellular aspects of dSAT and sSAT. As 
mentioned before, dSAT is more lipolytically active than sSAT, which can contribute to 
elevated levels of FFA in the circulation (18). This would also explain the correlation with 




hepatic steatosis is its high level of adiponectin, compared to dSAT (21). Adiponectin has been 
considered to be able to protect hepatocytes from TG accumulation, probably by increasing 
β-oxidation of FFA and/or decreasing de novo FFA production within hepatocytes (38, 39). 
Adipocytes in sSAT may have an increased cell size because they have an increased ability for 
fatty acid storage. In contrast, the presence of smaller cells in dSAT may be a reflection of their 
relative impairment to store fat, subsequently leading to inflammation and stress signals (40). 
In addition, dSAT and sSAT have different mRNA expression of inflammatory, lipogenic and 
lipolytic target genes (21, 29); ADIPOR1, an mRNA expression of adiponectin, is higher in sSAT 
compared with dSAT, while the mRNA expressions of leptin, hormone sensitive lipase and 
lipoprotein lipase (LPL) showed higher expression levels in dSAT compared with sSAT. The 
expression of genes involved in inflammatory pathways, such as interleukin-6 and MCP1, and 
genes involved in fatty acid synthesis, such as FASN, are higher in dSAT compared with sSAT 
(21, 29). In addition, Walker et al. also found an intermediate phenotype of dSAT with respect 
to the gene expression profiles of 11beta-HSD1, leptin and resistin (41).  
 
Based on the multivariate correlations between the abdominal adipose tissue compartments 
and the circulating concentrations of the metabolic parameters glucose, TG and HDL-c, dSAT 
seems to be an intermediate phenotype between sSAT and VAT, especially in men. This finding 
in men has been described earlier by Marinou et al. (29). In their study, fasting glucose was 
only associated with dSAT in men. Another study showed that both VAT and dSAT were 
associated with insulin-stimulated glucose utilization, HDL-c and TG, while sSAT showed 
weaker association with all these parameters (42). This study performed also no sex-stratified 
analysis. 
 
The main strength of our study is the large population size, which enabled us to investigate 
the differences between women and men. The assessment of both adipose tissue 
compartment volumes and hepatic fat content by MRI is another strength of the present study. 
Our study also has a number of limitations. Because of the cross-sectional design, no causal 
interpretations can be made of the associations observed. We only included participants of 
Western European ancestry, which precludes extrapolation of our results to other ethnic 
groups. As we included individuals who were 55-80 years of age and all women were 
postmenopausal, our results cannot be extrapolated to other age groups. Next to this, we only 
included individuals with overweight and obesity which could weaken the strength of the 
associations found in comparison to analyses of cohorts including subjects across a wide range 
of BMI. 
 
In conclusion, VAT as measured by MRI is positively correlated with hepatic steatosis in 
women and men. Men have relatively more dSAT compared to women, and only in men, dSAT 
correlated positively with hepatic fat content. Moreover, dSAT in men associated negatively 
with HDL-c in multivariate analyses; while in women with obesity sSAT correlated negatively 




sSAT and VAT. Therefore in future studies it is important to distinguish between dSAT and 
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Women have more subcutaneous adipose tissue and less visceral adipose tissue than men. 
The aim of our study was to determine whether these differences in body fat distribution 




We recruited 285 individuals with a BMI≥27 kg/m2, aged 55-81 years. Abdominal magnetic 
resonance imaging was performed around level L4-L5 to measure visceral adipose tissue 
(VAT), deep subcutaneous adipose tissue (SAT) and superficial SAT volumes. Circulating 
cytokines, leukocyte count and differentiation were measured and peripheral blood 
mononuclear cells (PBMCs) were stimulated ex vivo. Adipose tissue biopsies were taken from 
the superficial SAT and analysed for histology and gene expression of inflammatory genes. 
 
Results 
In women, SAT volumes showed positive associations with leukocyte number, monocytes and 
circulating IL-6, hsCRP and IL-18BP. In addition superficial SAT was positively associated with 
IL-6 and IL-1Ra production of stimulated PBMCs in women. Next to that, the gene expression 
level of different pro-inflammatory genes were related mainly to the volume of the superficial 
SAT in women. In contrast in men, VAT was positively associated to leukocyte number, 
circulating IL-6, hsCRP and IL-18BP. To investigate whether this association originates from the 
adipose tissue itself, we characterized adipocyte cell size and gene expression and found in 
men a positive association between the adipocyte cell size, VAT and SAT. 
 
Conclusion 
In an overweight and obese cohort, in women, SAT is the main contributing adipose tissue 
compartment for the low-grade inflammatory status. While in men mainly VAT is positively 





Fat distribution is known to play an important role in the propensity of an individual to develop 
CVD, for instance increased visceral adipose tissue (VAT) is related to an increased 
cardiovascular risk (1). Importantly, fat distribution is sex-specific, women tend to have less 
VAT and more subcutaneous adipose tissue (SAT). Chronic low-grade inflammation in the 
adipose tissue has been proposed to be one of the causal links  between obesity and 
atherosclerosis (2). Although this inflammation is present in low levels, even these modest 
increases in circulating inflammatory mediators have been strongly associated with the 
development of type 2 diabetes and CVD (3, 4). The CANTOS trial showed that inhibiting the 
pro-inflammatory cytokine IL-1β by canakinumab, reduces cardiovascular death, non-fatal 
myocardial infarction and non-fatal stroke (5). Very recently, the anti-inflammatory drug 
colchicine has also shown to reduce the risk of cardiovascular events in individuals with 
chronic coronary disease (6). These studies confirmed that chronic low-grade inflammation is 
a causal factor in the progression of atherosclerosis.   
We have previously shown sex-specific patterns in obesity-associated inflammation during 
metabolic dysregulation. Women with obesity-induced metabolic dysregulation were 
characterized by a deficiency of the anti-inflammatory adiponectin, whereas men with the 
metabolic syndrome have higher levels of the pro-inflammatory IL-6 and leptin (7). We also 
found in women that adiponectin was negatively associated with increased adipose tissue 
inflammation. In contrast in men, adipose tissue inflammation was only positively associated 
with circulating leptin and IL-6 only. This suggests a sex-specific role for adipose tissue on the 
obesity associated low-grade inflammatory state. Until now most studies investigating the 
effects of fat distribution on chronic low-grade inflammation have been performed in men. 
Therefore the aim of the study presented here was to investigate sex-specific differences in 
the association between the various fat compartments and measures of systemic 




Study population  
We enrolled 302 individuals aged between 55 to 80 with a BMI above 27 kg/m2 at screening 
in the 300-Obesity (300-OB) cohort study at the Radboud university medical center as 
previously described (7). Subjects with a recent cardiovascular event (MI, transient ischemic 
attack, stroke < 6 months), a history of bariatric surgery or bowel resection, inflammatory 
bowel disease, renal dysfunction, increased bleeding tendency, use of oral subcutaneous anti -
coagulant therapy, use of thrombocyte aggregation inhibitors other than acetylsalicylic acid 
and carbasalate calcium were excluded. All subjects filled out questionnaires about lifestyle 
and medication use. All lipid-lowering medication, when used, were discontinued for four 
weeks prior to the measurements. All participants received detailed printed and oral 
information and provided written informed consent. The study was approved by the Ethical 
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Committee of the Radboud University (nr. 34462.091.10). Experiments were conducted 
according to the principles expressed in the Declaration of Helsinki. 
 
MRI data acquisition 
As previously described (8), abdominal fat distribution were determined by magnetic 
resonance imaging (MRI). A 3.0 T Magnetom Skyra or Trio MR system (Siemens, Erlangen, 
Germany) was used to perform the MR examinations. Individuals were examined in the supine 
position with their arms positioned parallel to the lateral sides of the body. At the L4-L5 level, 
sixteen axial T1-weighted MRI slices of 0.5cm were acquired for each subject. Breathing 
commands were used to avoid motion-induced artifacts. 
 
VAT, SAT, sSAT and dSAT analysis 
The images acquired were retrieved from the MR scanner and analyzed with software 
developed in the IDL 6.0 environment, called HIPPO FAT (version 1.3, V. Positano) (9). Due to 
the T1-weighting, fatty tissues are represented with signal intensity in these images. 
VAT, SAT, dSAT and sSAT volumes were measured on 8 separate slices around the L4-L5 
intervertebrate level, with an interslice distance of 5 mm. HIPPO FAT automatically generates 
three contour lines at each image provided by an active fuzzy clustering algorithm (10) that 
allowed the separation of SAT from VAT: (1) along the outer margin of the SAT, (2) along the 
inner margin of the SAT and (3) around the smallest possible region in the visceral region that 
included all VAT. A histogram of signal intensities in the VAT region was provided, in which a 
Gaussian curve automatically fitted the high-intensity peak, which identified the visceral fat.  
After automatic segmentation, the analyst (TB), if necessary, manually adjusted both the 
contour lines and the shape of Gaussian curve by eyeballing. The MRI scan allows visualization 
of the scarpa fascia as a fine black line. A line was drawn manually over the scarpa fascia to 
divide sSAT from dSAT. Adipose tissue pixels between this line and the outer margin of the 
SAT were defined as sSAT. dSAT was calculated by the total subcutaneous adipose tissue pixels 
minus the superficial subcutaneous adipose tissue pixels (dSAT = SAT – sSAT).  
 
Biochemical analyses  
Biochemical characteristics were determined as described previously (7). Blood sampling was 
performed in the morning after an overnight fast. Blood glucose, triglycerides (TG) and high-
density lipoprotein cholesterol (HDL-c) were measured using standard laboratory procedures. 
Cell count data - Immune cell counts were determined in fresh whole blood EDTA samples 
using the Sysmex XE-5000. 
Circulating cytokines - Plasma concentration of circulating cytokines were determined using 
enzyme-linked immunosorbent assays (ELISA).  
 
Stimulation experiments 
PBMC stimulation experiments - Isolation of peripheral blood mononuclear cells (PBMCs) was 
performed as described in Oosting et al (11). 
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Whole blood stimulation experiments - A volume of 100 μl of heparin blood was added to a 48 
well plate (Corning) containing 400 µl stimulus (final volume 500ul/well) for 48 hours at 37°C 
and 5% CO2.  
ELISA analysis - Cytokine concentrations after stimulation were measured using commercially 
available ELISA kits.  
 
Stimuli and cytokines  
Table 1 in the supplementary material lists the concentrations of the stimuli used. The choice 
of pro-inflammatory mediators was based on the extensive body of evidence linking cytokines 
and adipokines to inflammation and CVD complications. Stimulation of PBMCs was performed 
with a comprehensive set of stimuli containing both purified innate immune stimuli that are 
associated with chronic inflammation (e.g. LPS, oxidized low-density lipoprotein (LDL)) and 
microorganism that are the source of microbial ligands that translocate in the circulation at 
the intestinal level. Interleukin (IL)-1β, IL-6, TNF-α, and IL-1Ra were measured after 24-hour 
stimulation with these stimuli. After 7 days of stimulation for C. albicans and S. aureus, IFN-γ, 
IL-17, and IL-22 were measured. 
 
Protein measurements  
Circulating plasma inflammatory markers were measured as previously described (12). In 
short, we used the commercially available Olink Proteomics AB (Uppsala Sweden) 
Inflammation Panel (92 inflammatory proteins), using a Proceek © Multiplex proximity 
extension assay (13). In this assay proteins are recognized by pairs of antibodies coupled to 
cDNA strands, which bind when they are in close proximity and extend by a polymerase 
reaction. A pooled plasma sample and an interplate control were included on each plate in 
triplicate to correct for batch differences. Detected proteins are normalized and measured on 
a log2-scale as normalized protein expression values. 
 
Adipose tissue analysis 
After an overnight fast, subcutaneous adipose tissue biopsies were obtained under local 
anaesthesia by needle biopsies performed 6-10cm lateral to the umbilicus in the right lower 
quadrant.  
Adipocyte size - The morphometry of individual fat cells was assessed using digital image 
analyses as described previously (14). For each participant, the adipocyte cell diameters of all 
adipocytes in four microscopic fields of view were counted and measured. On average, 219 
adipocytes (range 113 - 330) were measured per field. 
Immunohistochemistry - To detect macrophages, adipose tissue sections were incubated with 
a CD68-monoclonal antibody (Serotec, Oxford, UK). Sections were preincubated with 20% 
normal horse serum followed by overnight incubation at 4 °C with the primary antibody 
diluted 1:40 in phosphate-buffered saline, 1% bovine serum albumin. After incubation with 
the primary antibody (mouse anti-human), a horse anti-mouse IgG conjugated to horseradish 
peroxidise (Vector labs brunschwig) was used as a secondary antibody. Visualization of the 
48 
 
complex was done using 3,3’-diaminobenzidene for 12 min. Negative controls were used by 
omitting the primary antibody. Hematoxylin and eosin staining of sections was done using 
standard protocols. The percentage of macrophages was expressed as the total number of 
macrophages divided by the total number of adipocytes counted in 15 random microscopic 
fields of view. A crown-like structure was defined as an adipocyte surrounded by at least three 
macrophages (15). 
Adipose tissue inflammation score – To robustly quantify adipose tissue inflammation among 
study participants using histology, several parameters were assessed and combined into an 
adipose tissue inflammation score (AT score), as the phenotype by which inflammation in the 
adipose tissue presents is quite heterogenous (16, 17). This assessment led to a score including 
following parameters: a mean adipocyte diameter above the average diameter of the cohort 
(> 51.7um (mean diameters in the 300-OB cohort) was 
defined as one point in the AT score, the percentage of 
macrophages above the average of the cohort (> 
12.6% (mean in the 300-OB cohort) was defined as one 
point in the AT score  and the presence of crown-like 
structures (CLS) was defined as one point in the AT 
score. Hence, the adipose tissue inflammation score 
could ranges from 0 (no inflammation) to 3 (severely 
inflamed) (as shown in Figure 1).  
Figure 1 – Immunohistochemically illustration by CD68 staining of individual with a high level 
of adipose tissue inflammation, a crown-like structure is indicated by an arrow (adipose tissue 
score 3; mean adipocyte diameter of 60 um, 13% CD68 cells present and 5 crown-like structures 
in the analysed fields).  
 
RNA isolation and qPCR analysis – Total RNA was isolated from adipose tissue using Trizol 
reagent (Invitrogen) according to the manufacturer’s instructions. Concentrations and purity 
of RNA samples were determined on a NanoDrop 1000 spectrophotometer (Thermo Fisher 
Scientific, Landsmeer, The Netherlands). In total 1μg of RNA was used for reverse transcription 
using the iScript cDNA Synthesis Kit (Bio-Rad). Real-time PCR was done to study the mRNA 
expression levels of leptin, adiponectin, CD68, MCP-1, IL-1α, IL-1Ra, IL-18, IL-18BP, IL-18Rα, IL-
18Rβ and IL-37. The gene expression of IL-1Ra, IL-18, IL-18BP and IL-18Ra were present in low 
quantities in the majority of the individuals, as completion of the standard curve was not 
possible, we did not include these genes in our analyses. The  sequence-specific primer pairs 
of the other genes are listed in Table 2 in the supplementary material. qPCR was performed 
by platinum Taq polymerase (Invitrogen) and SYBR Green using an iCycler PCR machine (Bio-
Rad). Melt curve analysis was included to assure a single PCR product was formed. The mRNA 








Correlations and corresponding p-values were calculated using the rank-based Spearman 
correlation as implemented in the “cor.test()” function of the “R” programming language (R 
Foundation for Statistical Computing, Vienna, Austria).  
Regression analysis was performed using the ‘lm’ function, which is part of the ‘stats’ package, 
as implemented in the ‘R’ language. Before the regression analysis, the circulating cytokines 
of inflammation and were normalized using logarithmic transformation to get a distribution 
more closely resembling a normal distribution. Multiple testing correction was performed 
using the Benjamini – Hochberg False Discovery Rate method as implemented in the 
“p.adjust” function of the “stats” package in the R programming language (18). Standardized 
regression Coefficients (β) were calculated based on objects of class ‘lm’ using the ‘lm.beta’ 
function part of the ‘QuantPsyc’ package in the R programming language. The covariates 




The 300-OB cohort consists of 302 individuals of Western-European ancestry with a BMI 
higher than 27 kg/m2. We were unable to acquire MRI data in fourteen individuals, as seven 
individuals were claustrophobic and in seven individuals the MRI data were insufficient to 
calculate any abdominal adipose tissue volumes (mostly due to movement artefacts). So in 
total 128 women and 160 men were selected for these analyses. Incomplete MRI data were 
obtained from eleven individuals as we could not calculate VAT volumes due to low quality 
images. Baseline characteristics are shown in Table 1. There were no significant differences 
between women and men with regard to age, BMI, antihypertensive, lipid-lowering and 
antidiabetic drugs. Tobacco use was significantly higher in men.   
 
Sex differences in adipose tissue distribution 
BMI did not differ between women (30.5 kg/m2) and men (31.0 kg/m2). Women had significant 
more total abdominal fat, the sum of VAT and SAT, (288 cm3 vs 257 cm3, p < 0.0001) and more 
hip subcutaneous fat (158 cm3 vs 88 cm3, p < 0.0001). With regard to the separate abdominal 
adipose tissue compartments, women had less VAT (99 cm3 vs 123 cm3, p < 0.0001), but more 
superficial SAT (97 cm3 vs 49 cm3, p < 0.001) and slightly more deep SAT and 98 cm3 vs 87 cm3, 










  Total  
(n = 288) 
Women  
(n = 128) 
Men 
 (n = 160) 
P-value 
Age (y) 67.1 +/- 5.3 67.5  +/- 5.2 66.6  +/- 5.3 Ns 
BMI (kg/m2) 30.6 +/- 3.4 30.8  +/- 3.6 30.4  +/- 3.2 Ns 
WC (cm) 106.2 +/- 9.6 102.5  +/- 9.4 109.1  +/- 8.7 P < 0.001 
Pack years 15.1 +/- 18.4 12.0  +/- 16.9 17.6  +/- 19.2 P = 0.10 
Total cholesterol (mmol/L) 6.3 +/- 1.1 6.6  +/- 1.0 6.0  +/- 1.1 P < 0.001 
LDL-c (mmol/L) 4.1 +/- 1.0 4.4  +/- 0.9 3.9  +/- 1.0 P < 0.001 
HDL-c (mmol/L) 1.3 +/- 0.3 1.5  +/- 0.3 1.2  +/- 0.3 P < 0.001 
TG (mmol/L) 1.8 +/- 1.0 1.8  +/- 0.8 1.9  +/- 1.1 Ns 
SBP (mmHg) 129.6 +/- 13.9 129.9  +/- 14.6 129.2  +/- 13.3 Ns 
DBP (mmHg) 79.9 +/- 8.9 77.8  +/- 8.3 81.7  +/- 9.0 P < 0.001 
Glucose (mmol/L) 5.7 +/- 1.3 5.7  +/- 1.3 5.7  +/- 1.3 Ns 
Diabetes mellitus  (%) 11.5% 10.1% 12.5% Ns 
Hypertension (%) 59.7% 54.7% 63.8% Ns 
Lipid lowering med. (%) 25.4% 21.1% 28.9% Ns 
Antihypertensive med. (%) 44.8% 43.8% 45.6% Ns 
Antidiabetic med.(%) 8.0% 6.3% 9.4% Ns 
hsCRP (ug/mL) 2.95 +/- 3.21 3.65  +/- 3.73 2.39  +/- 2.61 P < 0.001 
IL-6 (pg/mL) 3.37 +/- 5.02 3.62  +/- 5.96 3.18  +/- 4.11 Ns 







IL-18BP (ng/ml) 1.77 +/- 0.55 1.79 +/- 0.57 1.75 +/- 0.53 Ns 
Table 1 - Baseline characteristics of 300-Obesity Cohort presented as mean +/- standard 
deviation or n (%) in total cohort, women and men. WC: waist circumference; TG: Triglycerides; 
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; Ns Not significant. 
 
Contribution of adipose tissue compartments to systemic inflammation is sex-specific  
Relation to white blood cell count and components 
One of the markers of systemic low-grade inflammation is a high white blood cell count of 
which especially the monocytes and neutrophils play a key role in the progression of 
atherosclerosis (19). In women, no significant relation was present between the VAT volume 
and total leukocyte count or individual components. However, there was a strong association 
present between the SAT with the total leukocyte count. Looking at the leukocyte subtypes, 
the association with monocytes was the strongest with a stand. β of 0.34, p < 0.0001. 
Significant positive associations with total SAT were also present for neutrophils and basophils 
(see Table 2). In contrast, in men not SAT but VAT was positively associated with the leukocyte 
count. Further subdividing this into the individual leukocyte subtypes, in men no associations 
are present anymore. To summarize, in women SAT was positively associated with leukocyte 






  VAT SAT sSAT dSAT SAT_hip VAT+SAT 
leukocytes 0.13 0.24 0.24 0.13 0.15 0.23 
lymfocytes 0.06 0.05 0.09 -0.03 0.05 0.05 
neutrophils 0.18 0.23 0.23 0.13 0.13 0.25 
monocytes 0.02 0.34 0.24 0.29 0.23 0.26 
basophils -0.05 0.26 0.18 0.23 0.03 0.20 
eosinophils -0.10 0.04 0.01 0.02 -0.05 -0.02 
 B 
Men 
  VAT SAT sSAT dSAT SAT_hip VAT+SAT 
leukocytes 0.16 0.13 0.12 0.12 0.13 0.17 
lymfocytes 0.10 0.15 0.17 0.12 0.13 0.15 
neutrophils 0.13 0.10 0.07 0.10 0.11 0.12 
monocytes 0.15 0.08 0.06 0.09 0.07 0.11 
basophils 0.03 0.08 0.07 0.08 0.04 0.05 
eosinophils 0.07 -0.03 -0.03 -0.03 0.04 0.04 
 
Table 2 – Heatmap of correlation between different adipose tissue compartment volumes and 
white blood cell count and component in women (A) and men (B). Standardized betas after 
adjustment for age, pack years and season. The intensity of the red and blue colours represent 
the strength of the significance.  
VAT Visceral adipose tissue; SAT Subcutaneous adipose tissue; sSAT Superficial subcutaneous 
adipose tissue; dSAT Deep subcutaneous adipose tissue; SAT_hip Subcutaneous adipose tissue 
at the hip region; VAT+SAT Visceral plus subcutaneous adipose tissue.  
 
Relation to circulating cytokines 
Leptin levels were strongly associated with SAT volumes in both women and men with stand. 
β of 0.60 vs 0.62 respectively, p < 0.0001 (see also Table 3). Adiponectin levels were also sex-
independently associated with VAT and total abdominal fat. For the other cytokines we 
observed significant sex-specific differences in the relation with fat compartments.  
Levels of IL-6 were associated in women only with SAT volume (stand. β = 0.30, p < 0.001), 
whereas in men this related to VAT and SAT (stand. β = 0.30, p < 0.0001). Also for IL-18BP, 
which we have previously shown to be associated with carotid atherosclerosis (van den 
Munckhof et al, under revision), the associations were sex-specific: in men IL-18BP levels were 
related to VAT (stand. β = 0.16 with p < 0.05), while in women these levels were only related 
to the amount of SAT (stand. β = 0.22 with p < 0.001). hsCRP levels showed a comparable 
association with the SAT and VAT volume in women and men. The amount of hip SAT in both 
women and men were significantly related to IL-6 levels (stand. β’s of 0.34 and 0.30 
respectively, p < 0.0001) and weaker, but still significantly, with hsCRP. 
 
P-value 
  P < 0.05 
  P < 0.01 
  P < 0.001 









  VAT SAT sSAT dSAT SAT_hip VAT+SAT 
hsCRP 0.20 0.21 0.20 0.19 0.20 0.23 
IL-6 0.30 0.30 0.27 0.29 0.30 0.36 
IL-18 0.07 0.11 0.10 0.10 0.11 0.08 
IL-18BP 0.16 -0.02 -0.03 -0.01 0.00 0.09 
VEGF 0.01 0.02 0.00 0.03 -0.05 0.01 
AAT -0.05 0.08 0.08 0.08 0.07 0.01 
Resistin -0.11 0.20 0.18 0.19 0.16 0.04 
Leptin 0.38 0.62 0.51 0.60 0.62 0.63 
Adiponectin -0.29 0.05 0.08 0.02 0.05 -0.16 
 
Table 3 - Heatmap of correlation between different adipose tissue compartment volumes and 
a panel of circulating inflammatory mediators in women (A) and men (B). Standardized betas 
after adjustment for age, pack years and season. The intensity of the red and blue  colours 
represent the strength of the significance. VAT Visceral adipose tissue; SAT Subcutaneous 
adipose tissue; sSAT Superficial subcutaneous adipose tissue; dSAT Deep subcutaneous 
adipose tissue; SAT_hip Subcutaneous adipose tissue at the hip region; VAT+SAT Visceral plus 
subcutaneous adipose tissue; hsCRP High sensitivity C-reactive protein; IL- Interleukin-; VEGF 
Vascular endothelial growth factor; AAT Alpha-1 antitrypsin. 
 
Relation to cytokine production capacity 
Cytokine production capacity of PBMC’s is an indicator of the intrinsic inflammatory 
responsiveness and has previously been related to the presence of atherosclerosis (20, 21). 
Production of the pro-inflammatory cytokine IL-6 after stimulation of PBMC’s with C. albicans 
and LPS is associated with the volume of the SAT in women (stand. β 0.25 and 0.17 
respectively, p < 0.01 and p < 0.05 respectively). The production of the anti-inflammatory 
cytokine IL-1Ra after stimulation with C. Albicans are both in men and women positively 
Women 
  VAT SAT sSAT dSAT SAT_hip VAT+SAT 
hsCRP 0.22 0.23 0.21 0.17 0.22 0.27 
IL-6 0.20 0.30 0.28 0.23 0.34 0.30 
IL-18 0.02 0.03 0.00 0.05 0.10 0.03 
IL-18BP 0.10 0.22 0.19 0.17 0.10 0.26 
VEGF 0.12 0.10 0.04 0.13 0.02 0.13 
AAT 0.09 -0.05 0.08 -0.13 0.00 -0.03 
Resistin -0.09 0.08 0.17 -0.03 -0.05 0.02 
Leptin 0.27 0.60 0.48 0.54 0.54 0.58 
Adiponectin -0.35 -0.04 0.02 0.01 0.00 -0.18 
P-value 
    P <  0.05 
    P < 0.01 
    P < 0.001 
    P < 0.0001 
    P < 0.00001 
    P < 0.000001 
    P < 0.0000001 
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associated SAT and total abdominal fat. All associations are shown in Table 3 in the 
supplementary material.  
 
Sex-specific contribution of fat distribution to low-grade inflammation measured with 
proteomics  
In addition to immunophenotyping, the quantification of circulating cytokines levels and 
stimulation experiments, we also measured the proteins levels of 92 different inflammatory 
proteins. After correction for multiple testing, in women 7 proteins were significantly 
associated with adipose tissue volume versus 12 in men  (Table 4). Supporting our other 
findings, most inflammatory proteins were positively related to the amount of SAT in women, 
whereas in men mainly the VAT showed positively associations. Both in women and men the 
strongest associations are seen between SAT and VAT respectively with IL-6, hepatocyte 
growth factor (HGF) and macrophage colony-stimulating factor (M-CSF). In women the 
relation with SAT was almost exclusively for sSAT, while in men the association with IL-6, HGF 




  VAT SAT sSAT dSAT SAT at hip VAT+SAT 
HGF 0.33 0.35 0.34 0.22 0.24 0.42 
M-CSF1 0.10 0.32 0.41 0.14 0.30 0.33 
IL-6 0.19 0.32 0.32 0.23 0.31 0.34 
TNF-r sm9 0.14 0.30 0.34 0.18 0.13 0.35 
C-CMC19 0.19 0.26 0.24 0.19 0.17 0.32 
IL-12B 0.22 0.23 0.25 0.14 0.22 0.36 
C-CMC20 0.31 0.07 0.12 0.00 0.12 0.21 
B 
Men 
  VAT SAT sSAT dSAT SAT at hip VAT+SAT 
IL-6 0.26 0.27 0.22 0.26 0.30 0.31 
HGF 0.31 0.19 0.08 0.23 0.10 0.30 
M-CSF1 0.26 0.23 0.17 0.23 0.17 0.29 
C-CMC19 0.23 0.21 0.15 0.20 0.20 0.27 
TNF-l sm14 0.23 0.18 0.07 0.21 0.18 0.25 
IL-18R1 0.26 0.10 -0.01 0.14 0.10 0.22 
FGF-21 0.25 0.06 -0.04 0.10 0.09 0.21 
 
Table 4 – Heatmap of correlation between top 7 protein levels in relation to different adipose 
tissue compartment volumes in women (A) and men (B). Standardized betas after adjustment 
for age, pack years and season and multiple testing. The intensity of the red colour represent 
the strength of the significance. VAT Visceral adipose tissue; SAT Subcutaneous adipose tissue; 
P-value 
  P < 0.05 
  P < 0.01 
  P < 0.001 
  P < 0.0001 
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sSAT Superficial subcutaneous adipose tissue; dSAT Deep subcutaneous adipose tissue; 
SAT_hip Subcutaneous adipose tissue at the hip region; VAT+SAT Visceral plus subcutaneous 
adipose tissue; HGF Hepatocyte growth factor; M-CSF1 Macrophage colony-stimulating factor 
1; IL- Interleukin-; TNF-r sm9 Tumor necrosis factor- receptor superfamily member 9; C-CMC19 
C-C motif chemokine 19; TNF-l Tumor necrosis factor- ligand; FGF-21 Fibroblast growth factor-
21. 
 
In conclusion, sex-specific differences are present in the relation between the various fat 
compartments with inflammatory mediators. The mechanism behind this difference is not yet 
known. As adipose tissue inflammation is an hallmark of chronic low-grade inflammation, we 
took fat biopsies from the sSAT in all our individuals and investigated the relation between the 
fat distribution and markers of adipose tissue inflammation.  
 
Sex-specific adipose tissue distribution in relation to adipose tissue inflammation 
We only found a higher expression level of leptin in the adipose tissue biopsies in women 
compared to men. Furthermore, no significant differences were found between women and 
men in the histology and gene expression profiles. When focusing on the relation of sSAT, of 
which the fat biopsies were taken, we found increased expression in women with increasing 
volume of sSAT, both for the pro-inflammatory leptin and TNF-alpha, as for the anti-
inflammatory adiponectin and the macrophage-marker CD68 (Table 5). In men, the gene 
expression of some cytokines were also related to the volume of sSAT, although less strongly. 
The size of adipocytes however showed quite strong associations with mainly the volume of 




 Histology VAT SAT sSAT dSAT SAT at hip VAT+SAT 
Adipocyte cell size 0.09 0.11 0.12 0.03 0.11 0.13 
CD68% 0.15 -0.08 0.01 -0.14 -0.02 0.01 
CLS 0.14 -0.18 -0.15 -0.17 -0.17 -0.05 
ATscore 0.09 -0.05 -0.07 -0.05 -0.11 0.00 
              
 Gene expression VAT SAT sSAT dSAT SAT at hip VAT+SAT 
Adiponectin 0.09 0.16 0.21 0.06 0.21 0.23 
Leptin 0.05 0.28 0.25 0.21 0.20 0.22 
CD68 0.18 0.18 0.26 0.04 0.24 0.28 
MCP-1 0.07 -0.11 -0.11 -0.08 -0.11 -0.08 
TNF-α 0.15 0.15 0.21 0.04 0.18 0.23 
IL-1α 0.14 0.15 0.21 0.04 0.15 0.22 
IL-18Rβ 0.16 0.17 0.21 0.06 0.17 0.23 





 Histology VAT SAT sSAT dSAT SAT at hip VAT+SAT 
Adipocyte cell size 0.16 0.30 0.22 0.31 0.27 0.30 
CD68% 0.05 0.03 0.05 0.02 0.02 -0.04 
CLS 0.00 -0.10 -0.18 -0.04 -0.07 -0.11 
ATscore 0.12 0.04 -0.05 0.08 0.05 0.11 
              
 Gene expression VAT SAT sSAT dSAT SAT at hip VAT+SAT 
Adiponectin -0.01 0.04 0.15 -0.02 0.06 0.01 
Leptin 0.11 0.10 0.14 0.07 0.18 0.15 
CD68 0.08 0.02 0.11 -0.03 0.04 0.05 
MCP-1 0.15 0.02 0.03 0.02 0.10 0.09 
TNF-alpha 0.04 0.07 0.15 0.02 0.02 0.06 
IL-1alpha 0.04 0.08 0.18 0.02 0.06 0.06 
IL-18Rβ 0.07 0.07 0.16 0.02 0.05 0.08 
IL-37 0.05 0.07 0.16 0.02 0.04 0.07 
 
Table 5 –  Heatmap of correlation between adipose tissue 
histology and adipose tissue gene expression of different 
adipokines and pro- and anti-inflammatory (after normalization to 
Ribosomal Protein L37a (RPL37A) gene expression) and different 
adipose tissue compartment volumes in women (A) and men (B). 
Standardized betas after adjustment for age, pack years and 
season. The intensity of the red and blue colours represent the 
strength of the significance. VAT Visceral adipose tissue; SAT Subcutaneous adipose tissue; 
sSAT Superficial subcutaneous adipose tissue; dSAT Deep subcutaneous adipose tissue; 
SAT_hip Subcutaneous adipose tissue at the hip region; VAT+SAT Visceral plus subcutaneous 
adipose tissue; CLS Crown-like structure; ATscore Adipose tissue score; MCP-1 Monocyte 
Chemoattractant Protein 1; TNF- Tumor necrosis factor-α; IL- Interleukin-; IL-18Rβ Interleukin-
18Receptor β. 
 
We previously reported that in women adiponectin was negatively associated with the AT 
score, while in men adipose tissue inflammation was positively associated with circulating 
leptin and IL-6 (7). We now expanded these analysis to all circulating markers and found that 
the relation between the AT score and adiponectin was dependent on the adipocyte cell size 
and number of crown-like structures. In women only IL-18 showed a positive association with 
the adipocyte cell size and AT score. The relation between the AT score and leptin in men, was 





    P < 0.05 
    P < 0.01 
    P < 0.001 





  hsCRP IL-6 IL-18 IL-18BP VEGF AAT Resistin Leptin Adiponectin 
Adipocyte cell size -0.02 -0.11 0.21 0.06 0.03 0.18 0.01 0.06 -0.21 
CD68% 0.03 0.16 0.11 0.07 -0.11 0.12 0.13 0.01 -0.12 
CLS -0.03 0.04 0.17 0.05 -0.01 0.17 -0.07 -0.13 -0.19 
ATscore -0.03 0.03 0.26 0.08 0.05 0.06 0.06 -0.05 -0.28 
B 
Men 
  hsCRP IL-6 IL-18 IL-18BP VEGF AAT Resistin Leptin Adiponectin 
Adipocyte cell size 0.03 0.11 0.02 0.01 0.19 0.00 0.05 0.37 -0.04 
CD68% 0.13 0.08 0.15 0.08 -0.11 0.07 0.04 0.13 -0.14 
CLS 0.15 0.14 -0.16 -0.01 -0.04 0.01 -0.03 0.08 -0.09 
ATscore 0.18 0.25 0.09 0.12 0.07 0.08 0.07 0.22 -0.16 
 
P-value 
    P < 0.05 
    P < 0.01 
    P < 0.001 
    P < 0.0001 
    P < 0.00001 
    P < 0.000001 
 
Table 6 – Heatmap of correlation between different adipose tissue inflammation histological 
parameters and circulating cytokines in women (A) and men (B). Standardized betas after 
adjustment for age, pack years and season. The intensity of the red and blue colours represent 
the strength of the significance. CLS Crown-like structure; ATscore Adipose tissue score; hsCRP 
High sensitivity C-reactive protein; IL- Interleukin-; VEGF Vascular endothelial growth factor; 
AAT Alpha-1 antitrypsin. 
 
DISCUSSION 
In the present study, we found clear sex-specific differences in the association between 
adipose tissue distribution, markers of chronic low-grade inflammation, and adipose tissue 
inflammation in overweight and obese individuals. We observed that in women SAT is mainly 
related to white blood cell count, circulating levels of inflammatory markers (hsCRP, IL-6 and 
IL-18BP) and higher levels of the production of pro-inflammatory cytokines after ex vivo 
stimulation experiments. We also found that SAT, mainly sSAT, was related to higher levels of 
the proteins IL-6, HGF and M-CSF. In contrast, in men VAT showed the strongest association 
with the number of leukocytes, whereas VAT and SAT were equally associated with circulating 
cytokines (hsCRP and IL-6). The relation with protein levels of IL-6, HGF and M-CSF was 
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significant positive with VAT volume and dSAT, but not sSAT, in men. This suggests that the 
hypothesis about a beneficial effect of SAT appears not to be applicable to women, at least 
not to women with overweight or obesity. We hypothesized that the possible mechanism 
behind this sex-specific difference would be present in the adipose tissue itself. We therefore 
took adipose tissue biopsies and analyzed them histologically and performed analysis on the 
expression of RNA. Indeed, in women the volume of sSAT showed a stronger association to 
the tissue expression level of inflammatory proteins, such as CD68 and TNF-α, than in men. In 
addition, as previously described we found significant sex-specific differences in the relation 
between the adipose tissue histology, in which in women the AT score was negatively related 
to adiponectin, while in men adipose tissue inflammation was related to leptin, hsCRP and IL -
6. In the current analysis we found in women a positive association between IL-18 and the AT 
score, which was not found in men. These findings call for a sex-specific approach with regard 
to interpretation of adipose tissue distribution and its contribution to low-grade inflammation.  
 
A number of studies investigated the contributing role of VAT and SAT on markers of low-
grade inflammation (22-25). However, a sex-stratified analysis to investigate sex-specific 
differences in the association between fat distribution and systemic inflammation was 
performed only in a minority of studies. A larger contribution of SAT to a pro-inflammatory 
status in women has previously been described. In a group of 145 healthy women and 208 
healthy men a mean age of 36.8 years and 42.2 respectively, and mean BMI of 26.6 and 26.0 
kg/m2 respectively, CRP levels were higher in women. Whereas the CRP concentrations in men 
were largely influenced by VAT, SAT was the key correlate of CRP in women (26). We extend 
these finding by showing that these sex differences in the role of different fat compartments 
are not only restricted to systemic inflammatory markers such as CRP, but can be found for 
different parameters of inflammation, including circulating leukocyte counts and an extensive 
panel of circulating inflammatory markers. The strong association in both women and men 
between SAT and VAT respectively with M-CSF and HGF suggest a possible relation between 
the adipose tissue and bone marrow. Both the M-CSF and HGF have been shown to be 
produced in the adipose tissue (27, 28). Possibly in women the leukocytes/monocytes that are 
present in the SAT  could produce M-CSF and HGF, which stimulates the bone marrow to 
produce more pro-inflammatory cells, while in men mainly the leukocytes in the VAT are 
responsible for this upregulation. A previous study has shown that obesity is associated with 
HGF (27). A recent study suggested that HGF inhibits the vicious cycle of adipocytes and 
macrophages through the inhibition of macrophage-mediated pro-inflammatory cytokines 
and upregulation of adiponectin in adipocytes (29). M-CSF on the other hand has long been 
known to play a role in adipocyte hyperplasia and the physiological regulation of adipose 
tissue growth (28). Maybe the sex-specific differences between fat distribution and 
inflammatory markers originates partly from differences in adipose tissue production of M-
CSF and HGF in SAT and VAT in women and men. 
The relation that SAT in women and VAT in men are respectively the most important fat 
compartment for a pro-inflammatory status is also supported by another large study 
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investigating a cohort of 4,261 women and men, aged 25-70 years. They found that a 
considerably higher percentage of variability in inflammatory markers was explained by body 
composition in women compared to men (30). One limitation is that the fat measurements 
were performed via bioelectric impedance. For IL-6, waist circumference explained in both 
women and men the highest percentage of variability. As it has been shown previously that 
WC in men is mainly influenced by VAT, whereas in women WC is mainly determined by the 
amount of SAT (31), this would suggest a higher contribution of SAT to IL-6 in women. 
However, conflicting data with regard to the contributing role of VAT and SAT to low-grade 
inflammation has been reported. In 1250 patients from the Framingham Heart risk study, VAT 
and SAT contributed similarly to CRP in women and men, while the contribution of both 
compartments in women was higher compared to men (32). Another large cohort of healthy 
elderly (Health ABC) found that after correction for BMI, VAT was most consistently associated 
with higher IL-6 and CRP concentrations in both women and men (33). However, as BMI is part 
of the causal chain of the relation between VAT, SAT and low-grade inflammation, we did not 
adjust for BMI as a confounding factor. When concentrating on this relation in the Health ABC 
study, SAT showed comparable associations as VAT to CRP and IL-6 levels in women, while in 
men SAT was only significantly related to CRP in black men.  
 
Etiology of systemic low-grade inflammation 
A contributing role of adipose tissue to inflammation was discovered by Hotamisligil et al. and 
colleagues more than 25 years ago. They found increased mRNA and protein levels of TNF-α 
in epididymal adipose tissue of rodent models of obesity and diabetes(34). Since then a 
growing body of evidence has shown a prominent role for low-grade inflammation in the 
pathogenesis of atherosclerosis. The current hypothesis on the obesity-associated low-grade 
inflammation and further cardiovascular risk states that fat mass expands due to a positive 
energy balance, which leads to adipocyte hypertrophy and finally to local hypoxia at adipocyte 
level. This leads to an altered secretion of adipokines and induces cell death, which provokes 
a pro-inflammatory reaction of both adipocytes and surrounding immune cells. During a 
healthy state, the adipose tissue constitutes for ~50% adipocytes and ~50% other cells as 
preadipocytes, endothelial cells, and mainly M2 macrophages (35). During obesity other 
inflammatory cells are attracted and cytokines produced by TH1 lymphocytes or bacterial 
products as LPS can mature the macrophages to a pro-inflammatory M1 macrophage (36). 
Both the adipocytes and the macrophages are important for cytokine production and probably 
act synergistically to amplify local inflammation (37). There are two important players in the 
pro-inflammatory process. The first is the inflammasome, which consists of intracellular 
sensor molecules, of which the NOD-like receptor family pyrin domain containing-3 (NLRP3) 
is one of the most important ones (38). The exact triggers for NLRP3 activation are not fully 
clear, but free fatty acids, reactive oxygen species, glucose, LPS and oxidized LDL-cholesterol 
among others have been demonstrated (39, 40). This results in caspase-1 activation, which 
cleaves multiple proteins, including pro-interleukin(IL)-1β and pro-IL-18, which then become 
biologically active (41). Caspase-1 and these cytokines have been shown to play a crucial role 
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in insulin resistance and adipocyte differentiation(42). The importance of the inflammasome 
has recently been demonstrated by the CANTOS trial. Inhibition of IL-1β by canakinumab in 
subjects with a previous myocardial infarction reduced the incidence of cardiovascular death, 
non-fatal myocardial infarction and non-fatal stroke during their 3.5 year follow-up (5). The 
second important player in the obesity-associated low-grade inflammation process is the 
production of adipokines. Next to the production of pro-inflammatory cytokines by the 
adipocytes and inflammatory cells, the adipocytes produce several kind of adipokines such as 
leptin and adiponectin. Leptin shows a linear relation with body fat. As SAT constitutes 
normally ~80% of the body fat, this explains the high relation between leptin and SAT (43). 
Leptin is a pro-inflammatory adipokine that regulates body weight by signaling nutritional 
status to other organs, especially the hypothalamus that then produces neuropeptides which 
modulate food intake and energy expenditure (44). Leptin acts pro-inflammatory via 
macrophages, T cells, and other immune cells to stimulate the production of a wide spectrum 
of cytokines (44, 45). Leptin levels are seldom used in clinical care, as individuals with obesity 
are resistant to leptin due to hyperleptinemia. Adiponectin has been shown to have different 
anti-inflammatory actions: it suppresses TNF-α production in obese mice; it can enhance the 
clearance of apoptotic cells by facilitating their opsonization and uptake by macrophages and 
has been shown to decrease NFκB activity leading to reduced monocyte adhesion to 
endothelial cells (44). The adiponectin levels are negatively associated with adiposity and 
fasting glucose (46). Circulating levels of adiponectin and leptin are in general higher in women 
than in men. This is at least partly caused by a higher percentage of adipose tissue in women 
(47). We found that adiponectin showed the strongest negative association with the adipose 
tissue score in women, while in men the strongest association was found between the 
adipocyte cell size with leptin. This is in line with our previous finding that overweight women 
with the metabolic syndrome are mainly characterized by a deficiency of the adiponectin, 
while men with the metabolic syndrome have a pro-inflammatory phenotype with increased 
levels of IL-6 and leptin (7). 
 
As shown above, the adipose tissue plays a crucial role in obesity associated systemic low-
grade inflammation in obesity. We therefore also took fat biopsies from the sSAT. We first 
examined whether the volume of the sSAT is associated with histological markers of tissue 
inflammation. In men, we found a significant association between the adipocyte cell size with 
the volume of sSAT, but also with the VAT and dSAT volume. This is in line with previous studies 
that found that men have a more hypertrophic type of white adipose tissue expansion 
compared to women (48). In contrast in women, while no association was seen with the 
histology at all in women, a stronger positive association is seen with the upregulation of 
multiple pro-inflammatory genes. This could explain the possible detrimental effect of sSAT in 







In addition to possible sex-specific differences that are present within the adipose tissue, the 
hormonal status has previously been shown to influence immune function and adipose tissue 
volumes (49). During puberty significant changes appear in body fat percentage and 
distribution. Women show an increase in adipose tissue mass and mainly in the SAT 
compartment, while men show an increase in the lean body mass during these years (50). 
During menopause, the amount of VAT increase in women (51, 52). It is hypothesized that the 
lower estrogen levels play an important causal factor in this body shape development. As all 
our women were post-menopausal, we hypothesize that estrogen would not add much to the 
sex-specific differences in the relation between fat distribution with inflammation. The 
transgender population is an intriguing population to investigate the interaction between 
gender, sex hormones and fat distribution. Transwomen (transformation from male to female) 
develop an increase in fat mass, with significantly more gynoid fat during a 1 year follow up 
study. Transmen (transformation from female to male) showed a significant decrease in total 
fat mass, while the android fat mass stayed the same (53). Another study found that the cross-
sex hormone administration in transwomen resulted in an increase in the SAT of 38%, but also 
an increase in VAT of 18%, while transmen have a reduction in SAT of 22% and increase in VAT 
of 13% (54). These studies underestimate a possible role for sex hormones in the distribution 
of fat, which could influence the relation between fat distribution and low-grade 
inflammation.     
 
Limitations 
Our study has a number of limitations. Due to the cross-sectional design of our study, no causal 
relations can be drawn from our 300-OB study. As we only include individuals of Western 
European ancestry, extrapolation of our results to other ethnic groups are uncertain. 
Furthermore, as we included individuals who were 55-80 years of age and all women were 
postmenopausal, our results cannot be extrapolated to other age groups and a possible role 
of sex hormones cannot be extracted from our data. Lastly, we only included individuals with 
overweight or obesity, this could weaken the strength of the associations found and 
extrapolation to lean individuals is not possible.  
 
Conclusion  
In the present study, we found clear sex differences in the relation between adipose tissue 
distribution and markers of chronic low-grade inflammation in overweight and obese 
individuals. In women SAT was linked to a pro-inflammatory state, also showing increased 
gene expression in the adipose tissue of pro-inflammatory genes. In contrast, in men VAT 
showed the strongest association with pro-inflammatory cells and comparable associations 
with circulating cytokines as SAT in men. In the adipose tissue histology, adipocyte 
hypertrophy was strongly associated to VAT and SAT in men.  
Combined, these findings call for a sex-specific approach with regard to interpretation of 
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24h PBMC stimulations + RPMI 
 
Stimulus 50uL/well Final concentration 
LPS low dose 1,00E+00 ng/mL 
LPS high dose 1,00E+02 ng/mL 
Pam3Cys 1,00E+00 ug/mL 
Candida Albicans Yeast 1,00E+06 /mL 
Porphyromonas gingivalis 1,00E+06 /mL 
Staphylococcus aureus 1,00E+06 /mL 
Escheria coli 1,00E+06 /mL 
Poly I:C 1,00E+01 ug/mL 
   
7d PBMC stimulations + RPMI + 10% human serum 
Stimulus 50uL/well Final concentration 
LPS 1,00E+00 ng/mL 
Candida albicans Yeast 1,00E+00 ug/mL 
Staphylococcus aureus 1,00E+06 /mL 
   
24h Whole Blood stimulations + RPMI  
Stimulus 50uL/well Final concentration 
LPS 1,00E+02 ng/mL 
PHA 1,00E+01 ug/mL 
Candida Albicans Yeast 1,00E+06 /mL 
Staphylococcus Aureus 1,00E+06 /mL 
Porphyromonas gingivalis 1,00E+06 /mL 
 
Supplementary Table 1 – Concentrations of stimuli used in the cytokine production capacity 
experiments. PBMC Peripheral blood mononuclear cells; Pam3Cys Tripalmitoyl cysteine; Poly 








Gene Forward primer Reverse Primer 
RPL37A TAATACGACTCACTATAGGCTTTCTGGGCTC TCTTCATGCAGGAACCACAG 
Leptin GGTTGCAAGGCCCAAGAA ACATAGAAAAGATAGGGCCAAAGC 
Adiponectin ATCGGTGAAACCGGAGTACC GCATGTTGGGGATAGTAACGTAA 
CD68 GCTGGCTGTGCTTTTCTCG GTCACCGTGAAGGATGGCA 
MCP-1 CCAGTCACCTGCTGTTATAAC TGGAATCCTGAACCCACTTCT 
TNF-α CTCTTCTGCCTGCTGCACTTTG ATGGGCTACAGGCTTGTCACTC 
IL-1α ATCATGTAAGCTATGGCCCACT CTTCCCGTTGGTTGCTACTAC 
IL-18Rβ  CTAAAATCATCTTGACACAACAGGC ATCCTTAATTCGCTCTCCTGCAAC 
IL-37 CAGCCTCTGCGGAGAAAGGAAGT GTTTCTCCTTCTTCAGCTGAAGGGATGGAT 
 
Supplementary Table 2 - Forward and reverse sequence-specific primers of the household gene 






Cytokine and stimulus VAT SAT sSAT dSAT SAT at hip VAT+SAT 
C.albicans.yeast_PBMC_24h_IL.1b -0.03 0.12 0.10 0.10 0.18 0.08 
C16_PBMC_24h_IL.1b -0.07 -0.04 -0.02 -0.07 -0.13 -0.10 
E.coli_PBMC_24h_IL.1b 0.00 0.09 0.15 0.00 0.15 0.03 
LPS.100ng_PBMC_24h_IL.1b -0.04 0.06 0.14 -0.02 0.16 0.02 
LPS.1ng_PBMC_24h_IL.1b 0.03 0.06 0.11 -0.01 0.16 0.03 
MSU.C16_PBMC_24h_IL.1b -0.04 -0.04 0.00 -0.07 -0.12 -0.04 
P.gingivalis_PBMC_24h_IL.1b -0.04 -0.14 -0.09 -0.13 -0.13 -0.15 
Pam3Cys_PBMC_24h_IL.1b -0.08 -0.05 -0.06 -0.02 0.01 -0.11 
Poly.I.C_PBMC_24h_IL.1b -0.02 -0.10 -0.12 -0.04 0.03 -0.07 
S.aureus_PBMC_24h_IL.1b -0.03 -0.04 0.05 -0.11 0.03 -0.07 
C.albicans.yeast_WholeBlood_48h_IL.1b -0.09 -0.12 -0.06 -0.15 -0.12 -0.14 
LPS.100ng_WholeBlood_48h_IL.1b -0.09 0.10 0.06 0.10 0.07 0.05 
P.gingivalis_WholeBlood_48h_IL.1b -0.13 -0.07 -0.02 -0.09 -0.07 -0.11 
PHA_WholeBlood_48h_IL.1b -0.14 0.00 -0.03 0.04 -0.02 -0.03 
S.aureus_WholeBlood_48h_IL.1b -0.15 0.00 -0.01 0.00 0.01 -0.11 
C.albicans.yeast_PBMC_24h_IL.6 -0.01 0.25 0.20 0.23 0.19 0.21 
C16_PBMC_24h_IL.6 -0.08 0.00 0.04 -0.05 -0.07 -0.06 
E.coli_PBMC_24h_IL.6 -0.01 0.14 0.20 0.05 0.12 0.07 
LPS.100ng_PBMC_24h_IL.6 -0.07 0.20 0.23 0.13 0.21 0.13 
LPS.1ng_PBMC_24h_IL.6 0.00 0.17 0.19 0.11 0.20 0.13 
MSU.C16_PBMC_24h_IL.6 0.01 0.03 0.06 -0.01 -0.02 0.03 
P.gingivalis_PBMC_24h_IL.6 -0.10 -0.07 0.00 -0.10 -0.11 -0.14 
Pam3Cys_PBMC_24h_IL.6 -0.11 0.04 0.01 0.06 0.02 -0.05 
Poly.I.C_PBMC_24h_IL.6 -0.06 -0.09 -0.06 -0.09 0.07 -0.10 
S.aureus_PBMC_24h_IL.6 -0.04 0.06 0.07 0.04 0.08 0.03 
C.albicans.yeast_WholeBlood_48h_IL.6 -0.14 -0.14 -0.15 -0.10 -0.08 -0.20 
LPS.100ng_WholeBlood_48h_IL.6 -0.07 -0.03 -0.05 0.00 0.06 -0.07 
P.gingivalis_WholeBlood_48h_IL.6 -0.23 -0.17 -0.13 -0.16 -0.05 -0.26 
PHA_WholeBlood_48h_IL.6 -0.05 -0.03 -0.04 -0.01 0.07 -0.06 
S.aureus_WholeBlood_48h_IL.6 -0.07 0.01 -0.05 0.07 0.04 -0.05 
C.albicans.yeast_PBMC_24h_TNF.a -0.04 0.11 0.09 0.10 0.11 0.07 
E.coli_PBMC_24h_TNF.a -0.16 0.02 0.14 -0.08 0.01 -0.07 
LPS.100ng_PBMC_24h_TNF.a -0.26 0.03 0.07 -0.01 0.04 -0.10 
LPS.1ng_PBMC_24h_TNF.a -0.17 0.04 0.11 -0.03 0.01 -0.04 
MSU.C16_PBMC_24h_TNF.a -0.04 -0.02 0.05 -0.07 -0.11 -0.06 
S.aureus_PBMC_24h_TNF.a -0.08 -0.11 -0.02 -0.15 -0.10 -0.13 
C.albicans.yeast_WholeBlood_48h_TNF.a -0.09 -0.02 -0.07 0.05 0.07 -0.09 
LPS.100ng_WholeBlood_48h_TNF.a -0.14 -0.04 -0.06 0.00 0.02 -0.09 
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P.gingivalis_WholeBlood_48h_TNF.a -0.06 0.11 0.00 0.22 0.09 -0.02 
PHA_WholeBlood_48h_TNF.a -0.13 -0.04 -0.08 0.01 0.01 -0.11 
S.aureus_WholeBlood_48h_TNF.a -0.07 0.07 -0.01 0.13 0.04 -0.04 
C.albicans.yeast_PBMC_7d_IFNg -0.07 -0.05 -0.06 -0.03 0.05 -0.07 
S.aureus_PBMC_7d_IFNg 0.02 -0.18 -0.16 -0.13 -0.15 -0.14 
C.albicans.yeast_PBMC_7d_IL.17 -0.04 0.12 0.08 0.10 0.19 0.09 
S.aureus_PBMC_7d_IL.17 0.01 0.11 0.09 0.10 0.12 0.08 
C.albicans.yeast_PBMC_7d_IL.22 0.03 0.06 0.03 0.08 0.19 0.09 
LPS.1ng_PBMC_7d_IL.22 0.07 0.03 0.01 0.06 0.12 0.07 
S.aureus_PBMC_7d_IL.22 0.00 -0.03 -0.11 0.05 0.03 -0.06 
C.albicans.yeast_PBMC_24h_IL.1Ra 0.00 0.18 0.07 0.23 0.18 0.14 
C16_PBMC_24h_IL.1Ra 0.04 0.03 0.09 -0.03 0.11 0.01 
E.coli_PBMC_24h_IL.1Ra -0.05 0.04 0.09 -0.02 0.13 -0.01 
LPS.100ng_PBMC_24h_IL.1Ra -0.11 0.15 0.11 0.15 0.15 0.06 
LPS.1ng_PBMC_24h_IL.1Ra -0.08 0.12 0.12 0.08 0.18 0.04 
MSU.C16_PBMC_24h_IL.1Ra -0.02 -0.02 0.01 -0.05 0.07 -0.03 
MSU_PBMC_24h_IL.1Ra 0.03 -0.10 -0.06 -0.11 0.00 -0.06 
P.gingivalis_PBMC_24h_IL.1Ra -0.06 -0.07 -0.03 -0.08 0.07 -0.10 
Pam3Cys_PBMC_24h_IL.1Ra -0.18 0.02 -0.05 0.07 0.07 -0.09 
Poly.I.C_PBMC_24h_IL.1Ra -0.11 0.08 -0.01 0.13 0.14 -0.01 
RPMI_PBMC_24h_IL.1Ra 0.04 0.06 0.10 0.01 0.08 0.07 
S.aureus_PBMC_24h_IL.1Ra -0.05 0.03 0.03 0.02 0.10 -0.02 
C.albicans.yeast_WholeBlood_48h_IL.1Ra 0.23 0.08 0.03 0.08 0.15 0.19 
LPS.100ng_WholeBlood_48h_IL.1Ra 0.16 0.17 0.16 0.10 0.19 0.17 
P.gingivalis_WholeBlood_48h_IL.1Ra -0.01 -0.01 0.03 -0.07 0.09 -0.06 
PHA_WholeBlood_48h_IL.1Ra 0.16 0.20 0.18 0.14 0.20 0.19 
S.aureus_WholeBlood_48h_IL.1Ra 0.10 0.03 0.01 0.03 0.13 0.05 
 
Men 
Cytokine and stimulus VAT SAT sSAT dSAT SAT at hip VAT+SAT 
C.albicans.yeast_PBMC_24h_IL.1b 0.04 0.02 0.00 0.03 0.02 0.02 
C16_PBMC_24h_IL.1b 0.12 0.12 0.07 0.14 0.07 0.11 
E.coli_PBMC_24h_IL.1b 0.07 0.14 0.04 0.18 0.10 0.10 
LPS.100ng_PBMC_24h_IL.1b 0.03 0.06 0.00 0.09 0.02 0.02 
LPS.1ng_PBMC_24h_IL.1b 0.13 0.02 0.01 0.03 0.00 0.06 
MSU.C16_PBMC_24h_IL.1b 0.09 0.05 0.02 0.06 0.00 0.10 
P.gingivalis_PBMC_24h_IL.1b 0.20 -0.02 -0.06 0.01 -0.03 0.09 
Pam3Cys_PBMC_24h_IL.1b 0.07 0.03 -0.01 0.05 0.03 0.03 
Poly.I.C_PBMC_24h_IL.1b -0.02 0.20 0.20 0.17 0.11 0.10 
S.aureus_PBMC_24h_IL.1b 0.12 -0.05 -0.10 -0.01 -0.12 0.01 
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C.albicans.yeast_WholeBlood_48h_IL.1b 0.02 0.03 0.02 0.03 -0.06 0.00 
LPS.100ng_WholeBlood_48h_IL.1b -0.03 0.01 0.03 0.01 -0.03 -0.01 
P.gingivalis_WholeBlood_48h_IL.1b -0.01 0.07 0.13 0.02 0.07 0.06 
PHA_WholeBlood_48h_IL.1b -0.05 0.08 0.15 0.04 0.00 0.00 
S.aureus_WholeBlood_48h_IL.1b 0.02 -0.02 0.00 -0.04 -0.05 -0.02 
C.albicans.yeast_PBMC_24h_IL.6 0.11 0.04 0.06 0.02 0.03 0.07 
C16_PBMC_24h_IL.6 0.02 0.09 0.03 0.11 0.03 0.01 
E.coli_PBMC_24h_IL.6 0.10 0.14 0.08 0.16 0.11 0.12 
LPS.100ng_PBMC_24h_IL.6 0.05 0.10 0.10 0.09 0.04 0.06 
LPS.1ng_PBMC_24h_IL.6 0.12 0.06 0.05 0.05 0.04 0.07 
MSU.C16_PBMC_24h_IL.6 0.12 0.05 0.04 0.05 0.02 0.11 
P.gingivalis_PBMC_24h_IL.6 0.17 0.08 0.03 0.10 -0.01 0.13 
Pam3Cys_PBMC_24h_IL.6 0.10 0.07 0.01 0.10 0.06 0.06 
Poly.I.C_PBMC_24h_IL.6 0.01 0.07 0.13 0.02 0.03 0.02 
S.aureus_PBMC_24h_IL.6 0.10 0.04 0.02 0.05 0.01 0.07 
C.albicans.yeast_WholeBlood_48h_IL.6 -0.01 0.03 0.03 0.04 -0.03 0.00 
LPS.100ng_WholeBlood_48h_IL.6 0.04 0.06 0.03 0.06 0.03 0.05 
P.gingivalis_WholeBlood_48h_IL.6 0.03 0.05 0.04 0.06 0.04 0.06 
PHA_WholeBlood_48h_IL.6 0.00 0.11 0.15 0.08 0.07 0.04 
S.aureus_WholeBlood_48h_IL.6 0.03 0.07 0.03 0.07 0.04 0.06 
C.albicans.yeast_PBMC_24h_TNF.a -0.02 -0.08 -0.05 -0.09 -0.10 -0.08 
E.coli_PBMC_24h_TNF.a -0.04 0.04 0.03 0.04 -0.05 -0.04 
LPS.100ng_PBMC_24h_TNF.a -0.15 -0.01 0.00 -0.02 -0.10 -0.17 
LPS.1ng_PBMC_24h_TNF.a 0.01 -0.04 -0.02 -0.04 -0.08 -0.06 
MSU.C16_PBMC_24h_TNF.a 0.09 0.05 0.02 0.06 -0.01 0.07 
S.aureus_PBMC_24h_TNF.a 0.05 -0.19 -0.20 -0.16 -0.25 -0.11 
C.albicans.yeast_WholeBlood_48h_TNF.a 0.06 0.06 0.04 0.07 0.04 0.09 
LPS.100ng_WholeBlood_48h_TNF.a 0.06 -0.01 -0.01 0.00 0.04 0.03 
P.gingivalis_WholeBlood_48h_TNF.a -0.07 0.10 0.11 0.08 0.04 0.04 
PHA_WholeBlood_48h_TNF.a 0.08 0.06 0.12 0.03 0.10 0.09 
S.aureus_WholeBlood_48h_TNF.a -0.05 0.06 0.06 0.05 0.02 0.02 
C.albicans.yeast_PBMC_7d_IFNg -0.05 0.06 0.08 0.04 0.15 0.03 
S.aureus_PBMC_7d_IFNg 0.10 -0.08 -0.07 -0.07 -0.11 -0.01 
C.albicans.yeast_PBMC_7d_IL.17 0.04 0.07 0.07 0.06 0.16 0.14 
S.aureus_PBMC_7d_IL.17 0.16 -0.04 -0.07 -0.03 -0.01 0.07 
C.albicans.yeast_PBMC_7d_IL.22 0.07 0.12 0.08 0.13 0.14 0.15 
LPS.1ng_PBMC_7d_IL.22 0.11 -0.06 -0.10 -0.04 -0.10 0.04 
S.aureus_PBMC_7d_IL.22 0.03 0.04 -0.01 0.07 0.02 0.02 
C.albicans.yeast_PBMC_24h_IL.1Ra 0.06 -0.01 0.05 -0.03 -0.05 0.01 
C16_PBMC_24h_IL.1Ra 0.10 0.07 0.05 0.07 0.05 0.06 
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E.coli_PBMC_24h_IL.1Ra 0.08 0.09 0.04 0.11 0.04 0.07 
LPS.100ng_PBMC_24h_IL.1Ra 0.03 0.05 0.08 0.03 -0.01 0.01 
LPS.1ng_PBMC_24h_IL.1Ra 0.10 0.02 0.08 0.00 -0.03 0.03 
MSU.C16_PBMC_24h_IL.1Ra 0.02 0.11 0.10 0.11 0.07 0.06 
MSU_PBMC_24h_IL.1Ra 0.05 0.02 0.01 0.03 0.02 0.00 
P.gingivalis_PBMC_24h_IL.1Ra 0.07 0.00 -0.01 0.01 -0.06 0.00 
Pam3Cys_PBMC_24h_IL.1Ra 0.00 0.03 0.04 0.03 0.01 -0.03 
Poly.I.C_PBMC_24h_IL.1Ra 0.02 0.02 0.02 0.02 -0.02 -0.01 
RPMI_PBMC_24h_IL.1Ra 0.03 0.12 0.11 0.12 0.06 0.04 
S.aureus_PBMC_24h_IL.1Ra 0.08 -0.02 -0.01 -0.02 -0.07 0.01 
C.albicans.yeast_WholeBlood_48h_IL.1Ra 0.09 0.14 0.06 0.16 0.17 0.15 
LPS.100ng_WholeBlood_48h_IL.1Ra 0.17 0.19 0.11 0.22 0.16 0.23 
P.gingivalis_WholeBlood_48h_IL.1Ra 0.11 0.14 0.08 0.16 0.15 0.14 
PHA_WholeBlood_48h_IL.1Ra 0.15 0.19 0.11 0.21 0.15 0.20 
S.aureus_WholeBlood_48h_IL.1Ra 0.14 0.13 0.02 0.17 0.09 0.16 
 
P-value 
    P < 0.05 
    P < 0.01 
    P < 0.001 
  
Supplementary Table 3 –  Heatmap of correlation between top 7 protein levels in relation to 
different adipose tissue compartment volumes in women (A) and men (B). Standardized betas 
after adjustment for age, pack years and season and multiple testing. The intensity of the red 
colour represent the strength of the significance. 
VAT Visceral adipose tissue; SAT Subcutaneous adipose tissue; sSAT Superficial subcutaneous 
adipose tissue; dSAT Deep subcutaneous adipose tissue; SAT_hip Subcutaneous adipose tissue 
at the hip region; VAT+SAT Visceral plus subcutaneous adipose tissue; C.albicans.yeast 
Candida albicans yeast; LPS.100ng Lipopolysaccharide 100ng; MSU monosodium urate; 
P.Gingivalis Porphyromonas gingivalis; Pam3Cys Tripalmitoyl cysteine; Poly.I.C 
Polyinosinic:polycytidylic acid; S.Aureus Staphylococcus Aureus; PHA Phytohemagglutinin; 
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Metabolic dysregulation and inflammation are important consequences of obesity, and impact 
susceptibility to cardiovascular diseases (CVD). Anti-inflammatory therapy in CVD is being 
developed under the assumption that inflammatory pathways are identical in women and men, 
but it is not known if this is indeed the case. In this study, we assessed the sex-specific relation 
between inflammation and metabolic dysregulation in obesity. 
 
Approach and results 
302 individuals were included, half with a BMI 27-30kg/m2 and half with a BMI>30kg/m2, 45% 
were women. The presence of metabolic syndrome was assessed according to the NCEP-ATPIII 
criteria, and inflammation was studied using circulating markers of inflammation, cell counts and 
ex vivo cytokine production capacity of isolated immune cells. Additionally, lipidomic and 
metabolomic data were gathered, and subcutaneous fat biopsies were histologically assessed.  
Metabolic syndrome is associated with an increased inflammatory profile that profoundly differs 
between women and men: women with metabolic syndrome show a lower concentration of the 
anti-inflammatory adiponectin, whereas men show increased levels of several pro-inflammatory 
markers such as interleukin-6 and leptin. Adipose tissue inflammation showed similar sex-specific 
associations with these markers. Peripheral blood mononuclear cells isolated from men, but not 
women, with metabolic syndrome display enhanced cytokine production capacity.  
 
Conclusions 
We identified sex-specific pathways that influence inflammation in obesity. Excessive production 
of pro-inflammatory cytokines was observed in men with metabolic syndrome. In contrast, 
women typically showed reduced levels of the anti-inflammatory adipokine adiponectin. These 
different mechanisms of inflammatory dysregulation between women and men with obesity 











The prevalence of overweight and obesity has increased dramatically over the last few decades. 
In 2016, globally 39% of adults were overweight (BMI>25 kg/m2) and 13% were obese (BMI>30 
kg/m2) (1), while in developed countries the percentages are often even higher. Overweight and 
obesity are strongly associated with atherosclerotic cardiovascular diseases (CVD), diabetes, and 
several types of cancer (2). Two important mechanism that drive CVD development in obesity 
are metabolic dysregulation and systemic inflammation, with low-grade chronic inflammation 
contributing to the development of metabolic syndrome and its complications (3). The metabolic 
syndrome serves as an indicator of obesity-related metabolic dysregulation and is strongly 
associated with atherosclerotic CVD (4).  
There are important sex differences in the pathophysiology of atherosclerotic CVD, with sex-
specific risk factors and differences in the prevalence and treatment (5). Differences in sex 
hormones and sex-specific effects of adipokines are all implicated in these differences, but 
knowledge on sex-specific regulation of inflammation and metabolic dysregulation in obesity is 
sparse.  
We have previously shown that sex, age, genes and the environment are important determinants 
of systemic inflammatory processes in healthy individuals (6, 7). While it is implied that the same 
mechanisms control inflammation in women and men with regard to CVD, this has never been 
systematically investigated. In this study, we investigated the impact of sex on the relation 
between inflammation and metabolic syndrome in overweight women and men. We further 
explored the role of circulating metabolites (metabolome) and circulating hormones on sex-
specific effects. We specifically focused on three groups of inflammatory parameters: plasma 
adipokine and cytokine concentrations, immune cell subpopulations in the blood, and the ex vivo 
cytokine production capacity of circulating immune cells (such as monocytes and T cells). These 
distinct inflammatory phenotypes are all known to be important in the pathophysiology of CVD, 
but are differentially regulated (8).  
 
METHODS AND MATERIALS 
Cohort and measurements 
Anonymized data and materials have been made publicly available at the Human Functional 
Genomics Project (HFGP) website and can be accessed at https://hfgp.bbmri.nl/. As part of the 
HFGP (9), we recruited a cohort of 302 individuals affected by overweight or obesity between 55 
and 82 years of age, with a BMI > 27 kg/m2 at screening, of mostly Western European ancestry, 
termed the 300-Obesity (300-OB) cohort. Most of these participants previously took part in the 
Nijmegen Biomedical Study – Non-Invasive Measurements of Atherosclerosis 1 (NBS-NIMA1) 
(10). Detailed information about the cohort is available in the Methods in the supplementary 




All individuals filled out questionnaires, which included questions about life style, environmental 
factors and medication usage. If used, participants temporarily discontinued lipid-lowering 
therapy four weeks prior to the measurements. Blood samples were taken in the morning 
following an overnight fast. All women were postmenopausal and were not receiving hormonal 
replacement therapy. All participants received detailed printed and oral information and 
subsequently gave written informed consent. The study was approved by the Ethical Committee 
of the Radboud University (nr. 46846.091.13). Experiments were conducted according to the 
principles expressed in the Declaration of Helsinki. 
 
The metabolic syndrome 
In our study, the metabolic syndrome is defined by the NCEP ATP III criteria as the presence of 
any three of the following five traits (11):  
- Abdominal obesity, defined as a waist circumference in men ≥102 cm (40 in) and in women ≥88 
cm (35 in)  
- Serum triglycerides (TG) ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated TG  
- Serum high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL (1 mmol/L) in men and < 50 
mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C  
- Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure  
- Fasting plasma glucose ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose  
 
Blood glucose, Triglycerides (TG), total cholesterol and HDL-C were measured using standard 
laboratory procedures. Before measuring systolic and diastolic blood pressure, participants took 
30 minutes of supine rest.  




Circulating mediators (cytokines and adipokines) were measured in human EDTA plasma using 
Enzyme Linked Immunosorbent Assay (ELISA).  
 
Stimulation experiments 
PBMC stimulation experiments 
Isolation of peripheral blood mononuclear cells (PBMCs) was performed as described in Oosting 
et al (12). 
Whole blood stimulation experiments 
A volume of 100 μl of heparin blood was added to a 48 well plate (Corning) containing 400 µl 






Cytokine concentrations after stimulation were measured using commercially available ELISA 
kits.  
Stimuli and cytokines 
Table 1 in the online supplementary material lists the concentrations of the stimuli used. 
Interleukin (IL)-1β, IL-6, TNF-α, and IL-1Ra were measured after 24-hour stimulation with these 
stimuli, and IFNγ, IL-17, and IL-22 were measured after 7 days of stimulation only for C. albicans 
and S. aureus stimulation. The choice of pro-inflammatory mediators was based on extensive 
literature linking cytokines and adipokines to inflammation and CVD complications. Stimulation 
of PBMCs was performed with a comprehensive set of stimuli containing both purified innate 
immune stimuli that are associated with chronic inflammation (e.g. LPS, oxidized low-density 
lipoprotein (LDL)) and microorganism that are the source of microbial ligands that translocate in 
the circulation at the intestinal level. 
 
Cell count data 





Blood was collected in EDTA tubes and plasma was extracted. Flow injection electrospray time-
of-flight mass spectrometry was performed by General Metabolomics (1 Broadway, Cambridge 
MA 02142) to identify metabolic features based on m/z. Details of the procedure can be found 
in Fuhrer et al (13). 1339 m/z signals could be assigned to one or more metabolites.  
Lipidomics 
A high-throughput Nuclear Magnetic Resonance (NMR) metabolomics platform (Nightingale's 
Biomarker Analysis Platform) was used to quantify a total of 231 lipid and metabolite measures. 
Most of these measures were very highly correlated to other measures from the same platform. 
Groups of lipoprotein particle characteristics were therefore made based on a correlation 
between variables of at least r>0.75 and expert knowledge. This led to 17 groups (see Table 2 in 
the online supplementary material), for each group a representative variable was selected to 
represent the whole group of measurements. This led to easier interpretation and less strict 
multiple testing correction. 
 
Adipose tissue analysis 
Subcutaneous adipose tissue biopsies were obtained under local anesthesia by needle biopsies 
performed 6-10cm lateral to the umbilicus in the right lower quadrant, after an overnight fast. 




previously (14). For each participant, the adipocyte cell diameters of all adipocytes in four 
microscopic fields of view were counted and measured. To detect macrophages, adipose tissue 
sections were incubated with a CD68-monoclonal antibody (Serotec, Oxford, UK). The percentage 
of macrophages was expressed as the total number of macrophages divided by the total number 
of adipocytes counted in 15 random microscopic fields of view. A crown-like structure was 
defined as an adipocyte surrounded by at least three macrophages (15). To robustly quantify 
adipose tissue inflammation among study participants using histology, several parameters  were 
assessed and combined into an adipose tissue inflammation score, as the phenotype by which 
inflammation in the adipose tissue presents is quite heterogenous (16, 17). This assessment led 
to a score including the following parameters: a mean adipocyte diameter above the average 
diameter of the cohort (> 51.7um (mean diameters in the 300-OB cohort) was defined as one 
point in the AT score, the percentage of macrophages above the average of the cohort (>12.6% 
(mean in the 300-OB cohort) was defined as one point in the AT score and the presence of crown-
like structures (CLS) was defined as one point in the AT score. Hence, the adipose tissue 
inflammation score ranged from 0 (no inflammation) to 3 (severely inflamed). 
 
Quantification and statistical analysis  
Data and software availability 
The R code (via R programming language (18)) used for the analyses will be made available upon 
request. Multiple testing correction was performed using the Benjamini-Hochberg FDR 
procedure (19).  
For the metabolic pathway analysis, we used an adaptation (Fast Gene Set Enrichment Analysis 
(FGSEA) (20)) of Gene Set Enrichment Analysis (GSEA) (21). The pathways provided by the KEGG 
pathway database (22) were used for enrichment analysis. Interesting pathways were visualized 
using Pathview (23). 




Figure 1 provides an overview of the clinical characteristics of the cohort, separated by sex: 55% 
are men and 45% are women, with a similar BMI distribution in both sexes (Figure 1B and S). 
Metabolic syndrome is defined as having three out of five cardiovascular risk factors mentioned 
in figure 1E till I (11). The prevalence of metabolic syndrome was 54.8% in women and 53.9% in 
men (Figure 1C), and a larger percentage of women had abdominal obesity and low HDL-C (Figure 







Figure 1 - Characteristics of the 300-OB cohort (A) Overview of some of the parameters measured 
in the 300-OB cohort. Each outlined square indicates a different data type and schematically 
describes the different measurements. circ. markers = circulating markers of inflammation (B) 
Baseline characteristics, also split by sex. (C) Percentage of individuals with the metabolic 
Syndrome as defined by the NCEP-ATP III criteria. left: overall percentage, right: subdivided into 
women and men. Yellow: people with the condition, green: people without the condition. (D) 
Percentage of individuals with other conditions. (E) Percentage of individuals with each of the five 
criteria used in defining metabolic syndrome, displayed in a similar style to (C): purple indicates 
people on medication for the condition (E) high blood pressure, (F) high glucose, (G) abdominal 
obesity; (H) low HDL cholesterol (HDL-c) (I) high triglycerides * = p-value ≤ 0.05 calculated using 
chi-square test. *** p-value ≤ 0.005 
 
Association between markers of inflammation in individuals with overweight or obesity 
The sex-specific values of circulating inflammatory markers and adipokines are depicted in Figure 
2A. We previously reported the effects of age and sex on inflammation in a healthy cohort (7) (n 
= 489, age 27.4 ± 12.5 years, BMI 22.7 ± 2.7 kg/m2). Overall, in the present study we observed 
similar effects of age (Figure 2B and Table 3 in the online supplementary material), i.e. 
interleukin(IL)-6 and IL-18BP circulating concentrations increase with age. In addition, we 
observed an effect of sex on various parameters;  higher levels of hsCRP, leptin and adiponectin 
were seen in women (Figure 2B).  
To better understand the regulation of inflammation in obesity, we evaluated the association 




regression models. Age, sex and season were added as co-factors, since they are known to have 
an influence on the immune system (7). Most markers of inflammation show positive associations 
with one another, specifically IL-6, IL-18, IL-18BP, high-sensitive CRP (hsCRP), VEGF and leptin 
(Figure 2C and Table 4 in the online supplementary material). IL-6 concentrations show 
particularly strong associations with leptin (Figure 2D, adjusted β = 0.31) and hsCRP (adjusted β 
= 0.53), which is in line with previous studies (24, 25). We observed a negative association of 
adiponectin with several inflammatory markers (Figure 2C), in line with its known anti-
inflammatory properties and its decrease with increasing BMI (26). Associations of these markers 
of inflammation are mostly the same between women and men (Table 5 in the online 
supplementary material). 
In addition to circulating inflammatory markers, we also measured immune cell populations. 
Absolute numbers of neutrophils and monocytes increase with age, and men generally have 
higher numbers of neutrophils, eosinophils and especially monocytes (Figure 2E and Table 7 in 
the online supplementary material), in line with previous findings (26, 27).  
 
We found strong associations between most inflammatory markers and the number of 
leukocytes, neutrophils and monocytes, most of them positive (Figure 2F, Table 7 in the online 







Figure 2 - Associations of various immune and host parameters in the 300-OB cohort. (A) Mean 
and standard deviations of several circulating inflammatory markers for women and men. (B) P-
values of associations between age and sex with markers of inflammation* (BH-FDR multiple 
testing corrected). (C) P-values of associations between markers of inflammation, corrected for 
age, sex and season (BH-FDR multiple testing corrected). (D) Example association between IL-6 
and leptin. (E) P-values of associations between age and sex with immune cell counts* (BH-FDR 
multiple testing corrected). (F) P-values of associations between immune cell numbers and 
circulating markers of inflammation, corrected for age, sex and season (BH-FDR multiple testing 
corrected). Note: All p-values were calculated using linear regression and testing the null 




interest. The data in the example plots (D) was corrected for age, sex and season and transformed 
using IRT (see methods). * = Associations with age corrected for sex and season, associations with 
sex corrected for age and season. 
 
The impact of sex on metabolic syndrome and inflammation 
The presence of metabolic syndrome was positively associated with several inflammatory 
markers IL-6, IL-18, IL-IL-18BP, hsCRP, leptin and VEGF (Figure 3A and Table 8 in the online 
supplementary material). Importantly, IL-6 and leptin show profound sex-specific effects: only in 
men, these are higher in the presence of the metabolic syndrome, whereas in women there is no 
association with the metabolic syndrome (Figure 3A, B, E and F). Similar trends are observed for 
hsCRP and IL-18, though the interaction between sex and metabolic syndrome was not significant 
when testing based on a linear regression model with an interaction term (Figure 3A and B, Table 
8 and 9 in the online supplementary material). In contrast to the pro-inflammatory mediators, 
the anti-inflammatory adiponectin was lower in individuals with metabolic syndrome. 
Interestingly, this effect was significantly stronger in women compared to men, as opposed to IL-
6 and leptin (Figure 3A, B and G). To validate this finding, we measured adiponectin levels in a 
subset of the NBS-NIMA1 cohort (28) of 441 participants, filtering for a BMI>27kg/m2. The 
individuals in this cohort were on average 4.4 years younger than the 300-OB cohort (2.8 years 
younger on average for men and 6.0 years for women). In this cohort, 33% of the subjects 
suffered from the metabolic syndrome (Table 10 in the online supplementary material). We were 
able to confirm the same pattern of a lower concentration of adiponectin in women with the 
metabolic syndrome, but not in men (Figure 3H). 
In addition, as inflammation originating from the adipose tissue is one of the main driving forces 
for systemic low-grade inflammation present in obesity (29), we examined the possible existence 
of sex-specific differences in the relation between circulating leptin, adiponectin and adipose 
tissue inflammation. We calculated AT scores for the 300-OB cohort based on fat tissue taken 
from the abdominal subcutaneous fat depot. After adjustment for age, pack years and season  
(7), AT scores showed significant association with circulating levels of leptin and IL-6 in men but 
not women (standardized βmen = 0.22, pmen < 0.001, pinteraction_sex:leptin = 0.02 for leptin; βmen = 0.25, 
pmen < 0.001, pinteraction_sex:IL6 = 0.07 for IL-6), while in women AT scores were more strongly 
negatively associated with circulating adiponectin (standardized β women = -0.28; pwomen < 0.0001). 
This provides further evidence of  sex-specific regulation of systemic low-grade inflammation. 
Since IL-6 and leptin concentrations are correlated, and the concentrations of these markers are 
elevated specifically in men with metabolic syndrome, we assessed the strength of this 
correlation separately by sex and presence/absence of metabolic syndrome. We observed that 
leptin and IL-6 are only correlated in men but not in women, and most strongly in men without 




The five factors (Figure 1E till I) that define metabolic syndrome might not have an equal 
contribution to the sex-specific effects described in the previous paragraphs. We therefore 
evaluated each of these factors separately, using the cut-off levels as defined by NCEP ATP-III 
criteria (see methods). Having high vs. normal TG levels appears to be the most important 
parameter in explaining the sex-specific effects of metabolic syndrome on both IL-6 in men and 
adiponectin in women (Figure 3D, compare to Figure 3B). The sex-specific changes in leptin with 
metabolic syndrome cannot be explained by any single parameter, and the full definition of 
metabolic syndrome is needed to explain that effect. 
We also observed changes in the number of immune cell subtypes in individuals with metabolic 
syndrome: specifically, total leukocytes, lymphocytes and monocytes numbers are higher in 
individuals with metabolic syndrome (Figure 3E). Importantly, these changes in both absolute 






Figure 3 - The effect of metabolic syndrome (MetS) on immune parameters. (A) Significance of the 
difference in levels of several inflammatory markers between individuals with and without MetS. 




blue means it is higher in those without. The first column is for all individuals, and the second and 
third are for women and men respectively (FDR corrected per column). (B) Significance of the 
interaction effect between sex and metabolic syndrome. Red indicates that the increase of women 
with metabolic syndrome vs. those without was significantly lower than men with metabolic 
syndrome vs. those without, i.e. red means men show a stronger increase than women or women 
show a stronger decrease than men. (C) Interaction effects for each individual medical condition 
used to score metabolic syndrome with sex. Each individual is scored as either having the 
condition or not, and interaction effects are calculated in a similar wat as in (B). Similarly, red 
means men show a stronger increase than women, or women show a stronger decrease than 
men; blue means the opposite. The left part shows the p-values not corrected for multiple testing, 
and the right part shows the FDR corrected p-values. (D) Same as A, but for cell counts. (E)-(H) 
Example plots split into women and men with and without metabolic syndrome. (E) IL-6, (F) leptin, 
(G) adiponectin. (H) Similar to (G), but for the validation cohort. (I) Plot showing Spearman 
correlations between leptin and IL-6 for the 4 categories: men with MetS, men without MetS, 
women with MetS and women without MetS.  
Note: P-values in (A and D) were calculated using linear regression by testing the null hypothesis 
that β = 0 for relationship between metabolic syndrome status (independent variable) and a 
continuous parameter (dependent variable), see methods for details. The interaction effects of (B 
and C) were calculated using linear regression, with the null hypothesis that β = 0 for the 
interaction effect between sex and metabolic syndrome status (independent variable) and a 
continuous parameter (dependent variable). 
 
Differential regulation of cytokine production capacity in women and men 
Cytokine production capacity of PBMCs, as an indicator of the intrinsic inflammatory 
responsiveness, has previously been linked to the presence of atherosclerosis (30, 31). 
Production of the pro-inflammatory cytokines IL-1β and IL-6 and the anti-inflammatory cytokine 
IL-1Ra show associations with circulating levels of IL-6 and hsCRP. Interestingly, in line with higher 
inflammatory markers in men with metabolic syndrome, there is a strong trend towards higher 
monocyte-derived inflammatory cytokine production capacity specifically in men, but not 
women, with metabolic syndrome (Figure 4A(left) and B, Table 12 and 13  in the online 
supplementary material). This effect does not appear to be limited to a single PBMC stimulation, 
and is most apparent for the cytokines IL-6 and IL-1β, and less so for TNF-α. Again, high TG is the 
main factor of metabolic syndrome showing sex-specific effects, with only men with high TG 
showing increased levels of cytokine production capacity (Figure 4A and C, Figure 2 and Table 14 
in the online supplementary material). There were no differences in the cytokine production 
capacity of IL-1Ra and the lymphocyte derived cytokines IL-22, IL-17 and IFNγ between women 






Figure 4 - (A) [left] Same as (A) but for IL-6, IL-1β and TNFα production in PBMC’s after different 
stimulations. [middle] Similar to the heatmap on the left but for high triglycerides instead of 
metabolic syndrome [right] Similar to (D), but solely plotted for high triglycerides (FDR corrected). 
The arrows mark those cytokines after stimulation that show a significantly stronger increase in 
men than in women. Note: if men show a non-significant difference between men with and 
without MetS and women also show a non-significant difference, the increase men show with 
getting MetS can still be significantly different from the change that women show. (B) Example 
plot showing the effect of metabolic syndrome and sex on IL-6 production in response to C. 
albicans stimulation. (C) Example plot showing the effect of having high triglycerides and sex on 
IL-6 production in response to C. albicans stimulation. Note: P-values were calculated in a similar 
fashion as for Figure 3. 
 
Changes in the metabolome of individuals with metabolic syndrome 
Metabolic dysregulation and systemic inflammation are important mechanisms that drive CVD 
development in obesity. To further explore whether the composition of circulating lipoproteins 
could contribute to the sex-specific association of the metabolic syndrome with IL-6, leptin, 
adiponectin, and cytokine production capacity, we measured lipoprotein subclasses, lipoprotein 
particles sizes, apolipoproteins and lipoprotein content using the Nightingale platform (Table 2 
in the online supplementary material). A principle component analysis (PCA) shows separation 
between both women and men and between individuals with and without metabolic syndrome 
(Figure 5A). The PCA and a linear regression analysis show that women have larger 
concentrations of HDL particles, HDL triglycerides, ApoA1 and cholesterol (Figure 5B and Table 
15 in the online supplementary material) and many lipoproteins have altered composition and 
concentration in subjects with metabolic syndrome, e.g. decreases in HDL particles and increases 




same patterns of change when comparing individuals with and without metabolic syndrome 
(Figure 5C[right]).  
To further explore metabolic changes associated with the metabolic syndrome beyond 
lipidomics, we used untargeted metabolomics assay that detected 1339 metabolite signals. We 
evaluated the association of metabolic syndrome with these metabolites. First, we applied PCA 
to these data to see if metabolic syndrome and/or sex impact on the variation of this data. PC2 
shows a clear separation between women and men (Figure 5D). However, using these untargeted 
analyses, no large differences between individuals with and without metabolic syndrome can be 
observed. Nonetheless, using a regression model we found many metabolites that were 
associated with metabolic syndrome. The associations for all metabolite hits with metabolic 
syndrome are listed in Table 16 in the online supplementary material. The top pathway found in 
a pathway analysis was “valine, leucine and isoleucine biosynthesis” though it did not reach 
statistical significance after multiple testing correction (Table 17 in online supplementary 
material). It is interesting to note that 5 out of the 7 metabolites of the “valine, leucine and 
isoleucine biosynthesis” pathway that are significantly associated with metabolic syndrome , also 
show significantly different levels between women and men (Figure 5E and Table 18 in the 
supplementary material). However, these metabolites did not show a sex-specific association 
with metabolic syndrome (Figure 5E). 
 
Hormonal changes do not explain sex differences 
The cause of the differences in inflammatory profiles between women and men with metabolic 
syndrome is not yet known, but one hypothesis is that it might involve differential homeostasis 
of sex hormones. To evaluate the potential role of sex hormones in the metabolic syndrome we 
measured baseline levels of several steroid hormones: testosterone, androstenedione, cortisol, 
11-deoxycortisol and 17-hydroxyprogesterone (Table 19 in the supplementary material). We 
found no significant difference in hormone levels associated with the metabolic syndrome in both 





Figure 5 - (A) PCA plot of PC1 vs PC2 for the lipidomics data. (B) Lipid groups that are significantly 
different between women and men. Blue indicates higher levels in women. (C). [left] significance 
(FDR corrected p-values) of the difference of lipid concentrations between individuals with or 
without metabolic syndrome. Calculated for the whole 300-OB cohort and calculated for women 
a women separately. [right] FDR corrected P-values for the interaction effect between metabolic 
syndrome and sex in predicting the lipids, i.e. showing if the increase/decrease of these lipids seen 
in metabolic syndrome is the same in women and men. (D) PCA plot of the metabolomics data 
after inverse rank transformation and standardization. The first two PCs are plotted, and the 
samples are split into four groups: women without metabolic syndrome (“Female_NoMetS”), 
women with metabolic syndrome (“Female_YesMetS”), men without metabolic syndrome 
(“Male_NoMetS”), men with metabolic syndrome (“Female_YesMetS”). PC2 shows some 
separation between women and men. (E) Significance of sex differences for the 7 metabolites 
from the “valine, leucine and isoleucine biosynthesis” that showed significant association with 
metabolic syndrome. Several of these metabolites also show clear differences between women 
and men. (F) Significance (FDR corrected p-values) of the difference in hormone concentrations 




Note: P-values in (B) and (E) were calculated using linear regression by testing the null hypothesis 
that β = 0 for relationship between sex (independent variable) and a continuous parameter 
(dependent variable), see methods for details. P-values in (C[left]) and (F) were calculated using 
linear regression by testing the null hypothesis that β = 0 for relationship between metabolic 
syndrome status (independent variable) and a continuous parameter (dependent variable), see 
methods for details. The interaction effect of (C[right]) was calculated using linear regression, 
with the null hypothesis that β = 0 for the interaction effect between sex and metabolic syndrome 
status (independent variable) and a continuous parameter (dependent variable). 
XL- Very large; L- Large; M- Medium; S- Small; XS- Extremely small; VLDL Very-Low-Density 
Lipoproteins; IDL Intermediate-Density Lipoproteins; LDL Low-Density Lipoproteins; HDL High-
Density Lipoproteins;-P Concentration of particles; -L Total lipids; -PL Phospholipids; -C Total 
cholesterol; -CE Cholesterol esters; -FC Free cholesterol; -TG Triglycerides; -D Mean diameter; 
Serum-C Serum cholesterol. 
 
Plasma metabolome effects on inflammatory markers  
To explore whether circulating metabolites influence inflammatory parameters and account for 
the sex-differences in inflammation in relation to metabolic syndrome, we evaluated the 
relationship between metabolites and inflammation. We see the strongest associations for 
adiponectin and IL-18BP, but hsCRP, resistin and IL-6 also show many associations with 
metabolites (Figure 6A and Table 20 in the online supplementary material).  
The results for the top 10 pathways that correlate with inflammatory markers are displayed in 
Figure 6B. Pathway analysis was performed using an adapted version of Gene Set Enrichment 
Analysis (21). “Central Carbon Metabolism in Cancer”, is particularly interesting, since an 
important part of it is the TCA cycle, which in the last years has been shown to have a strong 
impact on inflammation and the function of immune cells (32, 33). However, although we 
identified important correlations between metabolites and inflammation, these associations 
were not sex-specific and could not explain the sex-differences in inflammatory markers in 








Figure 6 - Metabolic comparison between normal weight and overweight individuals. (A) 
Visualization of the top 5% of metabolites (lowest p-values) associated with each of the circulating 
markers of inflammation to give an impression of the number of significant metabolites. For each 
marker the FDR corrected p-values were sorted independently to show the relative number of 
significant metabolites for each marker. (B) Top 10 metabolic pathways associated with 
circulating markers of inflammation in the 300-OB cohort. See methods for details. (C) Example 
pathway plot of “Central Carbon Metabolism in Cancer” for VEGF in the 300-OB cohort. 
Significance is indicated as -log10(p-values), any p-value below p = 1e-4 is rounded up to 1e-4 for 
this visualization. Red indicates a positive association, blue indicates a negative association and 
white indicates that the metabolite was not present in our data. Visualization was performed 






In this study, we aimed to understand the various regulatory layers of the adverse 
immunometabolic effects of overweight and obesity, and in particular which parts of that 
regulation differ between women and men. Therefore, we characterized in detail a cohort of 302 
individuals (approximately equally distributed between women and men, with or without 
metabolic syndrome) with overweight and obesity in terms of circulating inflammatory markers, 
immune cell counts, immune cell responsiveness, circulating metabolomics/lipidomics, and 
histological analysis of subcutaneous fat biopsies. The most important finding was that there is a 
sex-specific association of metabolic syndrome with various inflammatory parameters: metabolic 
syndrome is associated with lower circulating concentrations of the anti-inflammatory 
adiponectin, whereas only in men the presence of metabolic syndrome is associated with 
increased monocyte-derived circulating cytokines (mainly IL-6), and increased leptin. For 
adiponectin, these sex-specific associations were validated in an independent cohort. Adipose 
tissue inflammation is a central feature of metabolic syndrome, and we found that adipose tissue 
inflammation was positively associated with circulating leptin and IL-6 only in men, while in 
women adiponectin was negatively associated with the AT score. In addition, metabolic 
syndrome was associated with hyper-responsive circulating immune cells only in men. This 
suggests that the role of inflammation and the immune system in the adverse cardiometabolic 
consequences of obesity is different in women and men. Further analyses revealed sex-specific 
differences circulating metabolites, lipoprotein composition, and hormones, but these 
differences did not explain the differential association of inflammatory markers with metabolic 
syndrome between women and men. These findings call for a sex-specific approach with regard 
to inflammation as a pharmacological target to prevent CVD in individuals with obesity and for 
further research to unravel the mechanisms that drive the sex-specific differences. 
 
The metabolic syndrome serves as an indicator of metabolic dysregulation, is strongly associated 
with the development of atherosclerotic CVD5 and is often accompanied by a chronic low-grade 
inflammation (34). Differences in a selection of inflammatory parameters between women and 
men that have metabolic syndrome have been reported previously in small studies. Sarbijani et 
al. showed in a group of 40 subjects that men with metabolic syndrome have higher IL-6 levels 
than those without (35), though it should be noted that for women and men the characteristics 
of the case and control groups were different in this study. Ahonen et al. showed that absolute 
differences in adiponectin in individuals with and without the metabolic syndrome were larger in 
women than men, though the significance of this difference was not reported (36). However, a 
systematic overview of the differences between women and men with metabolic syndrome is 
still lacking. The strength of our current study, is that it provides a more comprehensive 
description of the sex-specific associations of metabolic syndrome with circulating inflammatory 




adipose tissue inflammation and an independent cohort, and explored potential underlying 
mechanisms. One of the most important observations of our study is the difference in the 
dysregulation of inflammation between women and men: in women, the presence of metabolic 
syndrome is characterized by a lack of the anti-inflammatory adipokine adiponectin, while in men 
it presents as an excess of pro-inflammatory mediators such as IL-6 and leptin. Interestingly, IL-6 
and leptin are only correlated in men, further suggesting a differential regulation of these 
inflammatory markers in women. We were able to validate the sex specific associations of 
adiponectin levels in women and men with metabolic syndrome in an independent cohort. These 
different inflammatory phenotypes in women and men with metabolic syndrome can have 
important therapeutic consequences, suggesting sex-specific approaches. 
 
In addition to systemic inflammation, there is accumulating evidence that the phenotype of 
circulating immune cells contributes to adverse cardiometabolic effects. We and others have 
recently reported that circulating monocytes have an enhanced cytokine production capacity in 
patients with risk factors for atherosclerosis, including familial hypercholesterolemia and 
elevated lipoprotein (a) (37, 38), and in patients with established coronary atherosclerosis (30, 
31). Interestingly, in the 300-OB cohort, a similar hyperresponsiveness of circulating PBMCs was 
present in men with metabolic syndrome compared to men without metabolic syndrome, 
whereas in women, these differences were not observed. In men, the presence of metabolic 
syndrome was associated with a higher production of IL-1β and IL-6 after stimulation with a wide 
range of inflammatory stimuli. This might well be related to the observation that circulating IL-6 
is higher in men with metabolic syndrome, since IL-6 is associated with ex vivo production of IL-
1β and IL-6 in response to several stimuli.  
 
To gain insight into the mechanism responsible for the sex-specific association of metabolic 
syndrome with adipokines, and inflammatory parameters, we first studied the association 
between adipose tissue inflammation and circulating adipokine and cytokine levels. Leptin and 
adiponectin are both produced in adipose tissue. Leptin is at the interface between metabolism 
and inflammation in fat tissue; leptin production by the adipose tissue facilitates the secretion of 
proinflammatory cytokines, and these, in turn, promote the release of leptin from adipocytes 
(39). Adipose tissue inflammation is a well-known feature of metabolic syndrome. Of great 
interest, we were able to demonstrate a positive association of adipose tissue inflammation with 
leptin and IL-6 specifically in men and a negative association of adipose tissue inflammation with 
adiponectin in women. However, the causality between adipose tissue inflammation and these 
circulating adipokines and cytokines, needs to be further established. We hypothesize that the 
increased adipose tissue inflammation associated with metabolic syndrome in men results in 
peripheral leptin resistance, which in turn leads to increased leptin levels and also impacts other 




limits adiponectin production. It is important to realize that the adipose tissue biopsy was 
obtained from the abdominal subcutaneous fat depot in both sexes, while women and men are 
known to have a difference in (abdominal) fat distribution: with the same BMI, men have on 
average a higher ratio of visceral/subcutaneous adipose tissue compared to women (40). This 
difference might impact on systemic inflammation and needs to be included in future analyses.  
 
Additionally, to gain more insight into what specific features of the metabolic syndrome drive the 
observed associations with circulating adipokines and cytokines, we individually evaluated the 
five parameters defining metabolic syndrome. We showed that circulating TG concentration 
appear to be the most important condition driving the sex-specific association. In women with 
high TGs, adiponectin levels are lower, whereas in men with high TGs, plasma IL6 is higher.  In 
addition, also the augmented cytokine production capacity of PBMCs in men with metabolic 
syndrome is mainly dependent on the presence of high TGs. Further lipidomic analyses showed 
that this differential effect is not due to sex-differences in the composition of circulating 
lipoproteins. Following high-fat loads, circulating triglycerides are associated with circulating 
cytokine levels such as IL-6 and with activation of circulating innate immune cells (41, 42). 
However, it is currently unclear why triglycerides are associated with higher IL-6 and higher 
cytokine production capacity only in men.   
 
As has been shown previously that for example testosterone can have immunomodulatory effect 
(43),  we tested the hypothesis that circulating hormones contribute to the observed sex-specific 
differences in inflammatory parameters by measuring the serum concentrations of five 
circulating steroid hormones, of which four show strong differential concentrations in women 
and men, including 17-OH-progesteron and testosterone. For these hormones, we did not 
observe any differential association with triglycerides or the metabolic syndrome, nor an 
association with circulating cytokines and cytokine-production capacity that could explain our 
findings. It is important to realize that we were only able to test a selection of hormones, and 
that we cannot exclude effects of progesterone or estrogens. Also, though changes in sex 
hormones with the metabolic syndrome do not explain the observed sex differences, contrasting 
baseline levels of steroid hormones between women and men might still play a role these 
differences (Table 19 in the online supplementary material). 
 
Following these observations of a differential association of adipokines, inflammatory markers 
and immune cell responsiveness, we further explored the role of other circulating metabolites 
that might play a role in metabolic syndrome. Metabolites are the end-point of many biological 
processes, and the metabolome thereby provides a snap-shot of the current physiological state. 
We observed strong differences between women and men in circulating metabolites. In our study 




metabolic syndrome, and is likely to be the most biologically relevant in terms of association with 
inflammatory parameters. This pathway has previously linked to metabolic syndrome, poor 
metabolic health, insulin resistance and type II diabetes (44, 45). However, women and men 
showed the same associations between these metabolite concentrations and metabolic 
syndrome. Lipid profiles of women and men with metabolic syndrome showed similar patterns: 
while levels of most lipid markers were different between women and men and these levels 
changed with metabolic syndrome, these changes were the same in women and men. This 
suggests that even though metabolites play an important role in metabolic syndrome, this role is 
similar in both sexes. 
 
There are several limitations to the current study. First, this is an observational study, and 
although we validated some of the major findings in an independent cohort, our data do not 
provide information about causality and mechanisms. Secondly, all individuals in the two cohorts 
studied here were of Western European descent, and it is difficult to extrapolate these data to 
other populations. Thirdly, we used metabolic syndrome as indicator of cardiometabolic 
dysregulation. It is important to realize that there are various definitions for metabolic syndrome 
and this syndrome is heterogeneous. To optimize external validation, we used the most 
frequently used definition of the NCEP ATP III. In addition, we performed all analyses separately 
for the various components of the metabolic syndrome, indicating triglycerides as major factor 
that contributes to the sex-specific differences. Finally, we have only studied a selection of 
circulating hormones and cannot exclude modulating effects of unmeasured hormones as an 
explanation of our findings.  
 
In conclusion, in this first study, we comprehensively analyzed the regulation of inflammation in 
overweight individuals, and we showed that there is as strong sex-dependent association of 
metabolic syndrome with circulating markers of inflammation. Importantly, we demonstrate that 
inflammatory dysregulation in women and men with obesity and metabolic syndrome is 
mediated by different mechanisms, which relate to adipose tissue inflammation. Women show 
defective anti-inflammatory mechanisms (adiponectin), whereas men have higher 
concentrations of pro-inflammatory mediators (leptin, IL-6) and their myeloid cells show a hyper-
responsive phenotype. These findings strongly argue for more in vitro and in vivo studies aimed 
at unraveling mechanisms that underlie this sex-specific inflammatory regulation. Moreover, 
these findings suggest that women and men might benefit from a differential sex-specific anti-
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Measurements and sample collection details 
The 300-Obesity (300-OB) cohort study consists of 302 individuals between 55 and 80 years 
of age with a BMI > 27 kg/m2 at screening. All participants were included between the year 
2014 and 2016. This 300-OB cohort described in this study is part of the Human Functional 
Genomics Project (HFGP) at the Radboud university medical center, which contains a 
collection of cohorts with various backgrounds. Most of these participants previously took 
part in the Nijmegen Biomedical Study – Non-Invasive Measurements of Atherosclerosis 1 
(NBS-NIMA1), a population-based survey of inhabitants of the municipality of Nijmegen, The 
Netherlands1. 949 of the 1,517 participants of the NBS-NIMA1 study (with a BMI > 25 kg/m2 
at the time of NBS-NIMA1) were invited to participate. 472 subjects were excluded, mainly 
because they did not fulfill the criterion BMI > 27 kg/m2. Another 250 subjects refused. This 
resulted in 227 individuals willing to participate and fulfilling all inclusion criteria. Additionally, 
we recruited 75 participants that were acquaintances of first 227 participants, fulfilling the 
inclusion criteria (age > 55 years and BMI > 27 kg/m2). Exclusion criteria for the 300-OB cohort 
were: 
- a recent cardiovascular event (MI, transient ischemic attack or stroke < 6 months) 
- prior bariatric surgery or bowel resection 
- inflammatory bowel disease (IBD)  
- renal dysfunction 
- increased tendency for bleeding  
- use of anti-coagulant therapy (oral or subcutaneous) 
- use of thrombocyte aggregation inhibitors other than acetylsalicylic acid or carbasalate 
calcium 
All subjects filled out questionnaires, which included questions about life style, environmental 
factors and medication usage. If used, participants temporarily discontinued lipid-lowering 
therapy four weeks prior to the measurements. Blood samples were taken in the morning 
following an overnight fast. All women were postmenopausal and were not receiving 
hormonal replacement therapy. All participants received detailed printed and oral 
information and subsequently gave written informed consent. The study was approved by the 
Ethical Committee of the Radboud University (nr. 46846.091.13). Experiments were 
conducted according to the principles expressed in the Declaration of Helsinki.  
 
The metabolic syndrome 
We used criteria defined in the National Cholesterol Education Program (NCEP) to diagnose 
the metabolic syndrome2. The metabolic syndrome at the time of this study is defined by the 
NCEP ATP-III criteria as the presence of any three of the following five traits: 
- Abdominal obesity, defined as a waist circumference in men ≥102 cm (40 in) and in 
women ≥88 cm (35 in) 
- Serum triglycerides (TG) ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated TG 
- Serum high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL (1 mmol/L) in men and 
< 50 mg/dL (1.3 mmol/L) in women or drug treatment for low HDL-C 
- Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure  






Blood glucose, TG, total cholesterol and HDL-C were measured using standard laboratory 
procedures. Before measuring systolic and diastolic blood pressure, participants took 30 
minutes of supine rest. Hypertension was defined as a systolic blood pressure (SBP) level > 
140 mmHg and/or diastolic blood pressure (DBP) > 90 mmHg, or currently undergoing 
treatment for hypertension. Type 2 diabetes mellitus was defined as a glucose level over 7.0 
mmol/L after an overnight fast or currently undergoing treatment for type 2 diabetes. Weight 
and height were determined during visitation, and this was used to calculate BMI. The BMI 
was calculated as body weight (kg) divided by the square of height (m). Waist circumference 
was measured at the level of the umbilicus and hip circumference was measured at the level 
of the trochanter major. Both of there were rounded to the nearest first decimal. 
 
Circulating mediators 
Circulating mediators (cytokines and adipokines) were measured in human EDTA plasma using 
Enzyme Linked Immunosorbent Assay (ELISA). Concentrations of circulating mediators 
resistin, leptin, adiponectin, hsCRP and alpha-1 antitrypsin (AAT) were determined in EDTA 
plasma using the R&D Systems ELISA kits following the Manufacturer’s protocol. Plasma 
interleukin(IL)-18, IL-6 and VEGF were measured in Simple Plex cartridges using the Ella 
apparatus (Protein Simple, San Jose, CA). IL-18 binding protein (IL-18BP) concentrations were 
measured using R&D Duoset kits following the manufacturer’s standard protocol.  
 
Stimulation experiments 
PBMC stimulation experiments 
At baseline, 20 mL EDTA venous blood was collected. Isolation of peripheral blood 
mononuclear cells (PBMCs) was performed as described in Oosting et al3. In short, the PBMCs 
were isolated within 6 hours by density gradient centrifugation of PBS diluted blood (1:1) over 
Ficoll-Paque, washed twice with PBS and subsequently resuspended in Dutch modified RPMI 
1640 medium (Invitrogen) supplemented with 50 µg/mL gentamicin (Centrafarm), 2 mM 
GlutaMAX and 1 mM pyruvate (Life Technologies). PBMC stimulations were performed with 
5x105 cells/well in round-bottom 96-wells plates (Greiner) at 37 °C and 5% CO2. Supernatants 
were collected after 24 hours and 7 days and stored at -20 °C until ELISA measurements were 
performed. The different stimuli and cytokines that were measured, are shown in Table 1 and 
2. 
  
Whole blood stimulation experiments 
At baseline, 10 ml heparin blood was collected. A volume of 100 μl of heparin blood was added 
to a 48 well plate (Corning) containing 400 µl stimulus (final volume 500ul/well) for 48 hours 
at 37°C and 5% CO2. Supernatants were collected and stored in -20°C until ELISA 
measurements were performed. The different stimuli and cytokines that were measured, are 
shown in Table 1 and 2. 
 
ELISA analysis 
Cytokine concentrations after stimulation were measured using commercially available ELISA 
kits. For the 24-hour PBMC stimulation and whole blood experiments the following kits were 
used: 
- IL-1β: R&D systems, DY201 




- TNFα: R&D systems, DY210 
- IL-6: Sanquin, M9316 
For the 7-day PBMC stimulation experiments the following kits were used, 
- IL-17: R&D systems, DY317 
- IL-22: R&D systems, DY782 
- IFNγ: Sanquin, M9333 
All measurements we done according to the protocols supplied by the manufacturer. 
 
Cell count data 
Immune cell counts were determined in fresh whole blood EDTA samples using the Sysmex 
XE-5000. The Sysmex XE-5000 was used in a laboratory automation configuration part of a 
routine clinical setting. All analyses were preformed following the manufacturer’s protocol. 





Blood was collected in EDTA tubes and plasma was extracted. Plasma samples were frozen 
and stored at -80°C before extraction. Prior to extraction plasma samples were allowed to 
thaw on ice for 30-60 minutes. 20 µL of serum/plasma was aliquoted into a labeled 2 mL 
microtube and then 180 µL of aq. 80% LCMS-grade methanol was added. The samples were 
thoroughly mixed on a vortex mixer for 15 seconds to precipitate protein and afterwards 
allowed incubate for 1 hour at 4°C. Samples were centrifuged (room temperature) at > 
14,000g for 15 minutes to pellet the precipitate. 100 µL of the supernatant was transferred to 
a fresh microtube tube. Samples were stored at -80°C prior to shipping. 
Flow injection electrospray time-of-flight mass spectrometry was performed by General 
Metabolomics (1 Broadway, Cambridge MA 02142) to identify metabolic features based on 
m/z. Details of the procedure can be found in Fuhrer et al.4. The total number of m/z signals 
that could be assigned to one or more metabolites was 1339 for the 300-OB cohort and 1979 
for the 500FG cohort. 
 
Lipidomics 
A high-throughput Nuclear Magnetic Resonance (NMR) metabolomics platform (Nightingale's 
Biomarker Analysis Platform) was used to quantify a total of 231 lipid and metabolite 
measures in EDTA plasma. Most of these measures were very highly correlated to other 
measures from the same platform. Groups of lipoprotein particle characteristics were 
therefore made based on a correlation between variables of at least r  > 0.75 and expert 
knowledge. This led to 17 groups comprising of lipoprotein subclasses, lipoprotein particles 
sizes, apolipoproteins and cholesterol (Table 12). For each of these 17 groups a representative 
variable was selected to represent the whole group of measurements. This led to easier 
interpretation and less strict multiple testing correction. 
 
Adipose tissue analysis 
Adipose tissue biopsies 
Subcutaneous adipose tissue biopsies were obtained under local anesthesia by needle 
biopsies performed 6-10cm lateral to the umbilicus in the right lower quadrant, after an 




single-use needle (4665473) from B/braun. Specimens were placed in embedding cassettes 
and fixed in 4% paraformaldehyde (37%, VWR). After at least 48 hours, cassettes were 
processed overnight (o/n) with the Excelsior™ AS Tissue Processor (Thermo Scientific). 
Thereafter, samples were embedded in paraffin. Sectioning of specimens was done to make 
8 µm thick coupes. Coupes were mounted per two on a glass slide and allowed to dry for 30 
minutes. At last the coupes were incubated overnight at 37°C and stored at 4°C until later use 
 
Adipocyte size 
Haematoxylin and Eosin (H&E) staining was done to determine adipocyte size. The slides were 
first incubated two times in xylene (Depot) for 5 minutes and subsequently 5 minutes in 100%, 
96% and 70% ethanol, respectively. The slides were then incubated for 20 minutes in 
haematoxylin (haematoxylin was prepared using the following protocol: first, 1 g 
haematoxylin (VWR) was added in 10 mL ethanol 96%. Then 200 mg sodiumlodate (VWR), 50 
g potassiumaluin (VWR) and the complete dissolved haematoxylin(10 mL) was added to 1000 
mL aquadest. Dissolved o/n at RT and 50 g chloralhydrate (VWR) and 1 g citric acid (Sigma) 
was added. Solution was mixed well, used after 2 days and filtered before use.) and rinsed in 
running tap water for 10 minutes. After that, the slides were incubated for 5 minutes in eosin 
(eosin was prepared using the following protocol: first, 1 g eosine-G (VWR) was added in 100 
mL aquadest, then 100 mL 96% ethanol was added. Before used, solution was diluted 1:5 with 
aquadest), rinsed short in 70% ethanol and incubated for 5 minutes in 96% and 100% ethanol, 
respectively. At last the slides were incubated two times in xylene (Depot) for 5 minutes. 
Finally, the slides were sealed with Permount (Fischer Scientific) and a cover slide. After 
staining, adipocytes were scored on their size with the KS-400 software. This was done with 
the microscope Zeiss Axiophoto. 
The morphometry of individual fat cells was afterwards assessed using digital image analyses 
as described previously 5. For each participant, the adipocyte cell diameters of all adipocytes 
in four microscopic fields of view were counted and measured. On average, 219 adipocytes 
(range 113 - 330) were measured per field. 
 
Presence of macrophages  
To detect macrophages, adipose tissue sections were incubated with a CD68-monoclonal 
antibody (Serotec, Oxford, UK). Sections were preincubated with 20% normal horse serum 
followed by overnight incubation at 4 °C with the primary antibody diluted 1:40 in phosphate-
buffered saline, 1% bovine serum albumin. After incubation with the primary antibody (mouse 
anti-human), a horse anti-mouse IgG conjugated to horseradish peroxidise (Vector labs 
brunschwig) was used as a secondary antibody. Visualization of the complex was done using 
3,3’-diaminobenzidene for 12 min. Negative controls were used by omitting the primary 
antibody. Hematoxylin and eosin staining of sections was done using standard protocols. The 
percentage of macrophages was expressed as the total number of macrophages divided by 
the total number of adipocytes counted in 15 random microscopic fields of view. A crown-like 
structure was defined as an adipocyte surrounded by at least three macrophages 6. 
 
Quantification and statistical analysis 
Data preprocessing and scaling 
For circulating markers and cytokines produced after stimulation, any value above or below a 
detection limit was set to that detection limit. Metabolomic data, lipidomic data, cytokine 




rank based inverse normal transformation (INT) before analysis unless stated otherwise. The 
following R code was used (R programming language7): 
 transformed = rank(original) 
 transformed = qnorm(transformed /(length(transformed)+0.5)), 
where “transformed” is the transformed data and “original” the original data.  
 
Metabolic syndrome and sex 
Analysis was performed in the R programming language7, using the ‘lm’ function from the 
“stats” package. A linear model was created with the following formula: 
markerOfInterest ~ intercept + β1*age + β2*sex + β3*season + 
β4*metabolicSyndromeStatus 
Details for the seasonality correction are provided below. The model was run 3 times, once 
for all data, once for just men and once for just women. In case the model was run for just one 
sex, the correction factor “sex” was removed. Each run p-values for regression coefficients of 
the relevant markers were corrected for multiple testing using the Benjamini -Hochberg FDR 
procedure8, using FDR < 0.05 after correction as the threshold for statistical significance. 
 
To assess if any of our biological markers (circulating markers of inflammation, cell subsets, 
cytokine production capacity) showed significant differences between women and men when 
comparing individuals with and without metabolic syndrome, we calculated interaction 
effects between someone’s “metabolic syndrome status” and sex: 
markerOfInterest ~ intercept + β1*age + β2*sex + β3*season+ 
β4*metabolicSyndromeStatus + β5*sex:metabolicSyndromeStatus 
The p-values were calculated for the estimate of the interaction term. Specifically, the “lm” 
function calculates a t-statistic to test whether the corresponding regression coefficient is 
different from 0. 
The significance of the correlation between leptin and IL-6 was calculated using Spearman 
correlation and the “cor.test” function in the R programming language7. The null hypothesis 
in this test is that ρ = 0. 
Similar approached were taken for each of the five factors that make up metabolic syndrome. 
In that case “metabolicSyndromeStatus” is replaced by one of these factors, for instance 
“highTriglycerides”. 
 
Associations between host factors, circulating markers, metabolomics, cell subtypes 
Associations between parameters were calculated using the ‘lm’ function from the “stats” 
package in the R programming language7. The following data-types were associated to one 
another in this way for different analyses: 
- age and sex with circulating markers of inflammation, cell subtypes (absolute and 
percentages), cytokine production capacity 
- circulating markers of inflammation with circulating markers of inflammation and cell 
subtypes (absolute and percentages), metabolomics 
A linear model was created with the following formula: 
parameter1 ~ intercept + β1*age + β2*sex + β3*season + β4*parameter2 
here, parameter1 and parameter2 are the parameters of interest. So, e.g. in the association 
between circulating markers of inflammation and cell subtypes, one comparison would be: 




So, the association between IL-6 and neutrophils% is evaluated, whilst correcting for age, sex 
and season. Seasonality correction is explained below. The function “lm” in R provides the p-
values. This function calculates a t-statistic to test whether the corresponding regression 
coefficient is different from 0. A hypothesis test using this t-statistic generates the p-value. 
Multiple testing correction was performed using the Benjamini-Hochberg FDR procedure8. 
 
Seasonality correction 
The seasonality correction was performed similar to Ter Horst et al.9. This was introduced to 
correct for seasonal differences in levels of inflammatory markers and cytokine production 
capacity. In short, the following terms were added to the regression formula: 
- sin(2 * pi * numDaysFromJan2014 / 365)  
- cos(2 * pi * numDaysFromJan2014 / 365)  
- numDaysFromJan2014 
So, in the regression formula the following would be inserted: 
β1*sin(2 * pi * numDaysFromJan2014 / 365) + β2*cos(2 * pi * numDaysFromJan2014 
/ 365) + β3*numDaysFromJan2014 
where sin(2 * pi * numDaysFromJan2014 / 365) and cos(2 * pi * numDaysFromJan2014 / 365) 
combined capture seasonality patterns with a periodicity of one year. The linear term 
“numDaysFromJan2014”, which indicates how many days after January 1st 2014 the sample 
was collected, was added to correct for potential sample storage degradation. For the 500FG 
cohort the same corrections were applied, though here numDaysFromJan2014 was replaced 
with numDaysFromJan2013, since samples were collected a year earlier.  
 
PCA and tSNE 
Principal component analysis (PCA) was applied to the inflammatory markers and circulating 
metabolite data. Any individuals with missing values for any marker were excluded from this 
analysis. The data was first inverse rank transformed followed by mean centering and 
standardization. PCA was performed in the R programming language using the “prcomp” 
function that is part of the “stats” package. 
 
Metabolic association analysis 
Associations between metabolite levels and circulating markers of inflammation were 
calculated using a linear model correcting for age, sex and seasonality. Seasonality corrections 
were performed as described in Ter Horst et al.9. The linear models were constructed using 
the “lm” function of the “stats” package in the R programming language. All p-values were 
calculated using linear regression by testing the null hypothesis that β = 0 for relationship 
between a metabolite and a marker of inflammation. Both the cytokine data and the 
metabolite data were transformed using a Rank-Based Inverse Normal Transformation. 
Associations were corrected for multiple testing using the Benjamini-Hochberg FDR-
procedure8. 
 
Metabolic pathway analysis 
Metabolic pathway analysis was performed using an adaptation of Gene Set Enrichment 
Analysis (GSEA), as originally developed by Subramanian et al.10. A fast implementation in the 
R programming language called Fast Gene Set Enrichment Analysis (FGSEA)11 was used, using 




Each mass/charge-ratio detected by the metabolomics could be the result of one or more 
metabolites. In the pathway analysis, all these metabolites were assigned the same score. 
However, if they mapped to any common pathways, the mass/charge-ratio was only counted 
once for that pathway, to avoid artificial enrichment. This was achieved by removing all but 
one of the metabolites with the same m/z value from each pathway. 
The pathways provided by the KEGG pathway database12 were used for enrichment analysis. 
Interesting pathways were visualized using Pathview13, plotting the -log10(p-values) for the 
metabolites, setting any p-value smaller than 1e-4 to exactly 1e-4 for visualization purposes. 
Negative associations are indicated in blue in these plots and positive associations with red. 
Top pathways for the circulating markers of inflammation were selected by taking the average 
of the lowest three p-values over all circulating markers and ordering them by these p-values. 
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The aim of the present study was to investigate the impact of systemic inflammatory 
mediators, especially from the IL-1 family of cytokines, on atherosclerosis in individuals with 
overweight and obesity. 
 
Background 
Although obesity is a well-known risk factor for metabolic dysregulation and atherosclerotic 
cardiovascular diseases, a sizeable number of individuals affected by obeity do not develop 
these complications. It is unknown whether inter-individual variation of chronic inflammation 
explain these differences in atherosclerotic risk in the obese population.  
 
Methods 
We measured a panel of circulating inflammatory markers, among which many related to the 
interleukin-1 pathway, and correlated them to indicators of carotid atherosclerosis and 
circulating lipoprotein particles in 302 individuals of European origin with a BMI ≥ 27 kg/m2 
(300-Obesity cohort).  
 
Results 
We identified that interleukin-18 binding protein (IL-18BP) showed a stronger relation to the 
presence of carotid atherosclerosis than currently used markers of inflammation (CRP, 
interleukin-6). IL-18BP correlated strongly with the lipoprotein particles from the very-low-
density lipoprotein (VLDL) groups and with the number of atherogenic lipoprotein particles 
(measured by apolipoprotein B levels). The association between IL-18BP and VLDL was 
validated in a cohort of young healthy individuals. The molecular mechanism may involve a 
decreased expression of genes known to be involved in hepatic lipid metabolism including 
PPP1R3G and ENHO regulated by the IL-18 pathway. 
  
Conclusions 
These findings identify IL-18BP as a novel biomarker of atherosclerosis in individuals with 
obesity, and the IL-18/IL-18BP pathway as a functional modulator of VLDL metabolism and 





The epidemic increase in obesity affects both developed and developing countries, making 
cardiovascular disease (CVD) the world’s leading cause of death (1). The cluster of obesity 
related cardiovascular risk factors is called the metabolic syndrome. Inter estingly, 
approximately 20-30% of the obese population is metabolically ‘healthy’ with a substantially 
lower risk for CVD (2). The factors that account for the heterogeneity within the obese 
population are not known.  
It is well established that obesity, especially visceral fat accumulation, leads to a state of 
chronic low-grade inflammation, which is a key regulatory process in the development of 
atherosclerosis (3-5). In approximately four out of ten people, the risk of recurrent 
cardiovascular events after myocardial infarction (MI) is directly related to increased systemic 
inflammation associated with atherosclerosis (6). Inflammation has been linked to endothelial  
dysfunction, fatty streak development, and plaque vulnerability (7). Recently, the CANTOS trial 
demonstrated that inhibition of the pro-inflammatory cytokine interleukin(IL)-1β lowers 
cardiovascular event rate in patients after MI (6). In addition to IL-1β, IL-18 is another cytokine 
from the IL-1 family (8), and important modulators of this pathway include IL-18 binding 
protein (IL-18BP) (9), alpha-1-anti-trypsin (AAT), and adipokines. IL-18 is associated with 
obesity, insulin resistance and dyslipidemia (10-13), while IL-18BP binds IL-18 and thereby 
inhibits its function. IL-18BP production is regulated under influence of interferon (IFN) 
gamma via a negative feedback loop with IL-18 (8), 
The aim of the present study was to investigate the impact of systemic inflammatory 
mediators, especially from the IL-1 family of cytokines, on atherosclerosis in individuals with 
obesity. We hypothesize that the propensity of an individual with obesity to display a more 
pro-inflammatory profile has an important impact on the likelihood to develop 
atherosclerosis. 
 
MATERIALS AND METHODS 
Human studies 
300-Obesity study 
We enrolled 302 individuals aged 55-80 years with a BMI > 27 kg/m2 at screening in the 300-
Obesity (300-OB) cohort study. This study was performed in the period between 2014 and 
2016 at the Radboud university medical center and is part of the Human Functional Genomics 
Project (14). Individuals with a recent cardiovascular event (MI, transient ischemic attack or 
stroke < 6 months), a history of bariatric surgery or bowel resection, inflammatory bowel 
disease, renal dysfunction, increased bleeding tendency, use of oral or subcutaneous anti -
coagulant therapy, use of thrombocyte aggregation inhibitors other than acetylsalicylic acid 
and carbasalate calcium were excluded. The majority of the individuals was derived from the 
cohort of the Nijmegen Biomedical Study – Non-Invasive Measurements of Atherosclerosis 
study, a population-based survey of residents of Nijmegen, the Netherlands (15). Of the 
original 1,517 participants from this study, 949 (with a BMI > 25 kg/m2 at that time) were 
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invited to participate, resulting in 227 individuals fulfilling all the inclusion criteria and willing 
to participate. 444 individuals were excluded, mainly because of a BMI < 27 kg/m2. Another 
249 individuals refused. During the 300-OB study, we additionally recruited 75 participants, 
fulfilling the inclusion criteria (age > 55 years and BMI > 27 kg/m2). All women were 
postmenopausal and did not use hormonal replacement therapy. All participants provided 
written informed consent. The study was approved by the Ethical Committee of the Radboud 
University (nr. 46846.091.13). Experiments were conducted according to the principles 
expressed in the Declaration of Helsinki. 
 
Baseline characteristics 
All individuals filled out questionnaires about life style and medication use. We took blood 
samples in the morning following an overnight fast. Participants who used lipid-lowering 
therapy, temporarily discontinued this medication 4 weeks prior to the measurements. Blood 
glucose, triglycerides (TG), total cholesterol, high-density lipoprotein (HDL) cholesterol and 
apolipoprotein B (ApoB) were measured using standard laboratory procedures. Systolic and 
diastolic blood pressure were measured after 30 minutes of supine rest. Hypertension was 
defined by systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg or 
current treatment for hypertension. Diabetes mellitus type 2 (DM 2) was defined as a glucose 
level > 7.0 mmol/L after an overnight fast or current treatment for DM 2. We used clinical 
criteria as defined in the National Cholesterol Education Program (NCEP) to diagnose the 
metabolic syndrome (16). The BMI was calculated as body weight (kg) divided by the square 
of height (m). Waist circumference was measured at the level of the umbilicus to the nearest 
0.1cm. Hip circumference was measured at the level of the trochanter major.  
 
Cardiovascular phenotyping 
All individuals underwent comprehensive cardiovascular assessment, including the 
measurement of carotid intima-medial thickness (cIMT), plaque presence and maximum 
plaque thickness. After a resting period of at least 30 minutes, baseline resting diameter, wall 
thickness, plaque presence and maximal plaque thickness of both carotid arteries were 
assessed by ultrasound (Esaote Biomedica, Genoa, Italy). The cIMT and diameter 
measurements were performed in the proximal 1cm straight portion of the carotid artery in 
three different angles (90°, 120° and 180°) for 6 heart beats. The outcome variable was defined 
as the mean cIMT of the 3 different angles. Subsequently the presence of plaque and the 
thickness of plaques in the common carotid, internal carotid, or external carotid artery or at 
the carotid bulbus were measured. The presence of a plaque was defined as focal thickening 
of the wall of at least 1.5 x the mean cIMT or a cIMT > 1.5 mm. 
 
Circulating mediators 
Cytokines and circulating mediators were measured in human EDTA plasma using Enzyme 
Linked Immunosorbent Assay (ELISA). Adiponectin, leptin, resistin, AAT and C-reactive protein 
(CRP) were measured using kits from R&D Systems following manufacturer’s instructions. IL -
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6 and IL-18 were measured by Simple Plex cartridges using the Ella apparatus (Protein Simple, 
San Jose). Levels of plasma IL-18BP were measured using the DuoSet ELISA (R & D Systems). 
 
Metabolomics 
We used a high-throughput targeted Nuclear Magnetic Resonance (NMR) metabolomics 
platform (Nightingale's Biomarker Analysis Platform) (17) to generate spectra for the 
quantification of 231 lipid and metabolite measures, either as absolute concentrations of each 
metabolic measure or as ratios. In this study, we focus on the lipoprotein profile with total 
lipid concentrations of 14 lipoprotein subclasses, lipoprotein particles sizes, apolipoproteins 
and cholesterol. Groups of lipoprotein particle parameters were made based on a correlation 
between variables of r > 0.75 (see online supplementary material from chapter 4).  
 
Adipose tissue analysis 
Subcutaneous adipose tissue biopsies were obtained under local anaesthesia by needle 
biopsies performed 6-10cm lateral to the umbilicus in the right lower quadrant, after an 
overnight fast. The morphometry of individual fat cells was assessed using digital image 
analyses as described previously (18). For each participant, the adipocyte cell diameters of all 
adipocytes in four microscopic fields of view were counted and measured. To detect 
macrophages, adipose tissue sections were incubated with a CD68-monoclonal antibody 
(Serotec, Oxford, UK). The percentage of macrophages was expressed as the total number of 
macrophages divided by the total number of adipocytes counted in 15 random microscopic 
fields of view. A crown-like structure was defined as an adipocyte surrounded by at least three 
macrophages (19). To robustly quantify adipose tissue inflammation among study participants 
using histology, several parameters were assessed and combined into an adipose tissue 
inflammation score, as the phenotype by which inflammation in the adipose tissue presents 
is quite heterogenous (20,21). This assessment led to a score including following parameters: 
a mean adipocyte diameter above the average diameter of the cohort (> 51.7um (mean 
diameters in the 300-OB cohort) was defined as one point in the AT score, the percentage of 
macrophages above the average of the cohort (> 12.6% (mean in the 300-OB cohort) was 
defined as one point in the AT score  and the presence of crown-like structures (CLS) was 
defined as one point in the AT score. Hence, the adipose tissue inflammation score could 
ranges from 0 (no inflammation) to 3 (severely inflamed). 
 
500FG cohort 
We validated the association between IL-18BP and lipoproteins in 500 healthy individuals from 
the 500 Functional Genomics (500FG) cohort (mean age 29 years and mean BMI 22.7 kg/m 2) 
using the same methodology for analysis of circulating mediators and metabolomics.(14) The 







Correlations and corresponding p-values were calculated using the rank-based Spearman 
correlation as implemented in the “cor.test()” function of the “R” programming language (R 
Foundation for Statistical Computing, Vienna, Austria). Before the regression analysis, the 
circulating markers of inflammation and the lipidomics data were normalized using 
logarithmic transformation to get a distribution more closely resembling a normal distribution. 
Regression analysis was performed using the “Rfit” package, as implemented in the “R” 
language. Multiple testing correction was performed using the Benjamini – Hochberg False 
Discovery Rate method as implemented in the “p.adjust” function of the “stats” package in 




IL-18 deficient (IL-18-/-) mice were generated on a C57Bl/6J background as previously 
described (24). Body weight of the mice was recorded every month. In an additional study, 
lean wild type (WT) C57Bl/6 mice were treated with recombinant IL-18 or phosphate buffered 
saline (PBS) for 18 hours. At the end of the experiments, animals were sacrificed and organs 
were isolated and used for subsequent analysis as described below. All animal studies were 
approved by the animal ethical committee of the Radboudumc. 
 
RNA isolation and qPCR analysis 
RNA from the liver was isolated using Trizol Reagent (Invitrogen) following manufacturer’s 
instructions. RNA concentration and purity was determined using a Nanodrop (Thermo Fisher 
Scientific, USA).  
 
Transcriptomics analysis 
Two datasets were used for transcriptome analysis. The first dataset consists of pooled 
samples of 4 treatment groups (WT vs IL-18-/- and WT-treated with PBS vs WT-treated with 
recombinant mouse IL-18 (18 hours of treatment)) that were subjected to expression profiling 
by microarray. To this end, purified total RNA of n = 5 mouse liver samples per group was 
pooled and labelled with the Affymetrix GeneChip RNA One cycle Amplification Kit 
(Affymetrix, Santa Clara, CA, U.S.; P/N 900652) and hybridized to Affymetrix Mouse Genome 
430 2.0 arrays (Affymetrix). Quality control and data analysis pipeline have been described in 
detail previously (25). A second dataset consisting of raw expression data of livers of WT and 
IL-18-/- mice of 12 weeks of age were extracted from the Gene Expression Omnibus 
(GSE64309) (26). Data was background corrected using the normexp+offset method (27), 
followed by quantile normalized using functions in the library limma (28). Next differentially 
expressed genes were identified by using linear models and an intensity-based moderated t-
statistic. Probe sets that satisfied the criterion of P < 0.05 were considered to be regulated. To 
identify IL-18 regulated genes, both datasets were combined using a FC > 1.3 and a P-value < 





The 300-OB cohort consisted of 302 individuals of Western-European ancestry with a BMI 
above 27 kg/m2. Approximately half fulfilled the criteria for metabolic syndrome and half had 
carotid atherosclerosis (Figure 1A through C). No differences were present between the 




Figure 1 - Baseline characteristics of 300-Obesity Cohort. (A) Sex and current smoking status 
as assessed by questionnaires. Plaque presence as measured by ultrasound of both carotid 
arteries. (B) The distribution of age, BMI, triglycerides and HDL-cholesterol. (C) The prevalence 
of cardiovascular diseases.  
BMI Body Mass Index; MI Myocardial Infarction; CVA Cerebrovascular Accident; PTCA 
Percutaneous Transluminal Coronary Angioplasty; TIA Transient Ischemic Accident; PAD 
Peripheral Arterial Disease. 
 
IL-18 binding protein is a marker of carotid atherosclerosis in individuals with obesity 
The correlations between all circulating markers and indices of atherosclerosis are shown in 
figure 2. After adjustment for factors known to influence cytokine production (age, sex, BMI, 
smoking, and season) (22), only IL-18BP concentrations remained positively associated with 
maximum plaque thickness (Figure 2A). There was a dose dependent association between 
plaque thickness and the IL-18BP concentration (Figure 2B). In contrast,  IL-18, IL-6 or CRP 
concentrations showed no association with plaque thickness. Markers of metabolic status, 
adiponectin, leptin and resistin did also not show an association with atherosclerosis after 
adjustment for factors known to influence cytokine production. To gain insight into whether 
the association between IL-18BP and atherosclerosis was independent of the classical risk 
factors, we additionally adjusted for systolic blood pressure, glucose level, HDL cholesterol 
and low-density lipoprotein (LDL) cholesterol, antihypertensive, antidiabetic and lipid-
lowering drugs. The association between IL-18BP and maximum plaque thickness remained 
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statistically significant after adjustment confirming an independent link between IL-18BP as 
marker of inflammation and atherosclerosis (supplementary material Figure 1).  
 
 
Figure 2 - (A) Heatmap of correlation between a panel of circulating inflammatory mediators 
and the mean carotid intima-medial thickness and maximum plaque thickness. Red indicates 
a significant positive association. Age, sex, BMI, smoking and season were taken into account 
as adjustment variables. (B) Box plot for relation between IL-18BP concentrations and  
maximum plaque thickness in mm.  
AAT Alpha-1 antitrypsin; CRP C-reactive protein; IL-18 Interleukin-18; IL-18BP interleukin-18 
binding protein; IL-6 Interleukin-6; cIMT carotid intima-medial thickness; maxPlaqueThickness 
maximum plaque thickness in millimeter.  
 
IL-18 and IL-18BP correlate with lipoprotein particle composition and number 
To investigate the underlying mechanism by which IL-18BP could be related to plaque 
thickness, we investigated the relation between IL-18, IL-18BP concentrations and the 
lipoprotein particles using a metabolomics platform focusing on CVD. Parameters of 
lipoprotein particles were first divided into seventeen groups based on a correlation between 
variables of r > 0.75 (see online supplementary material from chapter 4). We found a strong 
and significant univariate association between IL-18BP concentrations and very-low-density 
lipoprotein (VLDL) particles; namely the very large VLDL particles, the small -to-large VLDL 
particles, and very small VLDL particles, group 1, 2 and 3 respectively (Figure 3A). The strongest 
associations were seen within group 2 (Figure 3D). Furthermore, we observed a positive 
association between IL-18BP concentration and part of group 4, the intermediate-density 
lipoproteins (IDL) and LDL particles, with the non-HDL/non-LDL cholesterol (remnant) and free 
cholesterol from group 5. A strong association with the number of lipoprotein particles, as 
measured by ApoB in group 6, was seen with IL-18BP. IL-18 showed the same profile, but 
weaker correlations were seen with group 1, 2 and 3. Within group 4, IL-18 concentration was 
mainly associated with TG particles in the IDL and LDL lipoproteins. In this cohort of individuals 
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with obesity, we found no association between the lipoprotein profile and IL-6 or CRP plasma 
concentrations (supplementary material figure 2 through 5). Importantly, the association 
between IL-18BP and atherosclerosis was lost after adjustment for triglycerides and VLDL 
cholesterol (supplementary material Figure 1). 
 
Figure 3 - IL-18BP is strongly associated with components of the VLDL lipoproteins. (A) 
Heatmaps with correlations between total IL-18, IL-18BP, CRP, IL-6 and lipoprotein particle 
composition in the 300-OB Study. The intensity of the red color represents the strength of the 
significance. (B) Validation of this relation in healthy individuals from the 500FG Study. (C) 
Heatmap with the correlation between lipoprotein particles and markers of atherosclerosis. 
(D) Scatterplots of IL-18BP lipoprotein relation. 
XXL.VLDL.P Concentration of chylomicrons and extremely large VLDL particles; .L Total lipids; 
.PL Phospholipids; .C Total cholesterol; .CE Cholesterol esters; .FC Free cholesterol; .D Diameter; 
TG Triglycerides; XL.VLDL very large VLDL; L. Large; M. Medium; S. Small; XS. Extreme small; 
VLDL very-low-density lipoproteins; IDL intermediate-density lipoproteins; LDL low-density 
lipoproteins; HDL high-density lipoproteins; Remnant.C Remnant cholesterol (non-HDL, non-
LDL -cholesterol); Est Esterified;  IL-18BP Interleukin-18 binding protein; IL-18 Interleukin-18; 
CRP C-reactive protein; IL-6 Interleukin-6. cIMT carotid intima-medial thickness; 









IL-18 binding protein is a marker of adipose tissue inflammation in individuals with obesity 
One of the main driving forces for systemic low-grade inflammation present in obesity is 
inflammation originating from the adipose tissue (29). To investigate whether IL-18BP could 
serve as a marker for this adipose tissue inflammation, we analyzed subcutaneous fat taken 
from the abdomen in individuals with obesity. The AT score associated significantly with IL-
18BP; individuals with more adipose tissue inflammation had higher IL-18BP levels (Figure 4). 
This suggests that IL-18BP is a good systemic marker of adipose tissue inflammation.  
 
 
Figure 4 – IL-18BP is strongly associated with adipose tissue inflammation. (A) Box plots of 
adipose tissue inflammation score in relation to IL-18BP level. Components of the adipose 
tissue inflammation score; adipocyte diameter, percentage of macrophages, crown-like 
structures. (B,C) Immunohistochemically illustration of individual without adipose tissue 
inflammation (score 0) versus individual with extreme adipose tissue inflammation (score 3). 




Validation in cohort of lean individuals 
To investigate whether the association found between IL-18BP and lipoprotein particle profile 
was also present in young, lean individuals, we investigated this relation in the individuals of 
the 500FG cohort (30). In this cohort, the same associations between IL-18BP, IL-18 
concentrations and the different VLDL, LDL groups, serum TG, free and remnant cholesterol 
and ApoB were found (Figure 3B). In the 500FG cohort we found an association between CRP 
concentration and VLDL, most strongly for small VLDL and LDL. This is in contrast to the 
individuals of the 300-OB in which only the TG particles in the IDL and LDL lipoproteins were 
associated with CRP. 
 
Lipoproteins in relation to carotid atherosclerosis 
To investigate whether the association between IL-18BP and atherosclerosis could be 
attributed to a change in lipoprotein particle characteristics, we investigated the relationship 
between lipoprotein particle composition and atherosclerosis in the 300-OB cohort. Analysis 
on the relation with these lipoproteins was possible in 301 out of 302 individuals of whom we 
had all the data. In line with the data on IL-18/IL-18BP pathway, the strongest association with 
the maximum plaque thickness was observed for lipoprotein groups 1 and 2, including the 
small-to-very large VLDL particles (Figure 3C). The maximum plaque thickness was also related 
with the TG in the small LDL particles, but not with TG in other LDL particles, nor with LDL-
cholesterol, showing that in this obese population, remnant cholesterol has a stronger  relation 
to atherosclerosis than LDL-cholesterol. A significant association with atherosclerosis was also 
seen for the non-HDL/non-LDL cholesterol (remnant), free cholesterol, as well as for apoB 
concentrations. The associations between other lipoprotein clusters and atherosclerosis are 
shown in supplementary material figure 6 through 9. Based on these correlations, we 
hypothesized that IL-18BP impacts on atherosclerosis via modulation of lipoprotein 
metabolism. 
 
IL-18 induced changes in liver gene expression profiles 
One of the hypothesis on the relation between IL-18BP and atherosclerosis is that it influences 
lipoprotein metabolism in the liver by affecting IL-18 activity due to its binding to IL-18. To 
directly investigate the effect of the IL-18 pathway on lipoprotein metabolism in the liver, we 
used two mouse models with genetic/pharmacological disturbances in this pathway. In the 
combined analysis, we included liver samples from WT and IL-18-/- mice and WT animals 
treated with recombinant IL-18 with the ultimate goal to identify genes controlled by IL-18.  
Analysis of the gene expression profile of the liver showed 11 genes (absolute FC > 1.3, p-value 
< 0.05) involved in lipoprotein metabolism to be upregulated in WT vs IL-18-/- mice. 
Interestingly, two genes were consistently upregulated in the WT vs IL-18-/- mice and in the 
presence of (higher) IL-18 levels (Figure 5). Both genes Protein Phosphatase 1 Regulatory 
subunit 3G (PPP1R3G) and Energy-homeostasis associated (ENHO) have been found to play an 










Figure 5 – Effect of IL-18 on transcriptome of the 
liver. Transcriptome analysis of the liver in WT vs 
IL-18-/- animals and WT animals treated once 
with PBS vs recombinant IL-18 via intraperitoneal 






In the present study, we found that IL-18BP is strongly related to presence and severity of 
carotid atherosclerosis in individuals with a BMI above 27 kg/m2. We identified that in 
individuals with obesity, circulating IL-18BP concentrations showed a stronger association 
with the presence of atherosclerosis than the currently used markers of inflammation CRP or 
IL-6. By further investigating this association using a large metabolomics platform, we were 
able to show that IL-18BP was strongly positively linked to triglyceride-rich lipoprotein 
particles, especially VLDL particles. This association between IL-18BP and VLDL particles was 
confirmed in a cohort of younger and leaner, healthy individuals. In addition, we showed that 
IL-18BP was a good systemic marker of adipose tissue inflammation.  
 
The causal role for inflammation and in particular the IL-1 pathway in atherosclerotic 
cardiovascular disease was demonstrated by the positive results of the CANTOS tria l (6). We 
now demonstrate that IL-18BP, also a member of the IL-1 family inflammatory pathway, is 
linked to adipose tissue inflammation, metabolic and cardiovascular complications in obesity. 
We hypothesize that the IL-18/IL-18BP system impacts on atherogenesis via modulation of 
VLDL metabolism in the liver. This finding might identify potential future targets for 
pharmacological strategies to prevent cardiovascular disease.   
 
IL-18BP is strongly associated with VLDL lipoprotein particles, an association we found both in 
overweight and lean individuals. We found that remnant cholesterol, and in particular the 
small-to-large VLDL particles showed the strongest association with carotid atherosclerosis in 
our obese cohort. A recent study by Lawler et al. identified VLDL as the lipoprotein particle 
most strongly related to CVD in individuals treated by statins (33). On statin therapy, levels of 
the smallest VLDL particle subclass were associated with a 68% per-SD (standard deviation) 
increase in residual cardiovascular risk. Pechlaner et al. also found VLDL associated 
apolipoproteins to be the strongest predictor for cardiovascular events in a large prospective 
population based study (34). In our cohort, IL-18BP was also strongly related to apoB levels, 
which is also associated with cardiovascular risk (35). Together with the results of the 
validation studies in mice, these data support the hypothesis of an IL-18/IL-18BP 
pathway/lipoprotein axis with an important impact on cardiovascular complications.  
 
As IL-18BP binds IL-18, we investigated the effect of IL-18 on gene expression in the liver. To 
explain the effect of the IL-18 pathway on lipoprotein metabolism, we investigated which 
hepatic genes were regulated by IL-18 using both IL-18-/- vs WT animals, and WT animals 
treated with recombinant IL-18. We identified several hepatic genes with a known role in lipid 
metabolism to be regulated by IL-18. Two of those genes, PPP1R3G and ENHO, were of 
particular interest. PPP1R3G has previously been linked to glucose homeostasis and lipid 
metabolism (36). Transgenic mice with liver-specific expression of PPP1R3G demonstrated 
increased hepatic glycogen accumulation with increased clearance rate of postprandial blood 
glucose (31). In addition to PPP1R3G, ENHO was identified as a potential IL-18 regulated gene. 
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This gene encodes the peptide adropin, which has been shown to be able to attenuate 
steatohepatitis and insulin resistance independently of the effects on adiposity or food intake 
(32). Multiple studies have suggested a protective role for adropin in human plasma in 
atherosclerosis (37) and coronary artery disease (38). IL-18BP might impact on atherogenesis 
by limiting the circulating IL-18 availability, which subsequently increases VLDL formation in 
the liver.   
 
On the other hand, in our analyses we found a stronger relation between IL-18BP and 
atherosclerosis than for IL-18, indicating that the effect of IL-18BP might be moderated 
through other factors than only changes in IL-18 bioactivity. Another potential mechanism to 
explain the association of high IL18BP with high cardiovascular (CV) risk is modulation of the 
function of the anti-inflammatory cytokine IL37, as IL18BP binds to IL37 as well (39). Due to 
the high affinity of IL18BP, the large 10-20 fold molar excess of IL18BP over IL18, this results 
in near total binding of IL18, leaving the levels of IL18 in both health and disease in the low 
picogram level (8,30). As the concentrations of IL18BP increase, there may be greater binding 
to endogenous IL37. Since IL37 is a fundamental inhibitor of both innate inflammation and 
acquired immunity (40), a reduced bioavailability of endogenous IL37 with modulatory activity 
may become a risk factor for immune-mediated diseases. In fact, low levels of IL37 in adipose 
tissues of humans are linked to high insulin resistance and mice expressing human IL37 are 
protected against obesity-associated inflammation and insulin resistance (41). The current 
methodologies for measurement of circulating IL-37 concentrations are lacking sufficient 
accuracy, but future development of better methods and assessment of IL-37 circulating 
concentrations as well as its production by peripheral blood mononuclear cells (PBMC) are 
warranted. 
 
Limitations, strengths and conclusions 
There are some limitations to our study. First, the cohorts studied are relatively small (302 and 
500 individuals). Although the fact that we validated our findings in an independent cohort 
strongly supports the validity of our data, larger studies are needed to investigate the 
possibility of IL-18BP as a biomarker of atherosclerosis. Another limitation is related to the 
cross-sectional design of our study group. No causal relations can be drawn from the 300-OB 
study directly, experimental studies will need to confirm the causal  relation. Finally, a third 
limitation is that we related the IL18 pathway to the presence of asymptomatic carotid 
plaques, and the relation to clinical atherosclerotic cardiovascular disease remains to be 
established. Importantly, we related the circulating IL-18BP concentration to the incidence of 
major adverse cardiovascular events in a population of 927 patients undergoing coronary 
angiography. In this separate cohort IL-18BP was independently predictive for  cardiovascular 
morbidity and mortality (article under review). 
 
The strength of our study is the focus on individuals with obesity, with or without 
cardiovascular and metabolic complications with a deep phenotyping of clinical and 
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immunological parameters. Another important strength is the validation of the IL -18BP 
relation with the lipoprotein groups in another cohort of mostly younger healthy individuals, 
the 500FG cohort. This study has important implications for understanding the factors that 
influence metabolic and atherosclerotic derangement in individuals with obesity: we provide 
strong arguments that inflammation in general and the IL-18/IL-18BP pathway in particular, 
plays an important role. To translate this pathway to novel pharmacological strategies to 
prevent cardiovascular disease,  it is necessary to further elucidate the underlying mechanism 
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For additional supplementary methods see chapter 4. 
 
Cardiovascular phenotyping 
The measurements were performed after an overnight fast or in the afternoon six hours after 
a standardized breakfast. Participants were asked to abstain from caffeinated products for at 
least twelve hours and they were asked not to smoke for 12 hours before the visit. Testing 
was performed in a quiet, temperature-controlled room with the patients in supine position. 
After a resting period of at least 30 minutes, baseline resting diameter, distensibility, and wall 
thickness of the carotid artery were assessed by a well-trained sonographer. A 7.5-MHz 
transducer of a Mylab Class C ultrasound device (Esaote Biomedica, Genoa, Italy) connected 
to a computer with a data acquisition board (Art.lab). Ultrasound parameters were set to 
optimize longitudinal B-mode images of the lumen/arterial wall interface. The cIMT and 
diameter measurements were performed in the proximal 1cm straight portion of the carotid 
artery in three different angles (90°, 120° and 180°) for 6 heart beats. The measurements were 
recorded during the diastolic phase. Measurement of the cIMT was performed using an 
automatic boundary detection system based on RF processing-based measurement (Art.lab, 
Esaote Europe BV, Maastricht, Netherlands) (1). Analysis of the cIMT and diameter was 
performed by an independent blinded researcher. The primary outcome variable was defined 
as the mean cIMT of the 3 different angles (2). 
Subsequently the presence of plaque and the thickness of plaques in the common carotid, 
internal carotid, or external carotid artery or at the carotid bulbus were measured. 
 
500FG cohort  
The validation of the IL-18BP relation with the lipoproteins was performed in 500 healthy 
individuals from the 500FG cohort (mean age 29 years and mean BMI 22.7 kg/m2). This cohort 




Five male IL18-/- and five male wild type (WT) mice were generated on a C57Bl/6J background 
as previously described (4). Body weight of the mice was recorded every month. To induce 
obesity, animals were fed a high-fat diet (HFD) containing 45% energy from fat (D12451, 
Research diets, New Brunswick, USA). In an additional study, ten lean female WT C57Bl/6 mice 
were treated with recombinant IL-18 or PBS for 18 hours. At the end of the experiments, when 
the mice were aged 10-14 weeks, animals were sacrificed and organs were isolated and used 
for subsequent analysis as described below. All animal studies were approved by the animal 
ethical committee of the Radboudumc. 
 
RNA isolation and qPCR analysis in mice study 
 RNA from animal tissues was isolated using Trizol Reagent (Invitrogen) following 
manufacturer’s instructions. RNA concentration and purity was determined using a Nanodrop 
(Thermo Fisher Scientific, USA). 500 ng or 1 μg of RNA was used for reverse transcription using 




Transcriptomics analysis mice study 
Two datasets were used for transcriptome analysis. The first dataset consists of pooled 
samples of 4 treatment groups (WT vs IL-18-/- and WT-treated with PBS vs WT-treated with 
recombinant IL-18 (18hrs of treatment)) that were subjected to expression profi ling by 
microarray. To this end, purified total RNA of n = 5 mouse liver samples per group was pooled 
and labelled with the Affymetrix GeneChip RNA One cycle Amplification Kit (Affymetrix, Santa 
Clara, CA, U.S.; P/N 900652) and hybridized to Affymetrix Mouse Genome 430 2.0 arrays 
(Affymetrix). Quality control and data analysis pipeline have been described in detail 
previously (5). Briefly, normalized expression estimates of probe sets were computed by the 
robust multi-array analysis (RMA) algorithms implemented in the Bioconductor library 
AffyPLM (6). Probe sets were redefined using current genome information according to Dai et 
al (7). based on annotations provided by the Entrez Gene database, which resulted in the 
profiling of 18,075 unique genes (custom CDF v21). Genes that differed more than 1.3 fold 
between IL-18-/- and WT, or between IL-18 and PBS treatment were selected for subsequent 
analysis. A second dataset consisting of raw expression data of livers of WT and IL-18-/- mice 
of 12 weeks of age were extracted from the Gene Expression Omnibus (GSE64309) (8). Data 
was background corrected using the normexp+offset method (9). followed by quantile 
normalized using functions in the library limma.(10) Next differentially expressed genes were 
identified by using linear models and an intensity-based moderated t-statistic. Probe sets that 
satisfied the criterion of P < 0.05 were considered to be regulated. To identify IL-18 regulated 
genes, both datasets were combined using a FC > 1.3 and a P-value < 0.05 as selection criteria.    
Pooled samples of the 4 study groups (male mice (10-14 weeks of age): WT, IL-18-/-, and 
female mice (10-14 weeks of age): WT-PBS, WT-recombinant IL18 (18hrs of treatment) were 
subjected to expression profiling by microarray. To this end, purified total RNA of 2 (WT vs. 
IL18-/-) or 4 (WT-PBS vs. WT-rIL-18) liver samples per study group was pooled and labelled 
with the Affymetrix GeneChip RNA One cycle Amplification Kit (Affymetrix, Santa Clara, CA, 
U.S.; P/N 900652) and hybridized to Affymetrix Mouse Genome 430 2.0 arrays (Affymetrix). 
Quality control and data analysis pipeline have been described in detail previously (5).  
Briefly, normalized expression estimates of probe sets were computed by the robust 
multiarray analysis (RMA) algorithm as implemented in the Bioconductor library AffyPLM (6). 
Probe sets were redefined using current genome information according to Dai et al. (7) based 
on annotations provided by the Entrez Gene database, which resulted in the profiling of 
18,075 unique genes (custom CDF v21). Genes that differed more than 1.3 fold between IL18-
/- versus WT, or PBS versus recombinant IL-18 treatment were selected for subsequent 
analysis. 
Raw expression data of livers from wild-type and IL18-/- male mice of 12 weeks of age were 
extracted from the Gene Expression Omnibus (GSE64309) (8). Data was background corrected 
using the normexp+offset method (9) followed by quantile normalized using functions in the 
library limma (10, 11). Next, differentially expressed genes were identified by using linear 
models and an intensity-based moderated t-statistic (10, 11). Probesets that satisfied the 
criterion of moderated P < 0.05 were considered to be regulated. 
Results from our and the published dataset were compared as follows: all genes that were 
differentially expressed (moderated P < 0.05) in livers of the 12 weeks-old IL18-/- mice 
(GSE64309) were selected. Next, for these 52 genes, the log2FC were retrieved from our 
datasets and together with the log2FC of the published dataset visualized in a heatmap. The 





Regression analysis was performed using the “Rfit” package, as implemented in the “R” 
language. Rfit is a regression method that is more robust to outliers in response space than 
the standard linear models. Depending on the analyses, different factors were included as 
covariates to adjust for the effect of e.g. age, gender, BMI, smoking, drug usage and season. 
P-values are within Rfit calculated using the t-statistic, which is the ratio between the estimate 
and it’s standard error. The p-value is based on a t distribution with n-p-1 degrees of freedom 
where p is the number of regression parameters. Seasonality was corrected using the method 
described in Ter Horst et al.(12) 
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Supplemental Figure 1 –   IL-18BP is independently associated with maximum plaque thickness. 
IL-18BP was in an univariate analysis associated with maximum plaque thickness. In model 1, 
after adjustment for age, sex and smoking (pack years). In model 2, after additional 
adjustment for the classical cardiovascular risk factors (systolic blood pressure, glucose level, 
HDL and LDL cholesterol, lipid lowering, antihypertensive and antidiabetic drugs) IL -18BP 
remained significantly associated. However in model 3, after additional adjustment for 






Supplemental Figure 2 - Unadjusted relation between all lipoprotein groups, IL-18BP, IL-18, CRP and IL-
6. IL-18 and IL-18binding protein show the strongest positive spearman correlations with the small to 
large VLDL particles. Next to that they show strong positive associations with apoB levels and with the 
triglycerides in extremely large HDL. Both IL-18BP and IL-18 are negatively associated with HDL-
cholesterol. Neither CRP nor IL-6 showed a significant association. 
XXL.VLDL Chylomicrons and extremely large VLDL particles; XL. Very large; L. Large; M. Medium; S. 
Small; XS. Extreme small; VLDL Very Low Density Lipoproteins; IDL Intermediate Density Lipoproteins; 
LDL Low Density Lipoproteins; HDL High Density Lipoproteins; .L Total lipids; .TG Triglycerides; .PL 
Phospholipids; .D Mean diameter; Serum.C Serum cholesterol; ApoB Apolipoprotein B; HDL3.C Total 
cholesterol in HDL3; ApoA1 Apolipoprotein A1; IL-18BP Interleukin-18 binding protein; IL-18 Interleukin-




Supplemental Figure 3 - Relation of lipids in HDL groups with IL-18BP, IL-18, CRP and IL-6.  
Heatmap with relation between lipids in HDL groups, group 9,11 and 13 of the metabolites, 
and IL-18BP, IL-18, CRP and IL-6. 
L. Large; M. Medium; S. Small; HDL High Density Lipoproteins; .P Concentration of particles; .L 
Total lipids; .PL Phospholipids; .C Total cholesterol; .CE Cholesterol esters; .FC Free cholesterol; 
.TG Triglycerides; .D Mean diameter; Serum.C Serum cholesterol; HDL2.C; IL-18BP Interleukin-






Supplemental Figure 4 – Relation of HDL triglycerides with IL-18BP, IL-18, CRP and IL-6.  
XL. Very large; L. Large; M. Medium; S. Small; XS. Extreme small; HDL High Density 
Lipoproteins; IL-18BP Interleukin-18 binding protein; IL-18 Interleukin-18; CRP C-reactive 





Supplemental Figure 5 - Relation between all lipoprotein groups, IL-18BP, IL-18, CRP and IL-6 
adjusted for influencing factors. (A) Heatmap with the correlation between the lipoprotein 
group, IL-18binding protein, IL-18, hsCRP and IL-6, adjusted for age, sex, smoking and season.  
(B) With additional adjustment for BMI.  
XXL.VLDL Chylomicrons and extremely large VLDL particles; XL. Very large; L. Large; M. 
Medium; S. Small; XS. Extreme small; VLDL Very Low Density Lipoproteins; IDL Intermediate 
Density Lipoproteins; LDL Low Density Lipoproteins; HDL High Density Lipoproteins; .L Total 
lipids; .TG Triglycerides; .PL Phospholipids; .D Mean diameter; Serum.C Serum cholesterol; 
ApoB Apolipoprotein B; HDL3.C Total cholesterol in HDL3; ApoA1 Apolipoprotein A1; IL-18BP 








Supplemental Figure 6 - Unadjusted relation between all lipoprotein metabolites and 
atherosclerosis markers. Relation between all lipoprotein metabolites with the mean intima-
medial thickness of both carotid arteries and the maximum plaque thickness assessed by 
carotid ultrasound.  
XXL.VLDL Chylomicrons and extremely large VLDL particles; XL. Very large; L. Large; M. 
Medium; S. Small; XS. Extreme small; VLDL Very Low Density Lipoproteins; IDL Intermediate 
Density Lipoproteins; LDL Low Density Lipoproteins; HDL High Density Lipoproteins; .L Total 
lipids; .TG Triglycerides; .PL Phospholipids; .D Mean diameter; Serum.C Serum cholesterol; 
ApoB Apolipoprotein B; HDL3.C Total cholesterol in HDL3; ApoA1 Apolipoprotein A1; cIMT 







Supplemental Figure 7 - Relation of lipids in HDL groups with atherosclerosis markers.  
Heatmap with relation between lipids in HDL groups, group 7, 9,11, 13 and 14 of the 
metabolites, and the mean intima-medial thickness of both carotid arteries and the maximum 
plaque thickness assessed by carotid ultrasound 
L. Large; M. Medium; S. Small; HDL High Density Lipoproteins; .P Concentration of particles; .L 
Total lipids; .PL Phospholipids; .C Total cholesterol; .CE Cholesterol esters; .FC Free cholesterol; 
.TG Triglycerides; .D Mean diameter; Serum.C Serum cholesterol; HDL2.C; IMT intima-medial 





Supplemental Figure 8 - Relation of triglycerides in large HDL particles with atherosclerosis 
markers. Triglycerides in extremely large and medium HDL particles, group 8 and 12 of the 
metabolites respectively, are positively associated with maximum plaque thickness assessed 
by carotid ultrasound 
L. Large; HDL High Density Lipoproteins; TG Triglycerides; IMT intima-medial thickness; 





Supplemental Figure 9 - Relation between all lipoprotein groups and atherosclerosis markers, 
adjusted for influencing factors. (A) Heatmap with the correlation between the lipoprotein 
group, the mean intima-medial thickness of both carotid arteries and the maximum plaque 
thickness assessed by carotid ultrasound adjusted for age, sex, smoking and season. (B) With 
additional adjustment for BMI.    
XXL.VLDL Chylomicrons and extremely large VLDL particles; XL. Very large; L. Large; M. 
Medium; S. Small; XS. Extreme small; VLDL Very Low Density Lipoproteins; IDL Intermediate 
Density Lipoproteins; LDL Low Density Lipoproteins; HDL High Density Lipoproteins; .L Total 
lipids; .TG Triglycerides; .PL Phospholipids; .D Mean diameter; Serum.C Serum cholesterol; 
ApoB Apolipoprotein B; HDL3.C Total cholesterol in HDL3; ApoA1 Apolipoprotein A1; cIMT 
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Altered gut microbial composition has been linked to cardiovascular diseases (CVD), but its 




To systematically assess functional links between the microbiome and the plasma 
metabolome, cardiometabolic phenotypes and CVD risk and to identify diet-microbe-
metabolism-immune interactions in well-documented cohorts. 
 
Methods and Results 
We assessed metagenomics-based microbial associations between 231 plasma metabolites 
and microbial species and pathways in the population-based Lifelines-DEEP cohort (n = 978) 
and a clinical obesity cohort (n = 297). After correcting for age, gender and BMI, the gut 
microbiome could explain up to 11.1% and 13.4% of the variation in plasma metabolites in the 
population-based and obesity cohorts, respectively. Obese-specific microbial associations 
were found for lipid compositions in the VLDL, IDL and LDL lipoprotein subclasses. Bacterial L-
methionine biosynthesis and a Ruminococcus species were associated to cardiovascular 
phenotypes in individuals with obesity, namely atherosclerosis and liver fat content, 
respectively. Integration of microbiome-diet-inflammation analysis in relation to metabolic 
risk score of CVD in the population cohort revealed 48 microbial pathways associated to CVD 
risk that were largely independent of diet and inflammation. Our data also showed that 
plasma levels rather than fecal levels of short chain fatty acids were relevant to inflammation 
and CVD risk. 
 
Conclusions 
This study presents the largest metagenome-based association study on plasma metabolism 
and microbiome relevance to diet, inflammation, CVD risk and cardiometabolic phenotypes in 
both population-based and clinical obesity cohorts. Our findings identified novel bacterial 
species and pathways that associated to specific lipoprotein subclasses and revealed 
functional links between the gut microbiome and host health that provide a basis for 






The human gut is colonized by a highly complex community of microorganisms called the 
microbiome. The gut microbiome interacts closely with the host and is involved in digestion 
and degradation of nutrients, maintenance of digestive tract integrity, stimulation of the 
immune system and modulation of the host metabolism (1,2). Recent studies indicate a strong 
link between the gut microbiota and the development of various human diseases, including 
obesity (3,4), insulin resistance and type 2 diabetes (5,6), as well as gastrointestinal (7,8), 
autoimmune (9–11), and cardiovascular (12,13) disorders (CVD). Various studies have 
provided evidence that host-microbe interactions contribute to the etiology of many of these 
diseases through their impact on metabolism and immunity. Lower bacterial richness (a 
reduction in the number of different species or bacterial genes) has been associated with an 
overall increase in adiposity, insulin resistance, dyslipidemia and inflammatory phenotypes (3). 
The distinct gut microbiome profile found in overweight individuals has been shown to have 
an increased capacity to harvest nutrients from food (14). Moreover, the gut microbiome is 
also associated with an individual’s cytokine production capacity in response to different 
pathogens (15). Despite a large body of evidence from cross-sectional association studies, the 
underlying mechanisms are largely unknown and several putative mechanisms and functional 
links have been proposed. For instance, the impact of the gut microbiome on insulin sensitivity 
and glucose homeostasis may be mediated via microbial biosynthesis of branched-chain 
amino acids (5), short-chain fatty acids (SCFAs) and N-acyl amides (16,17). The fermentation 
products of dietary fibers, in particular SCFAs, also have potential roles in the host’s innate 
and adaptive immunity through modulation of cell proliferation and differentiation (18,19), 
hormone secretion (20), G protein-coupled receptor activation and regulation of colonic Treg 
cell homeostasis (21–23). Finally, inhibition of gut-microbiome-induced trimethylamine-N-
oxide (TMAO) production can attenuate atherosclerosis development in mice (12,24). 
However, our understanding of the functions of gut microbes and of diet-microbe-
metabolism-immune interactions in CVD remains limited, leaving a knowledge gap that 
greatly delays clinical translation. Evaluating the complex interactions between the gut 
microbiome, host metabolism and immune system—as affected by intrinsic host and external 
factors (diet, medication)—requires multi-omics, systems-biology-based approaches (25).  
To do so, we examined both a population-representative and an overweight patient cohort, 
collectively comprising 1,275 individuals. The obese cohort was deeply phenotyped for 
cardiometabolic traits, fat distribution and plasma level of TMAO, while the population-based 
cohort was deeply phenotyped for inflammation, diet and SCFAs (Figure 1A). We first aimed 
to identify microbial species and metabolic pathways associated with plasma metabolite 
profiles (Fig 1B). We then identified the relevance of these metabolism-related microbial 
factors to cardiometabolic phenotypes in the obese patient cohort. Finally, we assessed 
individual metabolic risk of CVD in the population-based cohort, and identified bacterial 
pathways associated to the CVD risk score and assessed the diet-microbe-metabolism-






Figure 1 – Study overview. A. This study included a population-representative cohort (LLD) with 
an average BMI of 25 kg/m2 and a cohort of individuals with overweight and obesity (300-OB 
study) with an average BMI of 31 kg/m2. In addition to metagenomics-sequencing data and 
plasma metabolomics generated for all individuals, unique phenotypic information was 
collected in each cohort. In the population-representative LLD, detailed lifestyle and 
phenotypic information was collected, including 78 dietary factors, 12 inflammatory markers 
and stool levels of 5 short-chain fatty acids (SCFAs). In the 300-OB study, detailed cardiome-
tabolic phenotyping was conducted, including assessment of carotid artery plaques and the 
amount of subcutaneous and visceral adipose tissue and liver fat measured using magnetic 
resonance imaging. B. Analysis scheme. The whole analysis can be divided into four steps: 1) a 
metagenome-wide association study (MWAS) to explore pair-wise association between 231 
metabolic traits and metagenomics-based 188 species and 562 pathways in LLD and 300-OB, 
respectively, 2) an MWAS to assess the relevance of metabolome-associated microbial fea-
tures to cardiometabolic phenotypes in the 300-OB cohort, 3) an MWAS to identify microbial 
factors associated with the metabolic risk score (MRS) of CVD in LLD, which was constructed 
using 33 metabolic biomarkers, and 4) an integration analysis to assess the relevance of 78 
dietary factors, inflammatory cytokines, and SCFAs in microbial association of MRS in LLD. 
 
METHODS 
All metegenomics and metabolism data have been made publically available at the European 
Genomics-phenome Archieve (EGA) at accession number EGAS00001001704 for the LifeLines-
DEEP cohort and EGAS00001003508 for the 300-Obese cohort. Because of the sensitive nature 
of clinic data collected for this study, requests to access clinical phenotypic data of the 
Lifelines-DEEP cohort and 300-Obese cohort may be sent to the LifeLines cohort study at 




LifeLines-DEEP cohort (LLD) 
LLD is a sub-cohort of the large, prospective, population-based LifeLines cohort (167,729 




Participants volunteered to participate in LLD from April to August 2013, with blood and fecal 
samples collected in the same period (within 2 weeks). High quality metagenomic data and 
detailed dietary (78 dietary factors) information are available for 1,135 LLD participants (13), 
and 1,046 LLD individuals were profiled for plasma metabolites and inflammation data (see 
sections below). We further excluded 57 participants who were taking antibiotics or lipid-
lowering medication and 11 non-fasting subjects. This left 978 subjects (411 males and 567 
females) for further analyses.  
 
300-Obesity cohort (300-OB) 
Between 2014 and 2016, 302 individuals aged 55 to 80 years were enrolled in the 300-OB 
study at the Radboud University Medical Center (RUMC), Nijmegen, the Netherlands. All had 
a body mass index (BMI) > 27 kg/m2, and the majority (n = 227) had participated in the 
Nijmegen Biomedical Study–Non-Invasive Measurements of Atherosclerosis 1 (NBS-NIMA1) 
study, a population-based survey of Nijmegen residents (28). We recruited another 75 
participants, acquaintances of previously-included subjects, who fulfilled the inclusion criteria 
of age > 55 years and BMI > 27 kg/m2. Most of these new participants were unrelated subjects, 
with only nine being family members of previously-included subjects; we therefore did not 
separately evaluate or incorporate the potential clustering of subjects. Subjects with a recent 
cardiovascular event (myocardial infarction, transient ischemic attack, stroke < 6 months), a 
history of bariatric surgery or bowel resection, inflammatory bowel disease, renal dysfunction, 
increased bleeding tendency, use of oral or subcutaneous anti-coagulant therapy, use of 
thrombocyte aggregation inhibitors other than acetylsalicylic acid and carbasalate calcium, or 
a contra-indication for magnetic resonance imaging (MRI) were excluded from the study. 
Participants who used lipid-lowering therapy temporarily discontinued this medication 4 
weeks prior to the measurements. All women were postmenopausal and did not use hormonal 
replacement therapy. All subjects completed questionnaires about lifestyle, medication use 
and previous diagnosis of hypertension and diabetes. For all participants, blood samples for 
metabolomics analysis were collected in the morning following an overnight fast. All 
underwent comprehensive assessment of cardiovascular profile and fat distribution, as 
detailed below. Five samples of metagenomic data failed to pass the quality control, leaving 
297 individuals for further analyses.  
 
Cardiovascular phenotyping in the 300-OB cohort 
Cardiovascular assessment was performed at Radboud UMC. Vascular studies included the 
measurement of carotid intima-medial thickness (cIMT), carotid plaque presence and 
maximum plaque thickness. Measurements were performed after an overnight fast or in the 
afternoon 6 hours after a standardized breakfast. Participants were asked to abstain from 
caffeinated products for at least 12 hours and to not smoke for 12 hours before the visit. 
Testing was performed in a quiet temperature-controlled room with patients in supine 
position. After a resting period of at least 30 minutes, baseline resting diameter, distensibility 




7.5-MHz transducer of a Mylab Class C ultrasound device (Esaote Biomedica, Genoa, Italy) 
connected to a computer with a data acquisition board (Art.lab, Esaote Europe BV, Maastricht, 
Netherlands). Ultrasound parameters were set to optimize longitudinal B-mode images of the 
lumen/arterial wall interface. The cIMT and diameter measurements were performed in the 
proximal 1cm straight portion of the carotid artery in three different angles (90°, 120° and 
180°) for 6 heartbeats. Measurements were recorded during the diastolic phase. 
Measurement of cIMT was performed using an automatic boundary detection system based 
on RF processing-based measurement (Art.lab) (29). The primary outcome variable was 
defined as the mean cIMT of the different angles (30). 
Subsequently the presence of plaque and the maximum thickness of plaques in the common 
carotid, internal carotid, external carotid artery and at the carotid bulbus were measured. 
Presence of plaque was defined as focal thickening of the wall of at least 1.5x the mean IMT 
or an IMT > 1.5mm, according to the Mannheim intima-media thickness consensus (31). 
Furthermore, fat distribution was assessed using MRI, including volumes of visceral adipose 
tissue (VAT) and subcutaneous adipose tissue (SAT), divided into deep and superficial 
subcutaneous adipose tissue (dSAT and sSAT), respectively. Hepatic fat content was quantified 
using localized proton magnetic resonance spectroscopy (1H-MRS) (detailed methods see 
online supplementary material). 
 
Microbiome data profiling 
Metagenomic shotgun sequencing 
High quality metagenomics data were already available for the 1,135 LLD participants (13). For 
this study, we performed metagenomic sequencing of the 300-OB cohort using a similar 
protocol and analysis pipeline. In brief, fecal and blood samples were collected within 2 weeks 
for LLD participants and within 1-2 days for 300-OB participants in order to reduce potential 
bias introduced by sampling. Further processing of all sample sets was identical to LLD. In brief, 
DNA was isolated with the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany; cat. #80204) 
with the addition of mechanical lysis. Metagenomic shotgun sequencing was performed using 
the Illumina HiSeq platform (Illumina, San Diego, California), with an average of 3.0 Gb data 
(around 32.3 million reads) obtained per sample. Reads were quality-filtered using our in-
house pipeline. Sequencing adapters were removed using Trimmomatic (v.0.32) (32). Human 
reads were removed by mapping the data to the human reference genome (version NCBI37) 
with Bowtie2 (v.2.1.0).  
 
Identifying microbial taxa abundances 
The profile of microbial composition was determined using MetaPhlan 2.2 (33), and it 
reported 1,772 microbial taxonomies in our data. We normalized the taxonomy data using 
log- and inverse rank sum transformation and further corrected for age and sex with linear 
regression. We confined the analysis to the 188 common microbial species (online 





Identifying abundances of bacterial metabolic pathways 
The abundance of metabolic pathways was determined using HUMAnN2 
(http://huttenhower.sph.harvard.edu/humann2), which maps reads to a customized 
database of functionally annotated pan-genomes. This analysis mapped reads to UniProt 
Reference Clusters (UniRef50, http:/www.uniprot.org), then further grouped them to 773 
pathways from the MetaCyc metabolic pathway database (www.metacyc.org). Only pathways 
present in > 25% of samples (562 pathways, online supplementary material Table 2) were used 
in our downstream analysis. For the non-zero gene counts per MetaCyc pathway, we 
performed log- and inverse rank sum transformations, followed by correction for the effects 
of age and sex using linear regression. 
 
Plasma metabolome profiling  
For both cohorts, we profiled a wide range of plasma metabolites using nuclear magnetic 
resonance (NMR) and Nightingale's Biomarker Analysis Platform (34). This platform provides 
measures of 231 plasma metabolome traits (online supplementary material Table 3), including 
total lipid concentrations and relative compositions of 14 lipoprotein subclasses, lipoprotein 
particle sizes, apolipoproteins, cholesterol, glycerides and phospholipid concentrations, 
various glycolysis components, fatty acid composition, inflammation, fluid balance, ketone 
bodies and amino acids. The NMR metabolomics platform has recently been used in several 
epidemiological, genome-wide association and functional genetic studies (35–37). To further 
validate platform precision, we compared NMR measures of several traits with corresponding 
routine lipid measurements, including concentrations of HDL, LDL, triglycerides and total 
cholesterol (supplementary material Figure 1). For these traits we observed very high 
correlation rates (R > 0.89), in agreement with earlier platform validation results (37). There 
were ~2.2% missing values across all data. Given the high correlation structure of metabolites, 
missing values could be imputed using the Principal Components Imputation method 
implemented in the “missMDA” package for R, using the first 10 principal components. Prior 
to microbiome-metabolome association analysis, due to non-linear dependency of 
metabolomic traits to covariates, we used locally weighted scatterplot smoothing (LOESS) to 
correct for sex-dependent age and BMI effects. 
 
Adipokine and cytokine profiling in LLD 
The panel of cytokines for the LLD cohorts (IL-1β, IL-6, IL-8, IL-10, IL-12p70 and TNF-α) was 
measured by ProcartaPlexTM multiplex immunoassay (eBioscience, San Diego, California, 
USA) according to protocols described before (38,39). Other inflammation markers were 
measured by using commercially available sandwich ELISA kits (R&D systems, Minneapolis, 








SCFA profiling in LLD 
For LLD, we measured fecal levels of acetate, propionate, butyrate, valerate and caproate by 
gas chromatography-mass spectrometry following the method of Garciá-Villalba et al (2012) 
(40). The abundance of acetate in plasma was obtained through plasma metabolome profiling 
using NMR. All SCFA measurements were corrected for age and gender using LOESS. 
 
TMAO, choline, betaine and citrulline profiling in 300-OB 
TMAO, choline, L-carnitine, betaine and γ-butyrobetaine in plasma were analyzed by ultra-
high performance liquid chromatography in combination with isotope dilution tandem mass 
spectrometry (UPLC-MS/MS). In short, 25μL plasma was pipetted into 96-well plates, 25μL 
internal standard solution was added (containing TMAO-D9, choline-D9, L-carnitine-D3 and 
betaine-D11), followed by 300μL 80% acetonitrile (ACN) and 1% formic acid (FA) in Millipore 
water. Mass spectrometric detection was performed on a XEVO TQ-s system (Waters). 
Analytes were detected in positive mode and selected reaction monitoring mode. The 
respective quantifier ion transitions were as follows: m/z 76.15 > 58.3 for TMAO, m/z 104.2 > 
60.3 for choline, m/z 162.2 > 103.25 for L-carnitine, m/z 118.2 > 59.3 for betaine and m/z 
146.25 > 60.3 for γ-butyrobetaine. All analytes were baseline separated from each other. 
 
Statistical analysis 
Microbiome-metabolome association and explained variance  
(a) To identify the associations between metabolic and microbial factors, association analyses 
were performed in both LLD and 300-OB. Microbiome features included both microbial 
pathways and species. After adjusting for age, sex, BMI and smoking, Spearman correlation of 
metabolic traits and microbiome features was used to identify associations. The analysis was 
confined to pair-wise non-zero values. False discovery rate (FDR) was estimated using 100x 
permutations. We also calculated the permutation-based family-wise error rate (FWER) and 
report the top association at FWER < 0.05 level. (b) To estimate the proportion of variation in 
plasma metabolism explained by microbial factors, we used a LASSO shrinkage model (41) that 
included all identified microbial pathways and species as predictors. The independent and 
most dominant microbial features were selected automatically, and the variation of each 
metabolite explained by the selected microbial factors was then estimated by LASSO. 
Moreover, we used the same LASSO algorithm to estimate the proportion of metabolic 
variation in 300-OB explained by microbial factors identified in LLD. 
 
Association to cardiometabolic phenotypes 
The bacterial pathways and species identified were further tested for association with 
cardiometabolic phenotypes in 300-OB, including fat distribution and atherosclerosis 
phenotypes. The analysis was performed using linear regression, with cardiometabolic 
phenotype as outcome and microbiome feature as predictor, and treating age, sex and BMI 
as covariates. Quantitative outcomes were adjusted using inverse rank-sum transformation; 




to assess to what extent bacterial-derived TMAO and its relevant metabolites could underlie 
microbial associations to cardiometabolic phenotypes, we performed extra analysi s with 
adjustment for the plasma levels of TMAO, choline, betaine and L-carnitine. Significant 
associations for each phenotypic trait are reported at empirical FDR < 0.05 level based on 100x 
permutations.  
 
Microbiome association to metabolic risk of CVD 
To estimate individual metabolic risk for CVD development in the population cohort, we used 
33 established metabolic biomarkers for CVD measured using the same NMR platform and 
associated with future CVD incidents in three perspective cohorts (36). We first constructed 
each individual’s CVD metabolic risk score (MRS) using a weighted risk model: 




where Mi is the scaled level of the i-th metabolic marker in serum, not adjusted for phenotypes, 
and bi is a hazard ratio for the corresponding effect of each metabolic marker on the CVD risk 
as reported by Würtz et al (36). The MRS score showed a normal distribution. We then tested 
MRS association to microbial pathways and species, adjusting for age, sex, BMI and smoking. 
The significance was controlled at FDR < 0.05 based on 100x permutations. For microbiome 
pathways, we also examined to what extent these pathways are driven by specific taxa by 
calculating Spearman correlations between pathways abundance and taxa abundance. 
 
Integration association with dietary factors, inflammatory markers and stool levels of SCFAs  
To better understand the functional properties of the MRS-associated bacterial pathways in 
relation to metabolism, inflammation, diet and SCFAs, we conducted an integration analysis 
with 12 inflammatory markers, 78 dietary factors and stool levels of 5 SCFAs.  
First, we computed pair-wise associations between MRS-associated pathways and each of 
these factors, using linear regression adjusted for age, sex, BMI and smoking and controlling 
for FDR 0.05 using 100x permutations per dataset (cytokines, diet, SCFA) separately. All traits 
were transformed using inverse rank sum transformation prior to analysis.  
Second, to elaborate if pathway-cytokine associations were dependent on MRS, we 
recalculated these associations using linear regression, additionally adjusting for MRS as a 
covariate.  
Finally, to explore if the microbial pathways were associated to variance of MRS independently 
of inflammatory markers and diet, we performed stepwise model selection for each pathway, 
with MRS as outcome and pathway, age, sex, BMI, smoking, all pathway-associated cytokines 
and all pathway-associated diet categories as predictors. This was done using the stepAIC 
function from R package MASS. At each selection step, predictors were selected by both 
forward and backward direction using AIC value (Akaike information criterion) as an indicator 
of goodness-of-fit. The model with the highest AIC was selected as the best model. Pathways 






Gut microbiome associated with plasma metabolomics in healthy individuals and 
individuals with obesity 
This study included 1,275 individuals from two independent Dutch cohorts: 978 subjects from 
the population-based cohort LifeLines-DEEP in the Northern part of the Netherlands (the 
provinces of Groningen, Drenthe and Friesland), with an average age of 44.5 years (18-81 
years), an average BMI of 25 (16-45) and 42% male and 297 individuals were from the 300-OB 
cohort on the territory of Nijmegen province, with an average age of 67 (54-81 years), an 
average BMI of 30 (26.3-45.5) and 55% male. Both the LLD and 300OB cohorts followed 
cohort-specific, disease- and drug-specific exclusion criteria (see Methods). We measured 
both serum metabolomics and gut metagenomics profiles in both cohorts (Figure 1A). After 
quality check and imputation of ~2.2% missing values, a total of 188 microbial species (online 
supplementary material Table 1), 562 bacterial metabolic pathways (online supplementary 
material Table 2) and 231 metabolic traits (online supplementary material Table 3) were 
subjected to association analysis. After correcting for age, gender and BMI, microbial 
associations were detected for 210 metabolites in LLD at FDR 0.05 level, with 64 associations 
to 12 species and 4,135 associations to 308 pathways. To evaluate if imputation of missing 
values in the metabolite data (see Methods) introduced any systematic bias, we re-conducted 
association analyses by removing missing values following two approaches, and found 
concordant results (supplementary material Figure 2). For instance, after removing missing 
values, 3,952 significant associations were detected at FDR 0.05 level, and 3,597 of these 
overlapped with 4,135 associations revealed by missing values imputation. In the 300-OB 
cohort, microbial associations were detected for 35 metabolites, with three associations to 
one species and 72 associations to 16 pathways. All significant associations at FDR < 0.05 level 
can be downloaded from https://github.com/alexa-kur/NMR_microbiome. Most of the 
microbial factors identified showed very modest effects and could jointly explain, on average, 
3.7% of the variation in LLD and 7.7% of the variation in 300-OB (Figure 2). The highest levels 
of variation explained were 11.1% for glycoprotein N-acetyls (Gp) in LLD and 13.4% for 
IDL_C_percent in 300-OB. The smaller number of associations in 300-OB was likely due to its 
smaller sample size, but our data also show that the microbial factors identified in LLD 
generally had lower predictive value for metabolic variation in 300-OB (Figure 2). This 
indicates there are some genuine differences in microbial associations between the 
population and the obese cohort. We further compared association strength and directions 
for the top associations from both cohorts (supplementary material Figure 3 and 4), including 
17 associations to microbial species (online supplementary material Table 4) and 297 
associations to pathways (online supplementary material Table 5) at FWER 0.05 level. We 
observed some obese-specific associations, particularly for the relative composition of 
lipoprotein subclasses. For instance, we found significant associations of Ruminococcus 
species sp_5_1_39BFAA to XXL-VLDL_PL_percent (r = 0.31, P = 2.3x10-7) and 
XL_VDL_CE_percent (r = -0.29, P = 1.25x10-6) in 300-OB that were completely absent in LLD (P 




also observed several opposite associations between LLD and 300-OB. For instance, the 
pathway of pyruvate fermentation to acetate and lactate (PWY-5100) was positively 
associated to S_VLDL_C_percent in LLD (r = 0.15, P = 1.35x10-6), yet showed a negative 









































Figure 2 – Variation of plasma metabolites explained by the identified gut microbiome. Bar 
plot shows the variation of 231 metabolites explained by identified microbial factors in LLD 
(left) and in 300-OB (right). Each bar represents one metabolite. Bar color indicates type of 
metabolite according to the color key at right. We also assessed to what extent the microbial 
factors identified in the LLD cohort could explain the metabolic variation in the 300-OB cohort. 
This data is shown by the gray bars on the right.  
 
Metabolism-related microbial factors linked to clinical phenotypes in subjects with obesity 
To investigate whether the microbial factors found to be associated with plasma metabolites 
were related to end-point phenotypes, we focused on the top associated species and 
pathways from both cohorts (online supplementary material Table 4-5) and further tested 
their associations to 27 cardiometabolic phenotypes in the 300-OB cohort (Figure 1B). After 
correcting for age, sex and BMI, two microbial factors were identified with FDR < 0.05 (online 
supplementary material Table 6): higher abundance of bacterial L-methionine biosynthesis 
(HSERMETANA-PWY) was significantly associated with the presence of plaque (P = 0.001) and 
Ruminococcus sp_5_1_39BFAA was positively associated to hepatic fat content (Liver-fat) (r = 
0.21, P = 5.0x10-4) (Figure 3). Previous studies have suggested that gut-microbiome-derived 
TMAO can increase CVD risk. We observed that plasma level of TMAO was positively 
associated to visceral fat (r = 0.167, P = 0.002) but not to atherosclerosis phenotypes and 
hepatic fat (online supplementary material Table 7), nor was it associated to metabolite-
associated species and bacterial pathways (online supplementary material Table 8). After 
correcting for TMAO and its related metabolites (L-carnitine, choline and betaine), 
associations of L-methionine biosynthesis and Ruminococcus sp_5_1_39BFAA to 
cardiometabolic phenotypes remained similar (online supplementary material Table 6).  
 
Figure 3 - Associations of gut microbial pathways and species with clinical outcomes in the 300-
Obese cohort. A. Abundance of the L-methionine synthesis pathway (HSERMETANA-PWY) is 
significantly higher in individuals with carotid atherosclerotic plaques. B. Ruminococcus 
sp_5_1_39BFAA is significantly correlated with liver fat content measured by magnetic 







Microbial pathways linked to metabolic risk of CVD in the LLD general population cohort 
We further assessed the association of the gut microbiome to individual MRSs of CVD in LLD 
(Figure 1B). To do so, we constructed CVD MRSs using 33 established CVD metabolic 
biomarkers that have been associated with future CVD incidents and that were independent 
of other known risk factors like age, gender, BMI and smoking status (36). At FDR 0.05 level, 
48 associations of MRS with microbial pathways were detected (Figure 4, online 
supplementary material Table 9).  
 
Figure 4 - Association of 48 microbial pathways with metabolic risk score of CVD, SCFAs in stool, 
cytokines and dietary factors. Bar plot on the right shows the associations of 48 microbial 
metabolic pathways with MRS of CVD. Y-axis refers to the association strength in terms of 
beta-value. Red bars indicate positive associations and blue bars indicate negative associations. 
The 3-panel heatmap on the left shows the associations of MRS-associated pathways with 
plasma levels of cytokines, stool levels of SCFAs and dietary factors, respectively. Blue cells 
indicate negative associations. Red cells indicate positive associations. White stars indicate 
significance at FDR < 0.05. The color key at the bottom shows association strength and 




The top associated pathways were related to GDP-mannose biosynthesis (PWY-7323), which 
was negatively associated with CVD MRS (beta = -0.122, P = 7.5x10-6). Interestingly, a large 
number of associated pathways were involved in amino acid (AA) metabolism, including 
metabolism of glutamate-family AAs (L-proline, L-arginine, L-histidine, L-histidine), branched-
chain AAs (L-valine), hydrophobic AAs (L-threonine), aromatic AAs (L-phenylalanine and L-
tyrosine) and sulfur-containing AAs (L-methionine). Most AA pathways were associated to 
lower MRS score, except for positive associations detected for L-methionine and L-threonine. 
Other associated pathways were mostly involved in, among others, fermentation, 
carbohydrates and sugar derivatives metabolism (online supplementary material Table 9). We 
also assessed to what extent specific bacterial taxa can drive MRS-related microbial pathways. 
For this purpose, we identified the top taxon for each pathway that showed the strongest 
association between the abundances of the taxon and the pathway (online supplementary 
material Table 9). What we found is that the relative contribution of the top taxa varied 
greatly: the correlation coefficients between top taxa and pathways ranged from 0.26 to 0.89, 
with an average value of 0.60. This suggests that some pathways are driven by one dominant 
bacterial player, while others may be attributed to many different players. For instance, 
phylum Bacteroidetes—including class Bacteroida and families Bacteroidaceae and 
Rikenellaceae—is the major player in 17 of 31 lower-MRS-associated pathways, in particular 
GDP-mannose biosynthesis and glutamate-family AAs (r > 0.8). In contrast, the top players in 
L-methionine metabolism, the Ruminococcus genus and Actinobacteria phylum, only 
contributed a very modest effect (online supplementary material Table 9).  
 
The linkage of MRS-related pathways to inflammation and diet 
To gain deeper insight into the contribution of host-microbe-diet interactions to metabolism 
and inflammation, which both underlie susceptibility to CVD, we conducted a systematic 
integration analysis between the 48 MRS-associated bacterial pathways and the plasma level 
of 12 cytokines (as a read-out of low-grade inflammation, online supplementary material 
Table 10) and 78 dietary factors (see Methods). After adjustment for age, sex and BMI, 14 
associations between 12 pathways and 5 cytokines were significant at FDR 0.05 level (Figure 
4, online supplementary material Table 10). The associations detected were also largely 
independent of MRS and remained significant after adjusting for MRS (online supplementary 
material Table 11). Most associations were found to interleukins members, namely 8 
associations to IL-10, 3 associations to IL-6, one to IL-12P70 and one to IL-18BP. Elevated levels 
of these interleukin members have previously been linked to increased risk of CVD (42). The 
pathways associated with these interleukins were related to bacterial AA biosynthesis (proline, 
ornithine, threonine, citrulline, tyrosine, arginine), although IL-10 and IL-18BP were also 
associated to GDP-mannose metabolism glycolysis and homolactic fermentation. Moreover, 
the bacterial glycolysis pathway (GLYCOYSIS) was positively associated to plasma level of 
adiponectin, which is known to be involved in glucose metabolism regulation. This finding 




Diet is known to be an important factor that affects metabolism, CVD risk and the gut 
microbiome. Among 78 dietary factors, 34 were associated to MRS-associated microbial 
pathways at FDR 0.05 level, after adjustment for age, sex and BMI and smoking (online 
supplementary material Table 12). The dietary factors linked with lower-CVD-associated-
pathways included higher intake of fruits, vegetables, nuts, fish, tea and red wine and a 
protein-rich or gluten-free diet. Higher intakes of carbohydrates, fat, total calories, sweetened 
drinks, bread and dairy products were associated with microbial pathways linked to higher 
CVD risk (Figure 4). 
To further estimate to what extent the microbiome-MRS associations were dependent on 
effects of diet and inflammation, we included diet and cytokines in the stepwise regression 
model and selected the best model with the highest AICs (see Methods). This analysis showed 
that 43 of 48 pathways survived feature selection and were included as predictors, which 
indicates that they were significantly associated to MRS variation independent of diet and 
inflammation (online supplementary material Table 13).  
 
Plasma levels rather than stool levels of SCFAs are more relevant to CVD 
As fruit and vegetable intake were mostly associated to MRS-associated pathways, we 
hypothesized that bacterial production of SCFAs by fiber fermentation may underlie the 
mechanism. We measured stool levels of five different SCFAs (online supplementary material 
Table 10) and found they were associated to most of the MRS-associated microbial pathways 
(Figure 4). To our surprise, the association directions we observed were in contrast to the 
previously suggested beneficial effect of SCFAs. Furthermore, no significant associations were 
found between stool levels of SCFAs and MRS (online supplementary material Table 14). Since 
95% of the SCFAs produced in the gut are rapidly absorbed by colonocytes, and only 5% are 
actually secreted into the feces (18), we hypothesized that blood levels of SCFAs might be 
more relevant to CVD risk. We therefore extracted the plasma level of acetate, the most 
abundant SCFA, from the NMR-based metabolic profiling. Indeed, the plasma level of acetate 
was associated to lower MRS (Beta = -0.09, P = 7.2 x10-4) and to 29 MRS-associated pathways 
at P < 0.05, all with the expected effect directions (online supplementary material Table 15).  
 
DISCUSSION 
This study presents a comprehensive exploration of the relationship of the gut microbiome 
with plasma metabolites, metabolic risk of CVD and cardiometabolic phenotypes in 1,275 
individuals from a population cohort and a cohort of overweight individuals with 
cardiovascular and metabolic complications. We conducted an integrated analysis of diet, 
metagenome, plasma metabolites, inflammatory cytokines and stool SCFAs. Previously, 
relationships of the gut microbiome to plasma metabolites and metabolic traits were 
investigated using 16S rRNA sequencing (43). To our knowledge, this study is the largest 
metagenome-based study to date and provides richer information into the functional link 
between the gut microbiome and CVD risk. It is also the first study to simultaneously address 




future development of CVD in a population-based non-patient cohort. Due to the scope of the 
NMR-based metabolic platform, this study primarily focused on lipid-related traits, including 
various lipoprotein subclasses and fatty acids. Microbial associations to a broader spectrum 
of metabolism therefore still need to be identified. 
While our group had previously established the association of the gut microbiome with 
routine blood lipid level, our current data show that it is not only levels of lipoproteins but 
also their size and composition that are important and differentially associated with 
microbiome taxonomic and functional composition. After correcting for age, gender, BMI and 
smoking, microbial associations were identified for 210 metabolic traits in the LLD population 
cohort and for 35 metabolic traits in the 300-OB obesity cohort. The microbial factors 
identified showed modest effects, jointly explaining up to 11.1% of the variation in plasma 
level of glycoprotein acetyls in LLD and up to 13.4% of variation in IDL_C_percent in 300-OB. 
Our data also show obese-specific microbial associations, in particular for lipid compositions 
in VLDL, IDL and LDL lipoprotein subclasses. Furthermore, our data identified that bacterial L-
methionine biosynthesis and the species Ruminococcus_5_1_39BFAA were associated to 
atherosclerosis and liver fat content, respectively, in our obese cohort, and that 48 bacterial 
pathways were associated to metabolic risk score of CVD in our population cohort. Finally, we 
integrated the microbiome and metabolomics with diet, SCFAs and low-grade inflammation, 
with most associations being detected to fruit and vegetable intake, plasma levels of 
adiponectin and several interleukin family members (IL-10, IL-6, IL-2P70 and IL-18BP). We also 
observed that the microbiome-MRS associations identified were largely independent of diet 
and cytokines. However, the current dietary information was obtained from food 
questionnaires, and the inaccuracy of self-reported data can attenuate the power in dietary 
analysis. Our data further shows that plasma level of SCFAs is more relevant to CVD risk than 
stool SCFA levels, but we did not confirm the previously observed association of TMAO to CVD. 
Among the bacterial associations we identified, the bacterial pathways of L-methionine 
biosynthesis showed consistent links with plasma metabolites, MRS of CVD and 
atherosclerotic plaques, and these pathways were driven by lower fruit intake. These 
observations are consistent with some previous findings. For instance, supplementation of the 
glutamine-family amino acids is predicted to have a beneficial effect towards decreasing CVD 
risk (45,46), while L-methionine and its metabolic products S-adenosyl-L-methionine (SAM-e) 
and L-homocysteine have been associated with CVD incidence and complication (47). 
Methionine has an essential role in a number of cellular processes, including the initiation of 
protein synthesis, the methylation of DNA and metabolism of xenobiotics. It is also a crucial 
factor in the biosynthesis of cysteine, phospholipids and polyamine (48). It is hypothesized 
that L-methionine induces atherosclerosis by increasing plasma homocysteine levels, as L -
methionine can be converted to homocysteine directly or through SAM-e. 
Hyperhomocysteinemia has also been related to CVD development (49,50). A recent meta-
analysis addressing the effects of low homocysteine by folic acid supplementation found a 
10% reduction in risk for stroke and a 4% reduction in risk for CVD (51). Individuals with 




from severe atherosclerotic disease at a young age (52). A number of mechanisms have been 
proposed to explain the induction of atherosclerosis by elevated homocysteine levels, e.g., 
through endothelial dysfunction, an increase in proliferation of vascular smooth muscle cells, 
oxidative damage with deterioration of arterial wall elastic material  (53), and a reduction of 
HDL-cholesterol levels (54). Furthermore, homocysteinemia has been shown to promote the 
attraction of monocytes and production of pro-inflammatory cells (55). Homocysteine also 
induces macrophage maturation in vessel walls with enhanced vascular inflammation (56). 
Recently, Wang et al. revealed a pro-inflammatory status via NLRP3 inflammasome activation 
in hyperhomocysteinemia induced by a high methionine diet in apoE-deficient mice (57). Our 
data thus highlight that bacterial metabolism of L-methionine is also associated to the 
development of CVD in humans, an observation that was confirmed in both our population-
representative cohort and the CVD-enriched cohort of overweight individuals. The association 
between bacterial metabolism of L-methionine and atherosclerotic plaques was observed to 
be independent of TMAO metabolism (L-carnitine, choline, betaine and TMAO) and BMI.  
Our study also identified several functional links between the gut microbiome and metabolic 
profile that may predict future CVD events, in particular the association of bacterial pathways 
related to metabolism of amino acids, carbohydrates and polysaccharides (specifically, GDP-
mannose) with MRS. This highlights the potential of microbiome-targeting therapy for CVD 
prevention and treatment. Some of these pathways are dominantly driven by a specific taxon 
such as class Bacteroidia. However, there are several pathways, including bacterial pathways 
of L-methionine metabolism, which are driven by many different taxa, each with modest or 
small effect. This suggests potential applications of different microbiome-targeting 
approaches in controlling a certain taxon or bacterial pathway, e.g., through personalized 
dietary control combined with prebiotic and ‘post-biotic’ treatment (58,59). Interestingly, the 
top players in MRS-related bacterial metabolism we identified were in line with previous 
findings. For instance, genus Faecalibacterium, Subdoligranulum, species Methanobrevibacter 
smithii, Eubacterium eligens and others were top players in lower-MRS associated pathways. 
Previous studies have suggested their health-promoting properties: Faecalibacterium 
members have been associated to lower intestinal and adipose-tissue inflammation (60,61), 
lower levels of members of Rikenellaceae family have been associated to liver disease and 
obesity (62,63), and levels of different members of Bacteroidaceae family have been 
associated with numerous host properties, acting as both mutualistic and pathogenic 
cohabitants (64). 
We acknowledge several limitations in our study. Firstly, both the LLD and 300-OB cohorts 
comprised of participants of Dutch ethnicity. The reported results are thus likely biased 
towards a region-specific genetic background and diet, and both are known to affect both 
metabolism and the gut microbiome. Secondly, this was an association analysis based on a 
cross-sectional design, which means that the underlying causality and mechanism remain 
unclear. The Mendelian randomization (MR) approach is considered to be a powerful method 
to assess causality. However, several recent studies have shown that genetics and microbiome 




others, blood lipid levels, CVD-related proteins and BMI (44,65,66). This may limit the power 
of our MR analysis to illustrate underlying causality. Longitudinal studies and further 
functional studies are thus essential to reveal the underlying mechanism and causality.  
 
Conclusions 
Our study presents an integrated analysis of the relationship between the gut microbiome and 
host metabolomics, cardiometabolic phenotypes and metabolic risk of CVD in humans. 
Importantly, we investigated microbial association in both a population-based and an obese 
cohort. 
We identified numerous associations of functional properties and microbial species in the gut 
microbiome with plasma metabolic traits, including lipoprotein particle composition, fatty 
acid saturation and glycoprotein N-acetyls. Some of the microbial factors identified were also 
linked with clinical outcomes in individuals with obesity, including hepatic fat content and 
atherosclerosis. In our population-representative cohort, the combined metabolic risk that 
represents the probability of having a CVD event in future is associated with numerous 
microbiome functional parameters such as biosynthesis and degradation of amino acids, 
fermentation, and carbohydrate and sugar derivative metabolism.  
Altogether, our study highlights microbial associations to current and future clinical outcomes 
related to CVD. The microbial factors identified and their interactions with diet and 
inflammation, such as association of bacterial L-methionine biosynthesis with CVD risk and 
current atherosclerosis, provide a rationale for the future studies, including intervention and 
prospective experiments. These may contribute to the development of preventive or 
therapeutic strategies aimed at modulating the microbiome to reduce the burden of 
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Supplemental Figure 1 – Correlation between blood lipids levels measured by NMR and blood 
lipid levels measured using biochemical methods. Each dot represents one individual. 
Spearman correlation coefficients are shown. Blood lipid levels measured by NMR were highly 
correlated to measurements made using routine biochemical methods. 
 
 





Supplemental Figure 2 – Comparison of P values between imputing and removing missing 
values. Each dot represents one correlation between two metabolites. Looking at the number 
of significant associations at FDR 0.05 level, the number of associations when excluding 
missing values was 3,952, which is slightly lower than the 4,135 significant associations we 






Supplemental Figure 3 – Top microbial associations to metabolites in LLD. 
A. 282 associations between bacterial pathways and metabolites at FWER 0.05 level. Y-axis 
shows bacterial pathway. X-axis shows metabolic traits. B. 15 significant associations between 
bacterial species and metabolites at FWER 0.05 level. Y-axis shows bacterial species. 
X-axis shows metabolic traits. Association strength and direction are shown by the color key. 
Red indicates positive association and blue indicates negative association. Significant 
association and its consistency with 300-OB is indicated by the white symbols: an open 
circles indicates no significant association in 300-OB; an asterisk indicates association in 300- 
OB at P < 0.05 with the same effect direction; a cross indicates association in 300-OB at 







Supplemental Figure 4 – Top microbial associations to metabolites in 300-OB. 
A. 282 associations between bacterial pathways and metabolites at FWER 0.05 level. Y-axis 
shows bacterial pathway. X-axis shows metabolic traits. B. 15 significant associations between 
bacterial species and metabolites at FWER 0.05 level. Y-axis shows bacterial species. 
X-axis shows metabolic traits. Association strength and direction are shown by the color key. 
Red indicates positive association and blue indicates negative association. Significant 
association and its consistency with 300-OB is indicated by white symbols: an open circle 
indicates no significant association in LLD; an asterisk indicates association in LLD at 
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A hallmark of obesity is chronic low-grade inflammation, which plays a major role in the 
process of atherosclerotic cardiovascular disease (ACVD). Gut microbiota is one of the factors 
influencing systemic immune responses, and profound changes have been found in its 
composition and metabolic function in individuals with obesity. This systematic review 
assesses the association between the gut microbiota and markers of low-grade inflammation 
in humans. We identified 14 studies which were mostly observational and relatively small (n 
= 10 to 471). The way in which the microbiome is analyzed differed extensively between these 
studies. Lower gut microbial diversity was associated with higher white blood cell counts and 
high sensitivity C-reactive protein (hsCRP) levels. The abundance of Bifidobacterium, 
Faecalibacterium, Ruminococcus and Prevotella were inversely related to different markers of 
low-grade inflammation such as hsCRP and interleukin(IL)-6. In addition, this review 
speculates on possible mechanisms through which the gut microbiota can affect low-grade 
inflammation and thereby ACVD. We discuss the associations between the microbiome and 
the inflammasome, the innate immune system, bile acids, gut permeability, the 
endocannabinoid system and TMAO. These data reinforce the importance of human research 




The worldwide pandemic of obesity has led to an increased prevalence of cardiovascular risk 
factors (diabetes mellitus, hypertension and dyslipoproteinemia) and atherosclerotic 
cardiovascular disease (ACVD). This complex of cardiovascular risk factors is labeled ‘the 
metabolic syndrome’, which is associated with a twofold higher risk for ACVD (1). Losing 
weight is notoriously difficult and most often only temporary. Interestingly however, not all 
individuals with obesity develop the metabolic syndrome and resulting ACVD. Approximately 
20-30% of the individuals with obesity are metabolically healthy and their risk for ACVD is 
substantially lower than in individuals with metabolically unhealthy obesity (2, 3). A better 
understanding of metabolically healthy obesity might offer novel treatment strategies to 
prevent ACVD in patients that are overweight (4). Individuals with obesity that develop ACVD 
are often characterized by a chronic low-grade inflammatory status, described as ‘meta-
inflammation’ (5, 6). It has been hypothesized that differences in inflammatory status partly 
explain the individual differences in cardiovascular risk. 
 
Since the discovery that tumor necrosis factor (TNF)-α is overexpressed in the adipose tissue 
of mice with obesity, numerous studies have focused on the role of adipose tissue in the 
development of inflammation (7). The current hypothesis states that fat mass expands due to 
a positive energy balance, which leads to a pro-inflammatory reaction of both adipocytes and 
surrounding immune cells. While initially considered to be of little relevance for metabolic 
dysregulation and cardiovascular risk in obesity-related disease, the modest increases in 
circulating inflammatory mediators have in recent years been found to be strongly associated 
with the development of non-alcoholic fatty liver disease, type 2 diabetes and atherosclerosis 
(8, 9). These pro-inflammatory pathways are partly mediated via pattern recognition 
receptors (PRRs). The beneficial effects of blocking inflammatory pathways on ACVD were 
recently underscored by the results of the CANTOS trial. Canakinumab, a human monoclonal 
antibody that inhibits the pro-inflammatory cytokine interleukin(IL)-1β reduced 
cardiovascular death, non-fatal myocardial infarction and non-fatal stroke (10). Despite this 
progress, the initial triggers of inflammation in patients with metabolic dysregulation remain 
obscure. 
 
Several studies suggest that the obesity-related systemic inflammation is at least partly driven 
by an altered gut microbial composition and function (11). The human gut microbiota consists 
of approximately 1013-1014 microbes, including bacteria, viruses, fungi and protozoa. Besides 
their function in intestinal epithelial homeostasis, development of the immune system, 
protection against pathogens and energy homeostasis (12-15), the gut microbiota also plays 
a role in pathophysiological mechanisms associated with different diseases (16).  
Profound changes have been observed in the composition and metabolic function of gut 
microbiota in individuals with obesity. Obesity was first reported to be associated with a 
change of gut microbiota by Ley et al. in 2005; characterized by obesity, ob/ob mice appeared 
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to have less phylum Bacteroidetes and more Firmicutes compared to lean phenotypes (17). A 
further major observation came from Turnbaugh et al. who reported that the core gut 
microbiome of individuals affected by obesity has an increased capacity for energy harvesting 
(18).  
 
To explore whether the gut microbiota contributes to chronic inflammation as driver for ACVD 
in humans, we conducted a systematic review of studies investigating the role of the gut 
microbiome in chronic low-grade inflammation. In this review we also discuss possible 
mechanisms by which the gut microbiota can influence chronic low-grade inflammation and 
thereby contribute to the development and progression of ACVD. 
 
METHODS 
Identification and selection of articles 
A systematic review of peer-reviewed studies examining the role of the gut microbiome on 
chronic low-grade inflammatory markers in human populations was undertaken. A protocol 
was developed a priori, outlining the review aim and procedure. The literature search was 
conducted using Medline (Pubmed), CINAHL and the Cochrane Library from inception until 
November 2017. Key MeSH subject terms and keywords pertaining to the gut microbiome and 
inflammation in correlation to obesity or ACVD were included. The following search string was 
employed: ((‘Gastrointestinal Microbiome’) OR (‘Gut microbiome’)) AND ((‘Inflammation’) OR 
(‘Inflammation Mediators’) OR (‘Host-Pathogen Interactions’) OR (‘Immune System’) OR 
(‘Immunity’) OR (‘Adaptive Immunity’)) AND ((‘Obesity’) OR (‘Overweight’) OR 
(‘Cardiovascular Diseases’) OR (‘Coronary Disease’) OR (‘Atherosclerosis’)) Filters: Humans.  
 
Two reviewers (I.v.d.M. and J.R.) independently evaluated eligibility of studies based on the 
title and abstract using the following inclusion criteria: (i) participants older than 18 years of 
age; (ii) investigation of the gut microbiome; (iii) investigation of a quantitative measure of 
inflammation, e.g. inflammatory cell count, hsCRP, cytokines or a potential trigger for 
inflammation like circulating lipopolysaccharide (LPS); (iv) full text availability in the English 
language. The presence of infectious or inflammatory diseases (i.e. inflammatory bowel 
disease, HIV and rheumatoid arthritis) in the study population was the only exclusion criterion. 
Afterwards, full-text articles were assessed independently by two reviewers (I.v.d.M. and 
J.R.).We also checked for cited articles in original research articles and reviews that addressed 
the mechanistic links between the gut microbiome and low-grade inflammation.  
 
Study Quality Assessment 
The included observational studies were assessed on their quality using an adapted scale from 
the Newcastle-Ottawa scale for quality assessment of cohort and case-control studies (NOS 
scale). This scale is a modified version of the NOS scale, as also used by several other studies  
(19, 20). For the included non-randomized intervention studies, we used the conventional 
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NOS scale. A study with a NOS score of 7 or more can be considered to be a study of ‘good’ 
quality (21). For the randomized intervention studies we used the Cochrane risk of bias2.0 (22). 
 
RESULTS 
Data extraction and quality assessment 
The search process identified 629 articles for potential inclusion. In total 260 manuscript 
contained original research data. After reviewing the titles and abstracts 61 studies met the 
initial inclusion criteria (Figure 1).  
 




















629 papers identified through initial electronic  
database searching (till 31-11-2017) 
Excluded based on full text: 
- No original study (n = 19) 
- No direct relation gut microbiome 
and inflammatory marker (n = 15) 
- No microbiome analysis (n = 8) 
- No inflammatory marker (n = 7)  
- Other inflammatory disease (n = 2) 
260 non-review articles  
assessed for eligibility 
369 review articles  
assessed for eligibility 
for cited articles  
61 articles  
assessed for eligibility 
49 review articles + 61 
non–review studies 
assessed for eligibility 
for cited articles 
10 articles included 
Excluded based on full text: 
- No direct relation gut microbiome 
and inflammatory marker (n = 9) 
- No microbiome analysis (n = 7) 
- No inflammatory marker (n = 6)  
- Mice study (n = 6) 
- No full text availability (n = 1) 
- Duplicate study (n = 1) 
- Participants < 18 included (n = 3) 
- Double publication (n = 1) 
4 articles included 
34 cited articles 
fulfilled the inclusion 
criteria  
14 studies (including 21 study populations) included  
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Following the initial selection, another 51 studies were excluded, mainly because they were 
not original studies or the study did not investigate the direct relation between the gut 
microbiome and inflammatory markers at baseline, leading to inclusion of 10 studies. We also 
checked the reference list of the 61 non-review studies that initially met the inclusion criteria. 
Additionally, we checked 369 reviews, of which 49 were of interest and of which we checked 
the reference list. In total 34 original manuscripts met the inclusion criteria. However, the 
majority of these studies were excluded, because they did not report on microbiome analysis 
or used a surrogate marker to assess the gut microbiome. An additional 5 articles were 
identified via these reference lists for cited articles. We identified one study that presented a 
data set that was published more than once (trial registered as ISRCTN88720134). For this 
data set, we selected the study reporting on the largest cohort (23). Two other studies used 
the same data set, however they performed different analyses (24, 25), therefore both studies 
were included. Finally, this resulted in 14 unique manuscripts. The 14 articles included 21 
populations with a total of 1,418 individuals (see Table 1 and supplementary material Table 1 
for detailed information of each study). For the intervention studies, we only included the data 
at baseline in order to overcome the effect of the intervention on the relation between the 
gut microbiome and inflammation. 
 
Table 1 – Detailed information of all studies included in this systematic review. BMI body mass 
index; qPCR quantitative polymerase chain reaction; 16S rRNA 16S ribosomal ribonucleic acid. 
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Eight out of the eleven observational and non-randomized studies were considered to be 
studies of good quality based on the NOS score (supplementary material Table 2 and 3). The 
methodological quality of the randomized intervention studies ranged from low risk to high 
risk for bias (three studies; supplementary material Table 4). 
 
Circulating immune cell counts 
Three studies investigated circulating immune cell counts as marker of inflammation. The 
details of these studies and the results are summarized in Table 2a. A low gene count (LGC) of 
the gut microbiome correlated with a higher white blood cell count in a large Danish 
population-based study employing metagenomics analysis (26). Another large Dutch cohort 
study that included mainly healthy younger individuals did not find a relationship between the 
gut microbiome composition and white blood cell count (27). In a small study in elderly, a 
higher white blood cell count correlated with the presence of the species Lactobacillus reuteri 
(L. reuteri) as analyzed by quantitative polymerase chain reaction (qPCR) (28).  
 
Table 2a – Summary of findings of included studies in this systematic review on gut microbiome 
measurements in relation to white blood cell counts 
Study Summary of finding 
Le Chatelier 
et al. (26) 
The phenotype of low gene count people was associated with a more marked 
inflammatory phenotype with higher white blood cell counts, model adjusted 
for age and sex (q = 0.014; P = 0.002). 
Schirmer et 
al. (27) 
No effect of microbial composition on the most important immune cell 
population (T/B lymphocytes, monocytes, neutrophils, NK cells) was detected.  
Mikelsaar 
M et al. (28) 
The higher white blood cells count was positively related (r = 0.434, P = 0.007) 
to the presence of L. reuteri, also after adjustment for age, sex, and BMI (adj. 




The majority of studies investigating the relation between the gut microbiome and low-grade 
inflammation used (hs)CRP as marker. In Table 2b we provide an overview of the details and 
results of these studies. An LGC phenotype was associated with increased hsCRP levels in the 
aforementioned Danish population-based study (26), and revealed a tendency towards an 
increased hsCRP in another smaller diet intervention study (25). The total bacterial cell counts 
related inversely with hsCRP in another study (29). Six studies examined the relationship 
between the phylum or species abundance with (hs)CRP levels. The largest study included 165 
older individuals and specifically measured 16S rRNA by massive parallel sequencing finding 
that lower levels of the Oscillibacter co-abundance group and higher levels of the Bacteroides 
co-abundance group coincided with increased levels of CRP (30). Two other small studies 
reported that lower levels of the genera Faecalibacterium and Ruminococcus, and 
Faecalibacterium prausnitzii (F. prausnitzii) species correlated with increased hsCRP levels (31, 
32). These studies were fairly similar in both samples sizes and methods of microbiome 
analysis. The first study was a randomized cross-over trial with four week diet intervention 
that included 28 young adults and used 16S rRNA gene sequencing to reconstruct microbiome 
taxonomic composition (31). The second study was an intervention study with bariatric 
surgery in 30 individuals with obesity. They analyzed the gut microbiota by 16S rRNA gene 
sequencing combined with qPCR analysis (32). For the current review, we only considered the 
correlation results at baseline from both studies. Next to that, the study by Rajkumar et al. 
who found that lower levels of the genera Lactobacillus, Bifidobacterium and Streptococcus 
and higher levels of the species Escherichia coli (E. coli) correlated with increased (hs)CRP in 
60 healthy adults affected by overweight (33), used bacterial culturing methods to identify 
bacteria. Plates were incubated in triplicate using selective media for enumeration of total 
aerobes, anaerobes, coliforms, E. coli, Bifidobacterium, Lactobacillus and Streptococcus 
thermophilus.  
 
Table 2b – Summary of findings of included studies in this systematic review on gut microbiome 
measurements in relation to (hs)CRP 
Study Summary of finding 
Le Chatelier 
E et al. (26) 
The phenotype of low gene count people was associated with a more marked 
inflammatory phenotype with increased hsCRP (q = 0.012; P < 0.001). 
Cotillard A 
et al. (25) 
The low gene count group had a trend towards higher inflammation (hsCRP). 
Tiihonen K 
et al. (29) 
An inverse correlation between the total faecal microbial counts and serum 
hsCRP (r = -0.51, P = 0.04) was found. 
Dao MC et 
al. (24) 
No difference in hsCRP between high and low Akkermansia group 
Claesson MJ 
et al. (30) 
A reduction in the Oscillibacter co-abundance group and increase in the 




et al. (31) 
Negative correlation between the family Ruminococcaceae (r = -0.59, P = 
0.0024) with hsCRP were revealed. Within this family, the genera 
Faecalibacterium and Ruminococcus displayed negative correlations with 
hsCRP (r = -0.48, P < 0.05 and r = -0.60, P < 0.01 respectively). 
Furet JP et 
al. (32) 
The strongest associations were found for the amount of the species F. 
prausnitzii, which was negatively correlated with serum concentrations of 
inflammatory circulating markers, hsCRP (Rs -0.54, P < 0.01) 
Rajkumar H 
et al. (33) 
Subjects with more than 3mg/L hsCRP has significantly lower Lactobacilli, 
Bifidobacteria, and Streptococcus and higher E. coli when compared with 
those who had less than 3mg/L. 
Brignardello 
J et al. (52) 
The G+C peak values correlated negatively with the higher CRP levels (r = -
0.68; P < 0.02). 
 
Cytokines 
Six studies investigated relationships between the abundance of gut microbiome species and 
pro-inflammatory cytokines. The details and results of these studies are summarized in Table 
2c. The total bacterial cell count was positively related to circulating TNF-α levels in a small 
Finnish cohort study using qPCR as microbiota analysis method (29). The largest study on the 
relationship between specific genera, species, and cytokines was mentioned before and 
included 165 older individuals (30). Lower levels of the Ruminoccocus and Prevotella co-
abundance group, as well as higher levels of the Oscillibacter co-abundance group coincided 
with higher interleukin 6 (IL-6) levels. Two small studies mentioned in the hsCRP section, also 
reported a negative correlation between the family Ruminococcaceae (31) and species F. 
prausnitzii (32) with IL-6 levels. The Italian study that included four different age groups, 
ranging between 25 and 104 years of age (34), showed a negative correlation between IL-6 
and species Eubacterium hallii, Eubacterium ventriosum, Eubacterium rectale, Clostridium 
nexile (C. nexile) and species in the Clostridium cluster XIVa. A positive correlation with 
circulating IL-6 was observed for the genera Haemophilus, Pseudomonas, Serratia, Yersinia, 
Vibrio and Bacillus, and species Eggherthella lenta, Eubacterium cylindroides, E.coli and 
Klebsiella pneumoniae. Increased levels of the genera Leminorella, Proteus and Bacillus, and 
species Alcaligenes faecalis, Eggerthella lenta and Eubacterium cylindroides correlated with 
higher levels of interleukin 8 (IL-8), while decreased levels of the species Eubacterium halli, 
Eubacterium ventriosum, Eubacterium rectale, C. nexile and species within the Clostridium 
cluster XIVa related to higher IL-8 levels; this study investigated the gut microbiome by 
microarray and qPCR analysis (34).  
Among all microbiome-interleukin association studies, Schirmer et al. included the largest 
number of individuals, n= 471, all healthy and mainly young. They investigated cytokine 
responses ex vivo in peripheral blood mononuclear cells (PBMCs) and whole blood stimulated 
with five different microbial pathogens in relation to microbial taxonomy and functionality, as 
analyzed by metagenomics (27). For the purpose of this review we have focused on the 
bacterial taxa and bacteria-derived stimulations: E. coli-derived LPS, Bacteroides (B.) fragilis 
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representing gram-negative bacteria, and Staphylococcus (Staph.) aureus representing gram-
positive bacteria. For these stimulations three monocyte-derived cytokines (interleukin 1β (IL-
1β), IL-6 and TNF-α) and three lymphocyte-derived cytokines (interferon (IFN)-γ, interleukin 
17 (IL-17) and interleukin 22 (IL-22)) were measured. No association was found between 
bacteria-derived stimulations and IL-1β. On the other hand, IL-6 production after Staph. 
aureus stimulation was negatively related to the species Lachnospiraceae bacterium 5 1 65FAA. 
After stimulating PBMCs with LPS, TNF-α production was negatively related with Alistipes spp, 
Clostridium spp and Bilophila spp among others. For IL-17, 5 positive associations with genera 
were identified, including genus Clostridium, as well as two negative correlations, with 
Faecalibacterium and Atopobium. A differential IFN-γ response was observed for all bacterial 
stimulations.  
 
Table 2c - Gut microbiome measurements in relation to cytokines 
Study Summary of finding 
Schirmer et 
al. (27) 
At genus level: A negative relation was present between Roseburia and IL-6 
levels (after B. fragilis stimulation). 
A negative relation was present between Faecalibacterium, Atopobium and 
IL-17 levels (after Staph. aureus stimulation).  
A positive relation was present between Escherichia, Anaerotruncus, 
Coprobacillus, Clostridium and Anaerostipes and IL-17 levels (after Staph. 
aureus stimulation).  
A negative relation was present between Oscillibacter (after LPS stimulation), 
Barnesilla (after LPS and B. fragilis stimulation), Leuconostoc (after B. fragilis 
stimulation) and IFN-γ levels. 
A positive relation was present between Megasphaera (after B. fragilis 
stimulation) and IFN-γ levels.  
A negative relation was present between Bilophila, Odoribacter and TNF-α 
levels (after LPS stimulation). 
A positive relation was present between Methanosphaera and TNF-α levels 
(after LPS stimulation). 
At species level: A negative relation was present between Lachnospiraceae 
bacterium 5 1 65FAA and IL-6 levels (after Staph. aureus stimulation). 
A negative relation was present between Parabacteroides johnsonii and IL-
17 levels (after Staph. aureus stimulation). 
A positive relation was present between Escherichia spp, B. intestinalis, 
Anaerotruncus spp and IL-17 levels (after Staph. aureus stimulation).  
A negative relation was present between B. eggerthii, Coprococcus comes 
and IL-22 levels (after Staph. aureus stimulation).  
A positive relation was present between B. cellulosilyticus and R. gnavus 
(both after Staph. aureus stimulation), Megasphaera sp., Eubacterium 
limosum, B. nordii (all after B. fragilis stimulation) and IFN-γ levels. 
A negative relation was present between Lachnospiraceae bacterium 9 1 
57FAA and IFN-γ levels (after Staph. aureus stimulation). 
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A negative relation was present between Clostridium leptum, Alistipes 
finegoldii, Bilophila spp, Bilophila wadsworthia, Alistipes onderdonkii, 
Enterococcus faecium, Collinsella intestinalis, Odoribacter splanchnicus and 
TNF-α levels (after LPS stimulation). 
A positive relation was present between Acidaminococcus intestini, 
Methanospaera stadtmanae, L. acidophilus and TNF-α (after LPS stimulation) 
Claesson 
MJ et al. 
(30) 
A reduction in abundance of Ruminococcus and Prevotella and increased 
abundance of Oscillibacter co-abundance groups was accompanied by an 
increase in IL-6 levels. 
Martínez I 
et al. (31) 
A negative correlation between the family Ruminococcaceae and IL-6 was 
revealed (P < 0.05). 
Biagi E et al. 
(34) 
IL-8 correlated positively with Alcaligenes faecalis et rel, Leminorella, and 
Proteus et rel, Bacillus, Egghertella lenta et rel, and Eubacterium cylindroides 
et rel. 
IL-6 correlated positively with E. coli et rel, Haemoplihus, Klebsiella 
pneumoniae et rel, Pseudomonas, Serratia, Yersinia et rel and Vibrio, Bacillus, 
Egghertella lenta et rel, and Eubacterium cylindroides et rel. 
Eubacterium halli, Eubacterium ventriosum, Eubacterium rectale, C. nexile, 
Clostridium cluster XIVa were inversely correlated with IL-6 and IL-8. 
Tiihonen K 
et al. (29) 
Serum TNF-α was associated with the total number of bacteria (r = 0.42, P = 
0.006). 
Furet JP et 
al. (32) 
The strongest associations were found for the amount of F. prausnitzii, which 
was negatively correlated with serum concentrations of inflammatory 
circulating markers, IL-6 (Rs -0.65, P < 0.001) 
 
Circulating LPS 
Three studies investigated the relationship between the gut microbiome and circulating LPS 
levels. The details of these studies and the results are summarized in Table 2d. In a cohort 
study of 49 individuals with overweight, no relationship was observed for Akkermansia 
muciniphila (A. muciniphila) with LPS levels (24). A very small Spanish study of 10 individuals 
found LPS concentrations to be negatively correlated with the genera Prevotella and 
Bifidobacterium (23). Another Mexican study of 60 individuals, analyzed the gut microbiota by 
qPCR and found that lower levels of the species E. coli correlated with lower levels of LPS, 
however a positive correlation between LPS and E. coli was only found in the second tertile 
(LPS = 1-1.3 EU/mL) presenting fewer E. coli compared to the first (LPS < 1 EU/mL) and third 











Table 2d - Gut microbiome measurements in relation to LPS 
Study Summary of finding 
Dao MC et 
al. (24) 
No difference in LPS between high and low Akkermansia group 
Radilla-
Vázquez RB 
et al. (35) 
A low number of E. coli comes along with a greater risk of having high LPS 
levels (OR = 4.378, P = 0.005). However a positive correlation between LPS 
and E. coli was only found in the second tertile (LPS = 1-1.3EU/mL) presenting 
fewer bacteria compared to the first (LPS < 1EU/mL) and third (LPS > 1.3 
EU/mL) tertiles (P = 0.036). 
Clemente-
Postigo M 
et al. (23) 
LPS concentrations correlated negatively with P. intermedia (r = -0.336, P = 
0.037) and with the genus Bifidobacterium (r = -0.411; P = 0.009). 
 
DISCUSSION 
Given the increased prevalence of obesity worldwide, the incidence of ACVD is concomitantly 
on the rise. Because ACVD events can only be partly explained by traditional cardiovascular 
risk factors, the gut microbiota is a new area to explore for new diagnostic and therapeutic 
tools in ACVD. It has already been shown that the gut microbiome contributes to a substantial 
proportion of the variation in blood lipids (36). Because chronic low-grade inflammation is one 
of the hallmarks of obesity, this provides another route for the gut microbiota to influence the 
atherosclerotic process. To our knowledge, this is the first systematic review of human studies 
investigating relationships between the gut microbiota and markers of chronic low-grade 
inflammation. Several associations between the gut microbiota and different markers of 
chronic low-grade inflammation were identified. A low gut microbial diversity has previously 
been reported in individuals with obesity compared to lean individuals. However, not just the 
diversity in gut microbiota, but also the presence of specific species has been shown to 
correlate with chronic low-grade inflammatory markers.  
 
Association of gut microbiome with inflammation 
A lower alpha diversity and gene count of the gut microbiome correlated with higher white 
blood cell counts and hsCRP levels. Le Chatelier et al. reported that the metabolic phenotype 
of subjects with an LGC correlated with increased insulin resistance, higher levels of 
triglycerides and free fatty acids, decreased high density lipoprotein-cholesterol, as well as a 
marked inflammatory phenotype compared to individuals with high gene count of the gut 
microbiome. These and other data suggest that individuals with an LGC suffer from metabolic 
disturbances leading to an increased risk of diabetes mellitus, dyslipoproteinemia and pro-
inflammatory status which might ultimately lead to ACVD (24, 37, 38).  
 
The abundance of the genus Bifidobacterium was inversely related to levels of LPS and hsCRP. 
Bifidobacterium belongs to the Actinobacteria phyla, whose abundance is related to a 
healthier diet with an increased intake of whole grain cereals and certain vegetables (e.g. 
black-eyed peas) (39). Several Bifidobacterium taxa are used as probiotics, of which a recent 
meta-analysis revealed protective effects for cellular immune function (40). Bifidobacterium 
species are associated with gut barrier functions, a reduction in systemic inflammation and a 
reduction in the incidence of diabetes in mice (41).  
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The abundance of the genus Faecalibacterium and species F. prausnitzii were inversely 
correlated with hsCRP and IL-17. Besides showing negative correlations with inflammatory 
markers in individuals with obesity, the proportions of F. prausnitzii were lower in patients 
with a history of stroke, in which the proportion also related with disease severity (42). 
Faecalibacterium is regarded as a next-generation probiotic for its several health-promoting 
and anti-inflammatory properties (43). 
 
In general, lower levels of Ruminococcaceae and Ruminococcus are associated with higher 
levels of hsCRP and IL-6. However, opposite correlations have been observed too; the genus 
Ruminococcus was highly positively correlated with both plasma TMA and TMAO levels, as 
well as atherosclerotic lesion area in female ApoE-/- mice (44). Another large study seems to 
confirm this relation as they found that the abundance of Ruminococcus gnavus (R. gnavus) 
was higher in ACVD patients compared to controls (45). However it’s important to mention 
that R. gnavus species were reassigned to the genus Blautia in 2008 on the basis of 16S rRNA 
gene sequencing and therefore belong to the family Lachnospiraceae (46). 
 
The abundance of Prevotella was inversely associated with LPS and hsCRP. Furthermore, 
individuals with obesity have a lower abundance of Prevotella species in their gut (47). 
However large differences have been observed within this genus. Human studies have linked 
the increased abundance of Prevotella species at mucosal sites to localized and systemic 
disease, including rheumatoid arthritis, metabolic disorders, as well as low-grade systemic 
inflammation (48). Prevotella mediates the inflammatory response via toll-like receptor(TLR)2 
activation and Th17 immune response. This Prevotella-mediated mucosal inflammation can 
lead to systemic inflammation. Certain Prevotella species are also suggested to play an 
important role in the pathophysiological relation between periodontitis and ACVD. Patients 
with ACVD have an enhanced abundance of Prevotella nigrescens (P. nigrescens) in subgingival 
plaques (49). 
 
Gut microbiota in cardiovascular disease 
The number of studies performed in humans to investigate the direct role of the gut 
microbiota in ACVD is relatively limited. Recently, the largest study in patients with ACVD was 
conducted by performing a metagenome-wide association study on stools from 218 
individuals with ACVD and 187 healthy controls (45). The abundance of E. coli, Klebsiella spp, 
Enterobacter aerogenes, R.gnavus, Eggerthella lenta, Streptococcus spp, L. salivarius, 
Solobacterium moorei, and Atopobium parvulum were elevated in patients with ACVD. In 
contrast, Roseburia intestinalis, F. prausnitzii, Bacteroides spp, P. copri and Alistipes shahii 
were relatively depleted in individuals with ACVD. Only smaller cohort studies and studies with 
methodological limitations have been published previously. In 2015 a study was published in 
which patients with large-artery atherosclerotic ischemic stroke and transient ischemic 
accident patients (n = 141) showed increased levels of Proteobacteria and reduced amounts 
of Bacteroides, Prevotella, and Faecalibacterium compared to 94 non-matched controls by 16S 
rRNA gene analyses (42). In another small cohort study, the genus Collinsella was found to be 
enriched, while the genera Roseburia and Eubacterium were depleted in twelve symptomatic 
atherosclerosis patients compared to thirteen controls (50). The apparently beneficial effects 
of Bacteroides, Faecalibacterium, Roseburia (intestinalis) and Alistipes spp have also been 
found in our review, as they relate to lower levels of inflammatory markers. Next to this, 
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higher levels of E. coli, Klebsiella spp and Eggerthella lenta associated with higher levels of 
inflammatory markers. 
 
Quality and limitations of included studies 
Gut microbiome in relation to white blood cell count 
Several studies showed a possible association of the gut microbiome with blood cell counts. 
The first study by Mikelsaar et al. had a number of limitations (28), in particular, focusing only 
on specific strains of Lactobacillus species. The associations could furthermore have been 
influenced by the inclusion of subjects with osteoarthritis and the lack of adjustment in the 
analysis for smoking status. Also, a large number of individuals were taking probiotics, which 
may have influenced the microbiota composition. The study by Schirmer et al. included only 
healthy and mainly young individuals of which the cytokine responses to different stimuli may 
not be influenced by meta-inflammation (27). The association of gut microbiome with cell 
counts was also addressed in a large cross-sectional study by our research group (51), where 
eight different blood cell types were measured and related to microbiome composition, 
diversity and pathways. However, as we also included a small number of individuals with 
inflammatory bowel disease, this study was not included in our systemic review. This study 
identified seventeen bacterial species that related to four different blood cell types and IL-6 
levels. A limited number of species/genera were also found in the current review to be related 
to markers of chronic low-grade inflammation. For example, Eubacterium ventriosum 
correlated negatively to the number of leukocytes and granulocytes, while R. torques 
correlated positively to the number of lymphocytes. We summarized the relationship 
between bacterial species, blood cell counts, as well as IL-6 as discussed in this study in 
supplementary material Table 5. After correcting for diet, medication, various physiological 
and biomedical measures, self-reported diseases and smoking status (in total >200 intrinsic 
and environmental factors), no significant association of cell counts was observed with 
bacteria and pathways. This observation may reflect that the reported cell counts are not 
dependent on the gut microbiota, however it is also likely that taking into account all available 
phenotypes to the analysis model leads to overcorrection and therefore missing the true-
positive results or the association is too small to be detected within the given sample size.  
 
Gut microbiome in relation to (hs)CRP 
To measure low levels of hsCRP, a high sensitivity analysis needs to be used, however not all 
studies adopted this method (30, 52). The number of individuals used in the analysis also 
varied from 12 to 292. The largest study by Le Chatelier et al. (26) also used the most robust 
method to analyse the gut microbiome, quantitative metagenomics. This contrasts the study 
by Rajkumar et al. that cultured and enumerated only six different species (33), or the study 
by Brignardello et al. who used G+C peak content analysis and was unable to find a direct 
relation between specific gut microbial species and CRP levels (52).  
 
Gut microbiome in relation to cytokines 
In addition to the large differences in gut microbiome composition, differences in the cytokine 
measurements exist. The study by Schirmer et al. investigated cytokine responses ex vivo in 
PBMCs and whole blood stimulations with five different microbial pathogens (27), while the 




Gut microbiome in relation to LPS 
A major limitation of all the three studies investigating the relation to LPS is the small sample 
size, with a maximum of 49 participants in the study of Dao et al., reducing the power to detect 
significant associations. LPS levels in the study by Radilla-Vazquez et al. and Clemente-Postigo 
et al. were assessed by the limulus amebocyte lysate assays, however large differences were 
observed in the concentrations with a mean level of LPS of 0.16 EU/mL in Spanish cohort (with 
a mean age of 48 and mean body mass index (BMI) of 28) (23) and a mean LPS level of 1.14 
EU/mL in the normal weight and 1.22 EU/mL in the young Mexican adults with obesity (35). It 
should be noted that measuring circulating LPS is notoriously difficult. 
 
General limitations 
After reviewing the literature, we could only include 14 studies that investigated the 
relationship between gut microbiota and markers of chronic low-grade inflammation in 
humans. Because the techniques used to analyze the gut microbiome were suboptimal in most 
studies, several of these studies could only investigate the gut microbiota at a specific 
taxonomic level. However, contradictive associations can exist in the relationship between 
different taxonomy levels with clinical markers. As already described before, we found an 
inverse correlation between the genus Prevotella and inflammatory markers, while increased 
abundance of certain Prevotella species was associated with low-grade inflammation in 
systemic diseases, such as rheumatoid arthritis (48). This emphasizes the complex networks 
among bacterial groups and the large functional differences between species and strains, 
which should be kept in mind when interpreting the results. Larger studies with state-of-the-
art gut microbiome analysis should further investigate this important association. Another 
important limitation is the heterogeneity between study populations. As mentioned before, 
the study by Schirmer et al. included only healthy and mainly young individuals of which the 
cytokine responses to different stimuli may not be influenced by meta-inflammation (27). This 
contrasts investigations by Claesson et al. where mainly older individuals were included (30). 
 
A major limitation in all studies is the cross-sectional design, which cannot prove causal 
relationships. Different human intervention studies have been performed with probiotics (53) 
and even feces transplantation (54). However, none of these studies investigated the specific 
effects of the microbiome species described here in relation to inflammatory markers. One 
meta-analysis demonstrated a protective role for several taxa of Bifidobacterium for cellular 
immune function in humans (40). Another limitation is the diversity in the statistical analysis 
methods. This depended mainly on the size of the study and the method of analysis of the 
microbiome. There is some hierarchy in the used statistical methods. The larger studies were 
able to perform regression analysis adjusting for covariates and multiple comparisons. Other 
studies used correlation analysis, either pearson’s or spearmans’s without corrections. A 
number of studies only compared differences between subgroups of subjects using the 
Kruskal Wallis, ANOVA or Mann Whitney U test. In Table 1 we give an overview of the applied 








Potential underlying mechanisms  





Figure 2 – Summary of possible gut microbiota derived mechanisms able to influence the 
process of chronic low-grade inflammation in ACVD. PAMPs, like peptidoglycans and LPS can 
stimulate NOD2 or TLR4 respectively and stimulate the production of pro-inflammatory 
cytokines via NFκB activation as part of the inflammasome. SCFAs can stimulate colonocyte 
proliferation, but also GPR43 and GPR109A activation which leads to the induction of Treg cells 
and the production of anti-inflammatory cytokines by Treg and denditic cells. SCFAs also 
stimulate the production of gut peptides. GLP-2 production improves tight junctions and 
mucosal barrier function. Specific species have an influence on these gut permeability 
mechanisms. Polyunsaturated fatty acids can stimulate the CB1 receptor, which promotes gut 
permeability. Specific species have shown to enhance Treg cell abundance and induce anti -
inflammatory molecules. On the other hand segmented filamentous bacteria can activate TGF-
β and thereby promote the development of Th17 cells. Primary and secondary bile acids can 
inhibit NFkB-dependent transcription of pro-inflammatory cytokines from macrophages and 
dendritic cells via the TGR5 receptor (88). Taurine increases the production of anti-
inflammatory cytokines via NLRP6 inflammasome. TMAO has shown to activate TXNIP-NLRP3 
inflammasome and increase the production of pro-inflammatory cytokines. PAMP pathogen 
associated molecular pattern; SCFA short chain fatty acid, NOD2 nucleotide-binding 
oligomerization domain-containing protein 2; NFκB nuclear factor kappa B; LPS 
lipopolysaccharide; TLR4 toll-like receptor 4; GPR G protein-coupled receptor; Treg regulatory 
T cell; GLP-2R glucagon like protein-2 receptor; GLP-2 glucagon like peptide-2; GHS-R Growth 
hormone secretagogue receptor; CB1 cannabinoid receptor 1; TGF-β transforming growth 
factor beta; TGR5 Takeda G-protein-coupled receptor 5. 
 
Our review focused on human studies, as humans and mice differ significantly in their gut 
microbiome composition and the pathophysiology of cardiovascular disease. Therefore it 
remains to be determined in the future whether data gathered in mice can be directly 
extrapolated to humans. However the human studies are mainly observational and therefore 
provide limited insight in the underlying mechanisms. Because the majority of mechanistic 
studies are performed using animal models, we included these data in this part of the 
discussion on potential underlying mechanisms.  
 
Pathogen-associated molecular patterns 
A possible mechanism for the pro-inflammatory cytokines is the appearance of pathogen-
associated molecular patterns (PAMPs) derived from microbiota in the gut and the circulation. 
Such PAMPS can be sensed by PRR. After activating a PRR, the inflammasome, an important 
part of our innate immune system that responds to danger signals (55), is activated with an 
enhanced production of the transcription factor nuclear factor kappa B (NF-κB). Different 
bacterial components have been demonstrated to be a PAMP and thereby initiate the 
inflammasome pathway with NF-κB production. LPS is believed to confer its deleterious effect 
on the cardiovascular system mainly via upregulation of pro-inflammatory cytokines, a 
process that is mediated via TLR4. Importantly, LPS derived from different gut microbial 
species are not equally toxigenic and can differently induce TLR4 signaling (56). LPS forms a 
complex with LPS-binding protein which then binds to CD14 (mainly from macrophages, but 
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also neutrophils, monocytes and hepatocytes) or nucleotide-binding oligomerization domain 
(NOD)1, to initiate an acute immune response mainly via TLRs and NF-κB (57). Humans with 
obesity exhibit elevated levels of LPS-binding protein (58), possibly contributing to the 
explanation of increased LPS levels in these individuals. Endotoxins derived from gut bacteria 
are normally detoxified in the liver. However when the influx increases, it may exceed the 
capacity of Kupffer cells and thereby enter the systemic circulation (59). The importance of 
LPS in ACVD has been demonstrated for the first time by the Bruneck study (60). Subjects with 
levels exceeding 50 pg/mL faced a 3-fold higher risk of developing incident atherosclerosis. 
Subclinical endotoxemia was shown in mice to accelerate atherosclerosis by programming 
monocytes into a non-resolving inflammatory state (61). High fat diet (HFD)-fed mice treated 
with antibiotics showed an increase in Prevotella species and a decrease in endotoxemia (62). 
This observation is in accordance with the findings by Clemente et al. and Claesson et al., 
which describe an inverse relationship between Prevotella species, LPS and IL-6 levels (23, 30). 
However, no causal relationships has been shown between the abundance of Prevotella 
species and levels of inflammatory markers. Another important PAMP is the peptidoglycan 
that can active the NOD receptors. NOD receptors can recognize bacterial determinants once 
they are phagocytosed by macrophages or dendritic cells. HFD-fed mice deficient in NOD2 
show increased bacterial translocation and insulin resistance (63). A role for NOD2 in 
atherosclerosis has also been demonstrated in human genetic and mouse knockout studies 
(64, 65).  
 
Short Chain Fatty Acids (SCFAs) 
SCFAs are produced by the microbiome through degradation of dietary fibers; the most 
important SCFAs are butyrate, acetate and propionate (66). An important function of these 
SCFA is to promote colonocyte proliferation, which can improve insulin resistance in mice via 
promotion of energy expenditure and induction of mitochondria function (67, 68). SCFAs are 
also important in the regulation of appetite via gut hormones (66). Activation of different G 
protein coupled receptors (GPR), mainly GPR41 and GPR43 have been shown to suppress 
inflammation, partly via epithelial survival and integrity, but also via induction of regulatory T 
(Treg) cells. Activation of GPR109A by butyrate has been shown to affect colonic macrophages 
and dendritic cell maturation and function, which stimulates the induction of transforming 
growth factor (TGF)-β to promote the induction of Treg cells and IL-10 producing T cells (69). 
Besides this, butyrate and acetate act as histone deacetylase (HDAC) inhibitors in dendriti c 
cells and T cells with modulation of gene expression and contributing to epigenetic modulation 
(70). This induces extrathymic generation of Treg cells from naïve T cells and limits the 
secretion of pro-inflammatory cytokines (71). F. prausnitzii, Eubacterium rectale, Eubacterium 
hallii and R. bromii appear to be responsible for the majority of butyrate production (72), this 
makes sense given the inverse correlation of these species with hsCRP and some pro-





Different gut hormones have been shown to support epithelial barrier formation and anti-
inflammatory properties. Ghrelin levels are decreased in response to HFD and can promote 
lymphocyte development in the primary lymphoid organs (73). Cani et al. reported that higher 
endogenous glucagon-like peptide 2 (GLP-2) production is associated with an improvement of 
the mucosal barrier function, improved tight junctions, as well as decreased plasma LPS 
concentrations. This was associated with an increased abundance of Bifidobacterium species 
(74) and might be one of the reasons for the inverse observation between Bifidobacterium 
species and inflammatory markers (23, 33). Obesity can also enhance the secretion of the pro-
inflammatory serotonin. Indigenous spore-forming bacteria, mainly Clostridium species can 
promote serotonin production from colonic enterochromaffin cells (75). In mouse models it 
was shown that serotonin could recruit T cells and stimulate the production of pro-
inflammatory cytokines (76, 77).  
 
Gut permeability & endocannabinoid system 
HFD negatively influences gut barrier function by inducing a number of changes in the gut 
microbiome and the endocannabinoid (eCB) system. The eCBs are derivatives of 
polyunsaturated fatty acids that can activate the G-coupled receptors CB1 and CB2. When the 
CB1-receptor is activated, an increase in the intestinal epithelial barrier permeability is 
induced, which can contribute to circulating LPS concentrations. HFD increases the expression 
of the colonic CB1 receptor of the eCB system (78). Treatment with prebiotics leading to a 
change in gut microbiome was associated with a reduction in metabolic endotoxemia and 
improvement of gut barrier function via reduction of the CB1 receptor (79). Activation of CB2 
receptor has been shown to improve glucose tolerance in rats (80). CB2 receptor expression 
can mainly be increased by Lactobacillus supplement, specifically L. acidophilus, and 
decreased by Clostridium supplement (80, 81). Administration of A. muciniphila in mice 
increased the levels of eCBs in the small intestine, which via activation of the CB2 receptor 
contribute to the anti-inflammatory effects and improved gut barrier function (82). Besides its 
effects on gut permeability, the eCB system has also been shown to control food intake and 
energy expenditure both centrally and peripherally (83). Furthermore, the microbiome can 
influence gut barrier function and inflammation directly via specific species like 
Bifidobacterium species as well as via the production of SCFA (74, 84, 85). However, it should 
be noted that even if relations exist between the composition of the gut microbiota and gut 




The gut microbiota can also influence the inflammatory state of the host through an extensive 
involvement in bile acid homeostasis (86). Primary bile acids are derived from the oxidation 
of cholesterol in the liver and are secreted into the intestine to solubilize lipids for absorption. 
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Microbial bile salt hydrolase, mainly produced by gut bacteria from the genera Lactobacillus, 
Bifidobacterium, Clostridium and Bacteroides can deconjugate primary bile acids to secondary 
bile acids (86). Free taurine, an amino acid to conjugate bile acids, can enhance the activation 
of the NOD-like receptor family pyrin domain containing 6 (NLRP6) inflammasome and 
thereby increase production of IL-18 by the intestinal epithelium, which supports epithelial 
barrier function (87). Primary and secondary bile acids can inhibit NF-κB-dependent 
transcription of pro-inflammatory cytokines from monocytes, macrophages, dendritic cells 
and kupffer cells via the farnesoid X and Takeda G-protein-coupled receptor (TGR)5 receptor 
(88). 
 
Development/differentiation of innate immune cells 
An important role for the gut microbiome exists in the development/differentiation of 
immune cells. In germ-free mice fed a diet with low LPS content, the mesenteric lymph nodes 
and Peyer’s patches contained fewer CD4+ T lymphocytes, mainly due to fewer amounts of 
CD4+ FoxP3+ Treg lymphocytes (89). Species belonging to the Clostridium cluster IV can 
enhance Treg cell abundance and induce anti-inflammatory molecules (90). This is in 
accordance with the seemingly protective role of Faecalibacterium and Ruminococcus species 
(30, 31). Furthermore, intestinal Th17 cell development is dependent on the microbiome. 
Dendritic cells and macrophages in the lamina propria sense segmented filamentous bacteria, 
such as Clostridia related bacteria, and produce IL-6 and integrin molecules that contribute to 
the activation of TGF-β and thereby promote Th17 cell development in the intestine (91, 92). 
It has been shown that jejunal T cell inflammation in human obesity correlates with decreased 
enterocyte insulin signaling (93). High fat feeding has also been shown to influence the 
immune cell populations in the digestive tract. In mice, after 12 weeks of HFD the proportion 
of Th1 cells and CD8+ T cells increased in the small bowel and colon, while the proportion of 
Treg cells decreased (94). 
 
Trimethylamine-N-oxide (TMAO)  
The most convincing link between the gut microbiota and ACVD is trimethylamine-N-oxide 
(TMAO) (95), a metabolite derived from dietary choline or carnitine through the action of gut 
bacteria. Bacteria from the phylum Proteobacteria and Firmicutes (96). TMA is converted in 
the liver to TMAO via flavin monooxygenase 3 (FMO3) (97). TMAO has shown to promote 
recruitment of activated leukocytes to human endothelial cells (98). This was supported by 
another in vitro study in which TMAO activated TXNIP-NLRP3 inflammasome and IL-1β and IL-
18 were released in a dose- and time-dependent manner, while endothelial nitric oxide 
synthase (eNOS) and production of nitric oxide (NO) were inhibited (99). The same research 
group later found that TMAO up-regulated vascular cell adhesion molecule-1 (VCAM-1) 
expression and promoted monocyte adherence (100). LDLR-deficient mice fed a choline diet 
showed elevated inflammatory gene expression compared with controls (98). ApoE-deficient 
mice treated with antibiotics had lower TMAO levels and a reduced atheroma size, while 
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supplementing the diet with 1% choline increased foam cell formation, which could be 
prevented by antibiotics (101). Fecal transplantation from high TMAO-producing mice to 
ApoE-deficient mice accelerates atherosclerosis (102). Plasma TMAO levels are an 
independent prognostic marker for ACVD in patients undergoing elective coronary 
angiography (95).  
 
Table 3 – Summary of findings and possible mechanisms. Correlations between gut microbial 
genera, species, and markers of low-grade inflammation that have been found in two 
independent cohorts. Furthermore, the possible mechanisms via which these gut bacteria 
could contribute to low-grade inflammation are shown. LPS Lipopolysaccharide level; WBC 
white blood cell count; (hs)CRP (high sensitivity)C-reactive protein level; TNF-α tumor necrosis 
factor alpha; IL Interleukin 
 
As discussed above, the gut microbiome can influence low-grade inflammation via several 
mechanisms. Because low-grade inflammation is a hallmark of obesity that is linked to ACVD, 
the gut microbiota composition could influence the risk for atherosclerosis and harbour 
possible diagnostic and therapeutic options. One human study demonstrated a positive result 
for fecal transplantation with regard to obesity-induced insulin resistance (54). Eighteen 
insulin resistant men who were randomized to duodenal infusion of microbiota from either a 
heterologous lean donor or an autologous fecal microbiota showed improvement in insulin 
sensitivity 6 weeks after infusion of microbiota from lean donors. The improvement in insulin 
sensitivity in recipient patients correlated with an increase in the number of butyrate-
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producing bacteria, pointing towards a regulatory role for butyrate derived from gut microbial 
metabolism leading to improved insulin sensitivity. Multiple studies are currently being 
undertaken to investigate the possibilities of fecal transplantation as treatment option for 
obesity and obesity-related complications. Indirect evidence for the influence of the gut 
microbiota on ACVD comes from animal studies. ApoE-deficient mice reared under germ-free 
conditions fed a low cholesterol diet exhibited atherosclerotic plaques in the aorta, in contrast 
to conventionally reared ApoE-deficient mice fed a low cholesterol diet who did not develop 
atherosclerotic aortic plaques (103). Germ-free mice receiving a fecal transfer from genetically 
or diet-induced obesity mice with obesity developed greater adiposity on a HFD than did 
recipients of microbiota from lean mice (18, 104, 105). Similarly, fecal transfer from humans 
into germ-free mice mirrored the adiposity of its donor (106). Not only the adiposity status, 
but also its complications, like insulin resistance and non-alcoholic fatty liver disease, were 
demonstrated to be transmissible via the gut microbiota (104, 107). This has been shown to 
be driven (at least partly) by pro-inflammatory microbial products (62, 108).  
 
Perspective 
While the gut microbiota is increasingly recognized as a determinant of obesity, its influence 
on the development of low-grade inflammation and ACVD remains largely unexplored. Future 
studies should investigate the underlying pathophysiology, with a focus on mechanisms 
leading to low-grade inflammation. This is especially important because the CANTOS trial has 
already shown that inhibiting a pro-inflammatory pathway reduced ACVD related mortality 
(10). The gut microbiota could serve as a diagnostic marker by which a more pro-inflammatory 
state could be detected in an early stage and could predict the risk to develop certain ACVD 
states. For these diagnostic options, first the gut microbiota leading to low-grade 
inflammation in humans needs to be established in more detail. Well-designed clinical studies 
with state-of-the-art analysis of the gut microbiota, like shot gun metagenomics are required. 
By using metagenomics analysis, not only the taxonomy of the gut microbiota, but also the 
functionality can be investigated and can possibly contribute to new diagnostic strategies. 
Future studies should include subjects at risk for ACVD, such as individuals affected by obesity. 
Future studies should also focus on prospective and intervention studies. Potentially, the use 
of prebiotics or probiotic strains or fecal microbiota transplantation via capsules could become 
a promising therapeutic option to prevent low-grade inflammation and ACVD in the future.  
 
Conclusions 
In this review, we have provided an overview of the relationships between the gut microbiota 
and markers of low-grade inflammation in humans and discussed the possible mechanisms. 
These data reinforce the importance of human research into the gut microbiota in relation to 
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Supplemental Table 1 - Extended version of characteristics of studies included in this systematic review. qPCR quantitative polymerase chain 
reaction; BMI body mass index; IL interleukin; IFN-γ interferon gamma; TNF-α tumor necrosis factor alfa; ELISA Enzyme Linked Immunosorbent 
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Supplemental Table 2 – Quality assessment of observational studies included in this systematic review using a modified version of the Newcastle-
Ottawa scale for quality assessment of cohort and case-control studies (NOS scale). 
  
Selection (max 4 stars) Comparability (max 2 
stars) 






















Schirmer et al. x x 
 







x x x 6/8 
Le Chatelier et al. x x 
 
x x x x x 7/8 
Claesson et al. x x 
 
x x x x x 7/8 
Brignardello et al. x 
  
x x x x x 6/8 




x x 5/8 
Biagi et al. x x 
 
x x x x x 7/8 
Tiihonen et al.  x x 
 





Table S3 – Quality Assessment of non-randomized intervention studies included in this systematic review using the Newcastle-Ottawa scale for 
quality assessment of cohort studies (NOS scale). NA not applicable. 
 
  Selection (max 4 stars) Comparability (max 2 
stars) 
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Dao et al. x NA x x x x x x x 8/8 
Cotillard 
et al. 
x NA x x x x x x x 8/8 
Furet et 
al. 




























Some concerns Low risk Low risk Low risk Low risk Some 
concerns 
Rajkumar et al. Low risk Low risk Low risk Low risk Low risk Low risk 
Martínez et al. Some concerns Some 
concerns 
Low risk Some concerns Some concerns High risk 
198 
 
Supplemental Table 5 – Findings from large cross-sectional study by Zhernakova et al. Relation between bacterial species, blood cell counts, and 





























































































































































































































CVD is one of the most important causes of death worldwide. A major contributing factor is 
the still increasing prevalence of obesity. To tackle this epidemic of the cardiovascular 
morbidity and mortality, the first goal should be to prevent people to become obese. This has 
proven to be a very challenging goal. Firstly, because food is available everywhere in high 
income countries and unhealthy food is generally even cheaper (1). Secondly, because modern 
society is characterized by a more sedentary life style. Therefore, to reduce the incidence of 
obesity the primary goal for governments worldwide should be to shift the dietary pattern to 
more healthy foods and to promote physical activity.   
The worldwide increase in obesity has led to an increased prevalence of cardiovascular risk 
factors, labeled the metabolic syndrome. Interestingly however, not all individuals with 
obesity develop the metabolic syndrome and resulting CVD. Metabolically healthy individuals 
with obesity have a substantially lower risk for CVD. The central hypothesis in our studies is 
that differences in inflammatory status partly explain the interindividual differences in 
cardiovascular risk within individuals with overweight and obesity. The overall aim of this 
thesis is to obtain more insight in factors influencing obesity-associated low-grade 
inflammation in relation to atherosclerosis. A better understanding of these factors and the 
role of low-grade inflammation in atherosclerosis might offer novel diagnostic tools and 
eventually treatment strategies to prevent or treat CVD.  
 
The first factor that I investigated is the distribution of adipose tissue. Men generally store 
more fat around and in their abdomen, while women have more fat at the hip and thigh 
region. Numerous studies have shown that VAT is related to a higher risk for cardiovascular 
events (2, 3). Conflicting results have been shown in the relation between SAT and 
cardiovascular risk. However, subcutaneous fat is not a homogeneous compartment. 
Furthermore, it is unknown whether differences in fat distribution can differentiate between 
metabolically healthy and unhealthy overweight subjects. Besides this, the question remains 
whether different adipose tissue distributions in men versus women are associated with a 
different inflammatory phenotype 
 
The second factor that influences CVD risk is sex. Important sex differences have been 
observed in the pathophysiology of atherosclerotic CVD. Sex hormones and adipokines are 
shown to have a sex-specific effect (4). While it is implied that the same mechanisms control 
inflammation in women and men with regard to CVD, this has never been systematically 
investigated. 
 
The third factor is the chronic low-grade inflammation itself. Although obesity is a well-known 
risk factor for atherosclerotic cardiovascular diseases, a sizeable number of individuals with 
obesity do not develop these complications. Obesity leads to a state of chronic low-grade 
inflammation, which is a key regulatory process in the development of atherosclerosis. Low-




shown to play a tremendous role in patients with CVD. It is unknown whether inter-individual 
variation of chronic inflammation explain the differences in atherosclerotic risk in the obese 
population. 
 
The last factor is the gut microbiota. Approximately 15 years ago, the first study was published 
that showed a relation between the gut microbiome and obesity. Nowadays, different strains 
and pathways have been related to cardiometabolic risk factors and diseases. The exact 
mechanism by which the gut microbiome influences the cardiovascular risk is not clear.  
 
Summary 
Role of fat distribution in relation to metabolic dysregulation 
In chapter 3 we investigated the sex-specific relations between the different adipose tissue 
compartments with hepatic fat content and the factors that define a person as metabolically 
healthy or unhealthy. We found clear sex-specific differences in the abdominal adipose tissue 
distribution. While women and men had similar BMI levels, women had significantly lower 
volumes of VAT, but higher volumes of dSAT and almost twice as high volumes of sSAT 
compared to men. In individuals with the metabolic syndrome, the hepatic fat content was 
significantly higher in women and men. Also, men with the metabolic syndrome had 
significantly more dSAT. After adjustment for other factors, only in men the dSAT was inversely 
associated with HDL-c. The sSAT volume showed no association with the metabolic syndrome 
traits. However, only in women with obesity we found an inverse association between the 
sSAT volume and hepatic fat content. When focusing on the SAT, it seems that dSAT has an 
intermediate metabolic phenotype between the VAT and sSAT. These different adipose tissue 
compartments should therefore be taken into account when assessing an individual’s 
cardiovascular risk. Next to that sex-specific analyses have been proven to be essential with 
regard to the contribution of fat distribution to metabolic dysregulation.  
 
Role of fat distribution in obesity-associated low-grade inflammation 
In chapter 4 we show that sex-specific differences in fat distribution influence it’s relation to 
chronic low-grade inflammation. In men VAT is positively associated to circulating leukocyte 
number, circulating IL-6, hsCRP and IL-18BP, while in women SAT is the main contributing 
adipose tissue compartment to their pro-inflammatory state. Next to this, we found in women 
a positive association between superficial SAT and IL-6 and IL-1Ra production of stimulating 
PBMCs with different stimuli. To investigate whether the origin of this inflammatory 
association is within the adipose tissue itself, we analyzed the adipose tissue and found in men 
a positive association between the adipocyte cell size, VAT and SAT. In women, the gene 
expression level of different pro-inflammatory genes was related to mainly the superficial SAT. 






Role of sex in immunometabolic regulation 
In chapter 5, we investigated the impact of sex on the relation between inflammation and 
metabolic syndrome in overweight women and men. We found that metabolic syndrome in 
women is mainly characterized by a deficiency of the anti-inflammatory mediator adiponectin, 
while in men metabolic syndrome presents with higher levels of proinflammatory mediators 
such as IL-6 and leptin. The metabolic syndrome traits might not have an equal contribution 
to the sex-specific effects and we therefore evaluated these factors separately. The 
triglyceride level appeared to be the most important parameter in explaining the sex-specific 
effects of metabolic syndrome for both IL-6 and adiponectin. Both in women and men, we 
found increased number of leukocytes, lymphocytes and monocytes in metabolically 
unhealthy individuals. Furthermore, we found only in men with the metabolic syndrome an 
enhanced cytokine production capacity.  
We were able to exclude various circulating metabolites and lipoproteins to be responsible 
for these differences. These findings suggest that the mechanisms by which inflammation and 
the immune system can cause adverse cardiometabolic consequences of obesity are different 
in women and men. We therefore argue for a sex-specific approach with regard to 
inflammation as therapeutic targets to prevent CVD in individuals with obesity.  
 
The contribution of cytokines to CVD risk, a crucial role for the IL-18 pathway 
To investigate whether differences in inflammation, especially from the IL-1 family of 
cytokines, contribute to the individual risk for atherosclerotic disease in individuals with 
obesity, we performed a systemic analysis of this relation in chapter 6. A few circulating 
cytokines were related to carotid atherosclerosis, however after additional adjustment for 
BMI, only IL-18BP concentrations remained positively associated with maximum plaque 
thickness. IL-18BP is known as an inhibitor of IL-18, which has actually been related to CVD. In 
order to investigate the underlying mechanism, we analyzed the relation with lipoprotein 
composition. IL-18BP was strongly associated with the VLDL particles, mainly the small -to 
large VLDL particles. This relation was validated in a younger, healthier cohort. In addition, in 
our 300-OB cohort we found that IL-18BP is a marker of adipose tissue inflammation. In a large 
clinical cohort from Boston we found that IL-18BP levels were positively related to 
cardiovascular events in patients with a history of a myocardial infarction. IL -18BP might 
therefore have diagnostic value and possible therapeutic consequences. 
 
The role of gut microbiota  
We performed a large metagenome-based study to assess the association between the gut 
microbiome, plasma metabolome and cardiovascular risk and describe the results in chapter 
7. We found specific microbial associations with the lipoprotein composition. Carotid 
atherosclerosis was associated with the bacterial pathway L-methionine and the 
Ruminococcus species with the hepatic fat content. The gut microbiome-derived TMAO levels 
in the plasma were positively associated with VAT. We also found significant associations 




glycoprotein N-acetyls. These data support further research in microbiome-targeted 
diagnostic and therapeutic approaches for CVD.  
The exact mechanisms by which the gut microbiome could influence the obesity-associated 
low-grade inflammation and atherosclerosis are not fully known. In chapter 8, we describe 
the results of a systemic review of human studies on the relation between the gut microbiome 
composition and markers of low-grade inflammation. Lower gut microbial diversity was 
associated with higher white blood cell counts and high sensitivity C-reactive protein (hsCRP) 
levels. We also found that hsCRP and IL-6 were related to the abundance of Bifidobacterium, 
Faecalibacterium, Ruminococcus and Prevotella species. In addition, this review speculates on 
possible gut microbiota associated mechanisms, such as the inflammasome, innate immune 
system, bile acids and gut permeability. These data also support additional human research to 




In this part, we reflect on our aggregated main findings in the broader context of the literature. 
 
Fat distribution 
Important sex-specific differences have been found in the distribution of adipose tissue. 
However, almost no study has investigated the separate contribution of the different layers 
of the SAT, quantified by MRI or CT on metabolic dysregulation or low-grade inflammation in 
individuals with obesity. We found that men had relatively more dSAT than sSAT and 
significantly higher volumes of VAT compared to women despite similar BMI levels. We found 
that only in men dSAT has an intermediate phenotype between the VAT and sSAT with regard 
to the traits of the metabolic syndromen. Previous studies found that the adipocytes from 
dSAT have higher lipolytic activity of adipocytes from dSAT compared to sSAT, which 
contribute substantially to FFA levels in the circulation (5). A potentially protective effect of 
sSAT in the development of hepatic steatosis in women is its high level of adiponectin, 
compared to dSAT (6). The expression of genes involved in inflammatory pathways, such as 
interleukin-6 and MCP1, were also higher in dSAT compared with sSAT (6, 7).  
 
A possible explanation for the difference between women and men in fat distribution and also 
possibly for the metabolic association could be the hormonal status. Hyperandrogenism in 
normal weight PCOS women has previously been associated with preferential visceral fat 
deposition and moreover an increased proportion of small subcutaneous abdominal 
adipocytes, which could limit subcutaneous fat storage (8). Moreover, six months of 
testosterone therapy in aging men with a low normal bioavailable testosterone decreased 






Not only did we find significant sex specific differences in the contribution of fat distribution 
to metabolic dysregulation, we also observed important sex differences in the relation with 
systemic low-grade inflammation. We identified in women that mainly SAT is related to white 
blood cell count, circulating levels of IL-6 and IL-18BP and production of pro-inflammatory 
cytokines after ex vivo stimulation. In contrast, VAT showed the strongest association with 
leukocytes and comparable associations with circulating cytokines as SAT in men. This 
suggests that the hypothesis about a beneficial effect of SAT is at least not applicable for 
women. Most previous studies did not perform sex-specific analyses or used a general 
population as cohort. Our study focused on individuals with overweight and obesity as they 
are at higher risk for CVD. Within this population the contribution of adipose tissue to low-
grade inflammation appears to be sex-specific. One hypothesis relates to the adipose tissue 
itself as we found a significant positive association between the amount of SAT with an 
upregulation of multiple pro-inflammatory genes. This could explain the possible detrimental 
effect of SAT in women compared to men. The other hypothesis relates to the differential 
status in sex hormones. Estradiol for example has been shown to upregulate the mRNA 
expression of both estrogen receptors the SAT in women, and one receptor in the SAT and 
VAT adipocytes in men (10). These findings call for a sex-specific approach with regard to 
interpretation of adipose tissue distribution and its contribution to low-grade inflammation. 
 
This emphasizes the need for future research on the role of fat distribution to distinguish the 
dSAT and sSAT and perform sex-specific analyses. By deciphering the immunometabolic 
effects of these different fat compartments, a better insight of its role in CVD is gained. This 
could eventually lead to new sex-specific diagnostic tools and possibly therapeutic options. In 
our study, we had the advantage of an MRI to evaluate the fat distribution. Most studies made 
use of ultrasound techniques to detect the amount of different adipose tissue compartment, 
however the accuracy in obesity is rather limited. When monitoring possible interventions, 
more sophisticated techniques as an MRI or CT scan are highly recommended. A limitation is 
the cross-sectional design of our study. Further prospective studies need to investigate the 
relation between the adipose tissue compartments and immunometabolic risk factors over 
time to identify the causal pathway.  
 
Sex differences  
Important sex-specific differences have been observed in the pathophysiology of 
atherosclerotic CVD. However, up till now sex is usually not taken into account with regard to 
diagnostic and therapeutic strategies for CVD. We have demonstrated that the 
immunometabolic relation with various adipose tissue compartment differs between women 
and men.  
 
In addition, we found a significant impact of sex on the relation between inflammation and 
metabolic syndrome in overweight women and men. Metabolic syndrome in women is mainly 




metabolic syndrome presents with higher levels of proinflammatory mediators such as IL-6 
and leptin, and also an enhanced cytokine production capacity. Previous studies have shown 
higher pro-inflammatory cytokines and a decrease in anti-inflammatory cytokines in the 
presence of metabolic syndrome (11, 12). However, no direct comparison has been made 
between women and men in larger studies. The circulating triglyceride concentration appears 
to be the most important condition influencing the distinct changes of the inflammatory 
parameters in women and men when they develop the metabolic syndrome. We did not find 
that sex-hormones are the causal factor, however we could not measure all sex hormones. 
This might still be of interest as colleagues found in vitro that progesterone for example can 
prevent the development of a pro-inflammatory phenotype of the macrophage by stimulation 
with oxidized low-density lipoprotein particles (unpublished data). Future research should 
investigate this possible role of the sex-hormones in obesity-associated low-grade 
inflammation.  
 
These findings suggest that the mechanisms by which inflammation can cause adverse 
cardiometabolic consequences of obesity are different in women and men. Future research 
on the diagnostic and therapeutic perspectives of low-grade inflammation should include sex-
specific analysis. Besides this, we argue for a sex-specific approach with regard to 
inflammation as a therapeutic target to prevent CVD in individuals with obesity.  
 
Obesity-associated low-grade inflammation and atherosclerosis 
As shown in this thesis, fat distribution, sex and gut microbiota have an influence on obesity-
associated low-grade inflammation and atherosclerosis. We also investigated the impact of 
(mainly) the IL-1 family of cytokines and its mediators on atherosclerotic CVD in individuals  
with overweight and obesity. We identified that IL-18BP showed a stronger relation to the 
presence of carotid atherosclerosis than currently used markers of inflammation (hsCRP, IL-
6). We found that the strong relation between hsCRP and IL-6 with atherosclerosis was largely 
mediated by BMI. This was recently also seen in a meta-analysis between hsCRP and all-cause 
mortality (13). We were initially surprised by the finding that IL-18BP had a stronger relation 
with carotid atherosclerosis, as IL-18BP down-regulates Th1 responses by binding IL-18 and 
thus reducing the bio-activity of IL-18. Multiple lines of evidence have shown that IL-18 is 
prospectively and independently associated with cardiovascular events in both women and 
men (14-17). We also found a significant association between IL-18 and IL-18BP, however 
within our 300-OB cohort after additional adjustment for BMI, only IL-18BP remained 
associated with the maximum plaque thickness. We could confirm this relation in a large 
clinical cohort; IL-18BP was associated with cardiovascular events, death and overall mortality 
among a population of patients undergoing coronary angiography. IL-18BP levels even 
improved cardiovascular risk prediction beyond the traditional risk factors (manuscript 
submitted). The recent data from the CANTOS trial support the importance of IL-18, as after 
IL-1β inhibition with canakinumab, there remains substantial residual inflammatory risk that 




the role of the IL-18 pathway in the atherosclerotic process. Further mechanistic insights need 
to be gained before therapeutic opportunities can be developed.  
 
We have a number of hypotheses on the pathophysiological role of IL-18BP on atherosclerosis. 
First, as we observed a strong relation between IL-18BP and lipoproteins, especially VLDL 
lipoproteins, we hypothesize that IL-18BP upregulates the VLDL production by the liver. We 
found in animals lacking IL-18 a decreased expression of genes known to be involved in hepatic 
lipid metabolism including PPP1R3G and ENHO. One possible explanation could be related to 
free IL-18. Previous studies have shown the importance of the free IL-18, as this is the bio-
active form (19, 20). As we calculated the free IL-18 but did not observe a relation between 
the free IL-18 and atherosclerosis markers, we suggest that it is not the free IL-18 itself that 
explains the influence of the IL-18 pathway on atherosclerosis.  
 
Another hypothesis for our finding is that IL-18 actually has a protective effect on the 
atherosclerotic process. We and others have shown results in line with this observation with 
increased atherosclerosis in the absence of IL-18 in mice (21, 22). This is in contrast to several 
lines of evidence that have implicated IL-18 in the development of obesity, type 2 diabetes 
and atherosclerosis. However, colleagues have previously demonstrated that the increased IL-
18 concentrations in patients with obesity are most likely a compensatory mechanism that 
increases IL-18 production due to “IL-18 resistance” at the level of cellular receptors (23). Next 
to this, recent evidence has shown that different types of inflammasomes produce different 
phenotypic action of IL-18. A recent study demonstrated that IL-18 production from the NLRP1 
inflammasome prevents obesity and metabolic syndrome (24). The cell type in which NLRP1 
functions to cleave IL-18 remains however unclear. In line with this, mice deficient in NLRP3 
or NLRP6 are also more vulnerable to colitis due to a lack of sufficient IL-18 (25, 26).  
 
Another possibility is that the increase in IL-18BP in metabolic syndrome is a compensatory 
mechanism for the increase in the IL-18 level equivalently to the rise in IL-1ra with increasing 
IL-1β (27). IL-18BP is present in the serum of healthy humans at a 20-fold molar excess 
compared to IL-18 (28). IL-18BP was a better predictor than IL-18 for carotid atherosclerosis 
and even future cardiovascular events. Differences in half-life might explain why IL-18BP is a 
better marker than IL-18 for activation of the IL-18/IL-18BP pathway, which is linked to IL-1β 
production. The prognostic properties of IL-18BP should be investigated in large studies.  
 
Besides binding IL-18, IL-18BP can also bind IL-37 and in doing so, enhances the ability of IL-
18BP to inhibit the induction of IFN-γ by IL-18 (29). IL-37 binds to the IL-18 receptor α with a 
very low affinity but in mice expressing human IL-37, a profound anti-inflammatory effect is 
observed (30). We and others have previously shown protective effects against obesity-
induced inflammation and insulin resistance by IL-37 (31, 32). By binding IL-37 the anti-




currently not possible. Hopefully future work will enable us to further explore the role of IL-
18BP and IL-37 in the atherosclerotic process.  
 
Gut microbiota 
Several studies suggest that the gut microbiota contributes to chronic low-grade inflammation 
and metabolic dysregulation observed in individuals with obesity. A large Danish study, found 
that a low gene count from the faeces was associated with increased insulin resistance, higher 
levels of triglycerides, decreased HDL-c as well as a more pro-inflammatory phenotype (33). 
Most studies on the role of the gut microbiota have been performed in mice up till now. 
However, the gut microbiota from mice is significantly different compared to human gut 
microbiota. In our systematic review we identified many associations on the relation between 
gut microbial species and markers of chronic low-grade inflammation.  
 
Gut microbial species 
First of all, a low-gene count was associated with higher white blood cell counts and a higher 
level of hsCRP. The hypothesis is that a lower gene count is associated with a lower diversity 
of the gut microbiota, which is important for the digestion of food and the production of short 
chain fatty acids (SCFA). Secondly, possible protective features of the genus Bifidobacterium 
and Faecalibacterium were found. This could be due to higher levels of the gut hormone 
ghrelin like peptide 2, which is related to a healthier mucosal barrier. The Bifidobacterium 
species are frequently used in probiotics nowadays. The Faecalibacterium has been related to 
the production of the SCFA butyrate, which can induce the production of regulatory T cells 
and limit the secretion of pro-inflammatory cytokines (34). Next to that, butyrate is an 
important energy source for colonic epithelial cells. A low level of Faecalibacterium species 
have earlier also been observed in individuals with a cerebral atherosclerotic event (35). We 
also identified in the LifeLines Deep study that the Faecalibacterium species were associated 
with a lower risk of CVD based on the metabolite composition. Metabolites are intermediate 
or end products of metabolism and have been related to CVD risk (36). They are a possible 
way by which the gut microbiota could influence the immune system and CVD risk. In our 300-
OB study we identified that the Ruminococcus species sp_6_39_BFAA related to VLDL 
lipoprotein composition and to hepatic fat content. Levels of members of the 
Ruminococcaceae family have been differentially related to pro-inflammatory cytokines and 
metabolites. In ApoE-/- mice, the genus Ruminococcus was highly positively correlated to the 
metabolite TMAO levels as well as atherosclerotic lesion area (37). Also, after correction for 
TMAO levels, we found a significant relation of the Ruminococcus species sp_6_39_BFAA with 
VLDL lipoprotein composition and hepatic fat content.  
 
Gut microbial pathways 
Aside from specific species, also bacterial pathways have been demonstrated to relate to 
cardiovascular risk, e.g. via lipoproteinemia (38). We found that the gut microbial L-




one microbial species was responsible for this L-methionine pathway activity, but many 
different species contributed in small proportions. The L-methionine pathway and its 
metabolic products have previously been associated with CVD. It is hypothesised that L-
methionine induces atherosclerosis by increasing plasma homocysteine levels. 
Hyperhomocysteinemia has also been related to CVD development in a meta-analysis and 
lowering homocysteine levels by folic acid supplementation found a 10% reduction in stroke 
risk and 4% reduction in CVD risk (39). Recently in mice, a high methionine diet in Apo-/- mice 
leading to hyperhomocysteinemie induced a pro-inflammatory status via NLRP3 
inflammasome activation. It would be very interesting to investigate the gut microbial 
composition of individuals with homocysteinuria. Next to this, further research should reveal 
the possible role of the gut microbiota when interventions as folic acid are given.  
 
Diagnostic possibilities of the gut microbiota 
The gut microbiota could possibly serve as a diagnostic tool to identify individuals at risk for 
CVD. We identified metabolites that are associated with the gut microbiota and relate to CVD 
risk. The gut microbial metabolites are secreted into the portal vein. Taking blood from this 
specific region in high risk individuals could further identify interesting metabolites. Further 
investigation into these metabolites and their mechanisms are needed. These can be 
performed first by adding such metabolites to in vitro cell cultures and then via ex vivo models. 
TMAO is a metabolite that has been shown to have prognostic value for CVD events. A meta-
analysis showed that higher circulating TMAO may independently predict the risk of 
subsequent cardiovascular events and mortality (40). In our 300-OB study, we identified a 
relation with the volume of the visceral adipose tissue compartment. Further research 
incorporating TMAO and possible other prognostic metabolites in risk stratification need to 
be performed.  
 
Therapeutic possibilities of the gut microbiota 
Given the associations found between gut microbiota and its metabolites with metabolic 
syndrome and cardiovascular disease, interventions aimed at modifying the gut microbiome 
could possibly reduce CVD morbidity and mortality. It would for example be very interesting 
to see whether individuals with a higher risk for CVD, and possibly especially those individuals 
with low-grade inflammation, would benefit from supplementation of Bifidobacterium and 
Faecalibacterium species. A few studies with probiotics containing these species have been 
performed (41), however all are limited by the fact that a mix of different species are used in 
the probiotic treatment. Not only supplementation with specific species via probiotics have 
been investigated as possible therapeutic interventions; one faeces transplantation study has 
been completed with regard to CVD. In 2012 Vrieze and colleagues were the first to identify 
that infusion of gut microbiota from lean individuals into individuals with metabolic syndrome 
could improve peripheral insulin sensitivity (42). However, further examination of the 
individual responses elucidated patients who responded the faeces transplantation, but also 




with specific strains appears to increase if this bacterial species already exists in the recipient 
(43). Individuals with high gut microbial gene richness at baseline showed no metabolic 
improvement (44), which suggests a complex contribution of different gut microbial strains to 
health. Further research should investigate whether a more personalized approach by 
analysing the gut microbiota to select the intervention could contribute to improved 
outcomes. Next to these host factors, also so-called superdonors have been identified (45). 
Superdonors are donors whose stool results in significantly more successful fecal microbiota 
transplantation outcomes than the stool of other donors. Nevertheless, whether these 
superdonors are good for all recipients and every disease type remains an open question (44). 
Furthermore, it is likely that the efficacy of one species depends on the network of other 
species that are present in the gut. The interpretation of gut microbiota modulating 
interventions are therefore quite complex and duplication of existing studies could reveal real 
interesting gut microbial species and pathways when consistent results are found. Further 
research is needed to get more insight into the complex networks of the gut microbiota in 
order to develop diagnostic and therapeutic opportunities of the gut microbiota on obesity 
related low-grade inflammation and eventually on CVD.  
 
Future perspectives 
The insights that we obtained in this thesis with regard to factors influencing the low-grade 
inflammatory status in individuals with overweight and obesity contribute to a better 
understanding of the development of CVD in patients with overweight and obesity. We have 
shown a sex-specific role of different abdominal adipose tissue compartments in the 
contribution to metabolic dysregulation and low-grade inflammation. We also found sex-
specific pathways that influence inflammation in obesity. Next to that, we found a possible 
new biomarker for atherosclerosis in subjects with overweight and obesity, IL-18BP, which 
might be related to increased hepatic production of lipoproteins. Lastly, we identified several 
bacterial species and pathways that were related to metabolites, hepatic steatosis and carotid 
atherosclerosis. 
Altogether, the results of our studies may add towards a better understanding of the 
pathophysiology of obesity-associated low-grade inflammation and its role in atherosclerotic 
CVD. Next to that, they highlight several factors that should be taken into account in future 
studies. First of all, we highlight the need for sex-specific analysis and the division of the SAT 
into dSAT and sSAT when investigating the role of fat distribution in CVD risk. Future studies 
should investigate further the sex-specific mechanisms leading to inflammatory dysregulation 
in obesity. As women with the metabolic syndrome were characterized by defective anti -
inflammatory mechanisms, whereas men had higher concentrations of pro-inflammatory 
mediators, this would propose that women and men might benefit from a differential anti -
inflammatory pharmacological intervention to prevent the adverse cardiometabolic effect of 
obesity. Sex-specific analyses are crucial to diminish the burden from CVD in both women and 
men. Also the role of IL-18BP should be further investigated. Not only should future studies 




also focus on possible underlying mechanisms. This would hopefully lead to more personalized 
diagnostic and possibly even therapeutic tools. Finally, our identified CVD related gut 
microbial species and pathways should be replicated in future studies. Further research is 
needed to confirm whether these gut microbial species and pathways can be used as 
diagnostic and therapeutic options in CVD risk management.  
In conclusion, by identifying these different factors and mechanisms that contribute to 
metabolic dysregulation and chronic low-grade inflammation, we hope to improve the 
diagnostics tools to identify individuals at risk for CVD at an earlier stage and to personalize 
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Hart- en vaatziekten en aderverkalking 
Hart- en vaatziekten blijven één van de belangrijkste oorzaken van sterfte wereldwijd. Het 
belangrijkste onderliggende mechanisme om hart- en vaatziekten te krijgen is aderverkalking, 
in medische termen ook wel atherosclerose genoemd. Aderverkalking is een chronisch 
ontstekingsproces van de slagaders. Witte bloedcellen eten het cholesterol op, waardoor ze 
aan de binnenzijde van het bloedvat blijven plakken en aldaar ontstekingsstoffen worden 
geproduceerd. Dit trekt andere ontstekingscellen aan, waardoor een ophoping aan de 
binnenzijde van het bloedvat optreedt, dit wordt een plaque genoemd. Wanneer deze plaque, 
of een afgescheurd deel hiervan, het bloedvat volledig afsluit, krijgt het achterliggende 
weefsel geen bloed en daarmee geen zuurstof meer. Wanneer dit in de kransslagaders 
optreedt, ontstaat een hartinfarct, wanneer dit in de hersenen vast komt te zitten ontstaat 
een herseninfarct.  
 
 
Figuur 1 – overzicht van de verschillende fases van aderverkalking 
 
Klassieke risicofactoren als overgewicht, een hoge bloeddruk, een hoog slecht cholesterol 
(LDL-cholesterol) of laag goed cholesterol (HDL-cholesterol) en veel vetten (triglyceriden) in 
het bloed worden geregeld gemeten bij personen met een verhoogd risico op hart- en 
vaatziekten. Deze combinatie van risicofactoren wordt ook wel het ‘metabool syndroom’ 
genoemd. Personen met het metabool syndroom hebben een 2x grotere kans op het krijgen 
van hart- en vaatziekten. Aangezien deze risicofactoren maar net iets meer dan de helft van 
hart- en vaatziekten kan verklaren, is men al lange tijd op zoek naar andere factoren. Bijna 
twintig jaar geleden ontdekten wetenschappers de belangrijkste andere factor: een 
chronische milde ontsteking. Deze milde ontsteking zit niet alleen in het bloed, maar ook in 
vele weefsels zoals het vetweefsel, de alvleesklier en de lever. 
Personen met overgewicht hebben meer ontstekingscellen in hun bloed, maar ook in het 
vetweefsel en in de lever. De hypothese hoe overgewicht tot hart- en vaatziekten kan leiden, 
is als volgt: personen die meer voeding binnen krijgen dan dat ze nodig hebben, slaan de 
energie die het lichaam uit deze voeding haalt op als vet. Wanneer steeds meer vet opgeslagen 
wordt in het vetweefsel, krijgen de vetcellen op een gegeven moment onvoldoende zuurstof. 
Dit leidt tot het afsterven van vetcellen, wat ontstekingscellen aantrekt, welke weer andere 
vetcellen en ontstekingscellen aanzet tot het produceren van ontstekingsstoffen. Deze 
ontstekingsstoffen worden meegenomen in het bloed, waardoor een milde ontsteking 




Er zijn verschillende onderzoeken geweest die gekeken hebben welke ontstekingscellen of 
ontstekingsstoffen meehelpen in het proces van aderverkalking. We kennen twee 
mechanismen ten aanzien van de ontsteking: ‘gewone’ ontstekingscellen maar ook cellen die 
juist de ontsteking tegen willen werken, de anti-ontstekingscellen. Recent onderzoek heeft 
aangetoond dat het remmen van het ontstekingsstofje IL-1β ervoor zorgt dat patiënten 
minder hart- en vaatziekten ontwikkelen. 
 
Mijn hypothese en onderzoek bij de proefpersonen 
Ondanks dat we weten dat ontstekingscellen en -stoffen een belangrijke rol spelen bij het 
ontstaan van hart- en vaatziekten, weten we nog niet volledig welke factoren een invloed 
hebben op deze ontsteking. In mijn thesis heb ik daarom een aantal factoren onderzocht die 
een mogelijke invloed hebben op deze ontstekingsstoffen en op aderverkalking. Deze factoren 
zijn: de vetverdeling binnen het lichaam, man-vrouw verschillen en darmbacteriën. Daarnaast 
heb ik gekeken welke ontstekingscellen en -stoffen het beste aderverkalking konden 
voorspellen.  
Dit heb ik gedaan door in totaal 300 proefpersonen te onderzoeken die allemaal overgewicht 
hadden. Deze personen hebben verschillende vaatmetingen ondergaan om te kijken of er 
aderverkalking zichtbaar was, daarnaast hebben we de klassieke risicofactoren zoals de 
bloeddruk en het cholesterol gemeten. Aangezien de ontsteking ook in het vetweefsel 
aanwezig is en hier nog niet zoveel van bekend is, heb ik bij iedereen een klein beetje vet 
afgenomen net onder de huid in een buikplooi. Om de ontstekingscellen en -stoffen beter in 
kaart te brengen, hebben we bloed afgenomen waarop allerlei experimenten zijn verricht. Alle 
proefpersonen hebben een klein beetje ontlasting opgevangen, waarna wij de darmbacteriën 
hebben kunnen meten. Alle proefpersonen hebben daarnaast een MRI ondergaan, hiermee 




Ons vetweefsel is een belangrijk orgaan dat vele hormonen produceert en nodig is voor de 
opslag van energie. Het grootste deel van het vetweefsel zit opgeslagen in de buik en bij de 
benen. Vet dat tussen de organen in de buik zit, het viscerale vet genaamd, is geassocieerd 
met een hoger risico op het ontstaan van hart- en vaatziekten. Dit kennen we als de appelvorm 
die met name bij mannelijke personen wordt gezien. Van het vetweefsel dat onder de huid 
zit, deels bij de heupen, het subcutane vetweefsel genaamd, zijn tegenstrijdige gegevens te 
vinden: we weten niet goed of dit een risicofactor is of juist mogelijk een beschermend effect 
heeft op het ontstaan van hart- en vaatziekten. We kennen dit met name als de peervorm bij 





Figuur 2 – Links de hoogte waar het MRI plaatje rechts gemaakt is. Rechts: vet op de 
verschillende plaatsen: vet tussen de organen, vet in de diepe vetlaag onder de huid en vet 
oppervlakkig om de huid.  
 
Ongeveer tien jaar geleden werd ontdekt dat het vetweefsel dat onder de huid zit, 
onderverdeeld kan worden in een diepe en een oppervlakkige laag. Daar dit alleen met 
geavanceerde technieken als een CT-scan of een MRI-scan goed in beeld kan worden 
gebracht, zijn er nog maar enkele studies die hebben gekeken of deze vetweefsellagen 
mogelijk een verschillende bijdrage kunnen leveren aan aderverkalking. Daar het jaren duurt 
voordat aderverkalking ontstaat en het zich langzaam uitbreidt, probeert men in 
wetenschappelijk onderzoek vaak te kijken of er een relatie bestaat met risicofactoren voor 
aderverkalking. Wij hebben daarom de volumes van de verschillende vetlagen: vet tussen de 
organen, het diepe vet en het oppervlakkige vet net onder de huid gerelateerd aan onze 
gemeten ontstekingscellen en -stoffen, de ontsteking die in het vetweefsel zit, maar ook aan 
de klassieke risicofactoren die tot nog toe bekend zijn. Hierin hebben we interessante nieuwe 
bevindingen gedaan die ook verschillend bleken te zijn voor mannen en vrouwen. 
Het vet dat tussen de organen zat bleek bij mannen en vrouwen slecht te zijn, terwijl het vet 
dat dieper onder de huid ligt alleen bij mannen slecht bleek te zijn. Bij vrouwen met obesitas 
(een ergere variant van overgewicht) bleek het oppervlakkige vet onder de huid juist 
beschermend te zijn hiervoor. 
Ten aanzien van de relatie met de ontstekingswaarden zagen we ook een opvallend man-
vrouw verschil. Bij mannen draagt het vet dat tussen de organen zit het sterkste bij aan meer 
ontstekingscellen en -stoffen in het lichaam, terwijl bij vrouwen juist het vet dat onder de huid 
zit, het oppervlakkige en het diepe, vooral gerelateerd is aan meer ontstekingscellen en -
stoffen. Een deel van de verklaring zit in het vetweefsel, aangezien de vrouwen daar meer 
ontstekingsstoffen produceren. Hierdoor lijkt het ook dat de klassieke risicofactoren en de 
chronische milde ontsteking echt een ander mechanisme hebben waarmee ze hart- en 








Zoals hierboven beschreven, zijn er reeds duidelijke verschillen aanwezig in de verdeling van 
het vetweefsel en de bijdrage van dit vetweefsel aan risicofactoren voor het ontstaan van 
aderverkalking. In het wetenschappelijk onderzoek worden vrouwen vaak als semi-man 
gezien, veel medicijnstudies zijn bijvoorbeeld alleen op mannen onderzocht, terwijl er op vele 
vlakken grote verschillen zijn. We hebben daarom gekeken of mannen en vrouwen met de 
klassieke risicofactoren ook een ander profiel van hun ontstekingscellen en -stoffen hadden, 
en dat bleek zo te zijn! Terwijl bij mannen met de klassieke risicofactoren de gewone 
ontstekingscellen werden aangezet, bleken vrouwen met de klassieke risicofactoren juist een 
verlaging van de cellen te hebben die de ontstekingscellen tegenwerken, zij hadden dus 
minder anti-ontstekingscellen. Dit heeft ook consequenties voor mogelijke behandelingen die 
gericht zijn op ontsteking bij hart- en vaatziekten. Bij mannen zouden de interventies zich 
moeten richten op de ‘gewone ontstekingscellen’ zoals ontstekingsremmende medicatie, 
terwijl bij vrouwen mogelijk juist meer anti-ontstekingscellen gegeven of aangezet moeten 
worden. Hopelijk draagt dit bij aan een nieuwe stap binnen de geneeskunde en zullen de 




Zoals eerder aangegeven weten we eigenlijk nog niet volledig welke ontstekingscellen en -
stoffen het belangrijkste zijn bij aderverkalking. Uit vele onderzoeken blijkt de IL-1 familie 
belangrijk te zijn, waar onder andere IL-1β en IL-18 toe behoren. Om meer inzicht te krijgen in 
deze familie, hebben we verschillende stofjes die tot deze familie behoren óf die invloed 
hebben op stofjes binnen deze familie in het bloed geanalyseerd. Van deze ontstekingsstofjes 
hebben we vervolgens gekeken of ze een relatie tonen met de klassieke risicofactoren en met 
aderverkalking. Hierbij deden we een verrassende bevinding. We hadden een nieuw stofje 
ontdekt dat een betere relatie vertoonde met aderverkalking dan de ontstekingsstoffen die 
tot nog toe gebruikt werden. Deze stof heet IL-18BP, dit was uiteraard reuze interessant! 
Toevallig hadden collega’s reeds muizenstudies verricht waarin o.a. de rol van dit stofje 
onderzocht werd en een mogelijke rol bevestigd kon worden. Door een samenwerking met 
een groot cohort aan patiënten met hart- en vaatziekten in Boston hebben we vervolgens ook 
aan kunnen tonen dat IL-18BP een betere voorspelling van een nieuw hartinfarct kon doen 
bovenop de klassieke risicofactoren. We hebben verscheidene hypotheses waarom IL-18BP 
een betere maat is voor hart- en vaatziekten en deze dienen we in de toekomst goed te gaan 
onderzoeken. Daarnaast dient de prognostische waarde van IL-18BP in toekomstige 
onderzoeken bevestigd te worden alvorens het in de praktijk toegepast zou kunnen worden. 
Het zou prachtig zijn als we op deze manier een bijdrage kunnen leveren aan het beter 








Het laatste onderdeel dat ik in mijn thesis onderzocht heb, is de relatie van de darmbacteriën 
met de aan overgewicht veroorzaakte chronische milde ontsteking en de relatie met 
aderverkalking. Dit is echt een nieuw onderdeel in de geneeskunde, waarvan pas een aantal 
jaren geleden duidelijk is geworden dat het een rol kan spelen bij ziekte en gezondheid. De 
eerste studies toonden aan dat personen met overgewicht minder diversiteit in hun darmflora 
hadden wat invloed had op de vertering van hun voedsel. Vervolgonderzoeken hebben in 
kleine groepen aangetoond dat bepaalde darmbacteriën vaker voorkomen bij personen met 
hart- en vaatziekten dan bij gezonde personen. Onze hypothese is dat de darmbacteriën 
stoffen produceren waardoor ons afweersysteem wordt aangezet en daarmee een invloed 
heeft op aderverkalking. We hebben daarom in onze 300 personen met nieuwe 
geavanceerdere technieken de samenstelling van de darmbacteriën onderzocht en vele 
stofjes onderzocht die een mogelijke rol konden spelen. Hierbij vonden we inderdaad een rol 
voor enkele specifieke darmbacteriën en een paar specifieke stofjes. Deze dienen nu in nieuwe 
onderzoeken bestudeerd te worden. Mogelijk dat het onderzoeken van de ontlasting bij kan 
dragen aan het eerder ontdekken van een verhoogd risico op hart- en vaatziekten en kan het 
herstellen van de darmflora bijdragen aan het voorkomen van hart- en vaatziekten. 
 
Het toekomstplaatje 
Uiteindelijk is het natuurlijk de droom om personen met een verhoogd risico op hart- en 
vaatziekten in een vroeger stadium op te sporen door verder te kijken dan alleen de klassieke 
risicofactoren. Hopelijk kun je die personen vervolgens op een persoonsgerichte wijze gaan 
behandelen. Dat betekent mogelijk dat de ene persoon behandeld dient de worden met 
cholesterolverlagers, terwijl de andere persoon onstekingsremmers moet krijgen of juist anti-
ontstekingsstoffen, en weer een ander mogelijk een herstel van de darmflora nodig heeft. 
Hopelijk kunnen we door middel van onze onderzoeken uiteindelijk een echte bijdrage leveren 
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Zo. En dan is het precies zeven jaar later dat ik de eerste woorden van mijn dankwoord typ. 
Waarschijnlijk zal dit het meest gelezen hoofdstuk zijn van mijn thesis, ik hoop daarom dat ik 
niemand vergeet!  
Wat heb ik een geluk gehad te mogen werken met zulke fantastische mensen. Door de vele 
samenwerkingen heb ik zoveel mensen ontmoet die allemaal gepassioneerd met hun werk 
bezig zijn. Ik wil iedereen die een bijdrage heeft geleverd aan de afgelopen jaren onderzoek 
dan ook enorm bedanken.  
 
Allereerst gaat mijn dank uit naar alle proefpersonen. Ik ben erg onder de indruk van jullie 
bereidheid, enthousiasme en toegewijdheid. Niet één, niet twee, maar drie maal moesten de 
meesten naar het Radboudumc komen om alle onderzoeken te ondergaan. Zelfs een vetbiopt 
en MRI weerhield jullie er niet van om deel te nemen. De onderzoeksdagen vlogen voorbij 
door jullie prachtige levensverhalen. Dank voor de continue interesse die is gebleven, ook al 
heeft het een aantal jaar geduurd voordat jullie de eerste onderzoeksresultaten te zien 
kregen. Ik voel me vereerd dat meerdere van jullie via de livestream meekijken. Nogmaals 
dankjewel voor jullie toewijding en vertrouwen!  
 
Dr. Rutten, beste Joost, wat hebben wij een fijne samenwerking gehad de afgelopen jaren! Je 
gaf me het volste vertrouwen om alles op mijn eigen manier te ontdekken en op te zetten en 
stond altijd open voor vragen. Van ondersteuning bij het aanleren van praktische 
vaardigheden tot het kritisch superviseren van mijn papers (waar je in het begin best veel tijd 
mee kwijt was ;)). Jouw aanstelling in het Radboudumc was perfect getimed. Ik ben enorm 
dankbaar dat je mijn co-promotor wilde zijn en ik weet zeker dat de vasculaire geneeskunde 
inmiddels al niet meer zonder jou kan. Dank voor je vertrouwen, heerlijke humor en interesse! 
 
Prof. Dr. De Graaf, beste Jacqueline, wat ben ik blij dat je aan me dacht toen jullie de grant 
binnen hadden gehaald. Ik heb diep respect voor de manier waarop jij alle taken wist te 
combineren. Ondanks je opleiderschap wist je precies waar ik mee bezig was en hield je het 
overzicht. Je had altijd goed advies en keek telkens mee hoe ik me verder kon ontwikkelen. Ik 
dank je voor al het vertrouwen dat je me gegeven hebt! Door de afwisseling van opleiding en 
onderzoek strekte mijn PhD tijd zich uit, waardoor je in de tussentijd de stap naar 
opleidingsdirecteur hebt gemaakt. Een begrijpelijke keuze, maar voor mij uiteraard jammer 
dat we niet nog langer samen hebben mogen werken tijdens mijn opleiding Interne 
Geneeskunde. Naast al die functies die je uitstekend wist te vervullen, heb ik je ook nog eens 
leren kennen als een prachtig mens die oog heeft voor de persoon, waarbij ik altijd terecht 






Prof. Dr. Riksen, beste Niels, wat had ik een geluk dat jij aansloot bij mijn promotieteam! Door 
jouw onuitputbare kennis op atherosclerose gebied wist jij vele linken snel te leggen. Dit 
gecombineerd met je snelle denkvermogen zorgde ervoor dat nieuwe onderzoeken en 
experimenten in razend tempo bedacht werden. Daarnaast hebben je vele collaborators 
wereldwijd een nieuwe boost gegeven aan ons Il-18BP onderzoek. Dank voor je inzicht, de 
goede tips ten aanzien van mijn manuscripten en de fijne samenwerking.  
 
Prof. Dr. Joosten, beste Leo, ik leerde jou samen met Mihai tijdens ons eerste CVON overleg 
in oktober 2013 kennen. Het eerste wat me opviel was jouw gevoel voor humor, dit breidde 
zich daarna uiteraard uit met jouw enorme kennis op immunologisch gebied en je 
sneldenkende vermogen om relaties in de wirwar aan data te zien en hier nieuwe 
experimenten op te kunnen bedenken. Je bent tijdens mijn PhD tijd prof geworden en dat is 
meer dan terecht. Ik zal onze CVON overleggen gaan missen. 
 
Prof. Dr. Netea, beste Mihai, ondanks dat je niet in mijn promotieteam zit, heb je me wel 
ontzettend gesteund met jouw onvoorstelbare vermogen om uit alle data weer een duidelijke 
boodschap naar voren te krijgen. Je bent echte inspiratiebron voor alle beginnende 
wetenschappers. Het is indrukwekkend hoeveel je weet van allerlei vakgebieden en hoe je 
deze kennis ook nog eens moeiteloos weet te combineren. Na ieder overleg kon ik vol 
enthousiasme weer verder. Bedankt voor de inspiratie en het vertrouwen. 
 
Kiki, mijn ‘partner in crime’. Wat ben ik blij dat jij op hetzelfde project werd aangesteld. We 
hadden vanaf de eerste ontmoeting een erg fijne klik. 
Terugkijkend hebben we samen enorm veel werk 
verricht. Samen hebben we veel tijd doorgebracht 
met de proefpersonen op onze biomaterial woensdag 
en MRI donderdag. Door jouw aanwezigheid was het 
altijd gezellig en kon ik lekker ontspannen door een 
half uur naar jouw heerlijke geratel te luisteren. Ik 
begrijp het volkomen dat je je hart hebt gevolgd naar 
waar je sterke didactische vaardigheden en 
enthousiasme beter tot zijn recht komen, maar ik mis 
je aanwezigheid wel in het Radboud. Alle goeds voor 
de toekomst, we moeten maar weer eens snel onze etentjes oppakken! 
 
Leden van de manuscriptcommissie, prof. dr. Maas, prof. dr. Joosten en prof. dr. Lutgens: 
hartelijk dank voor het kritisch beoordelen en goedkeuren van mijn manuscript. 
 
Mijn onderzoek zou onmogelijk zijn geweest zonder de financiële steun vanuit 
CardioVasculair Onderzoek Nederland (CVON), welke mede gesubsidieerd wordt door de 




Een onderzoek, met name het mijne, komt alleen tot een goed einde indien je terug kunt 
vallen op fijne collega’s en dat kon ik! 
  
Allereerst wil ik de dames en Berry van poli blauw bedanken voor de praktische 
ondersteuning die ik mocht krijgen. Dit varieerde van het ontvangen van mijn proefpersonen, 
tot het regelen van polikamers, tot zelfs proefpersoon zijn om de vaatmetingen goed te 
kunnen leren. Dankjewel voor de fijne samenwerking, we zien ons vast snel weer in het 
Radboudumc!  
Deze ondersteuning had ik uiteraard ook nodig vanuit de afdeling Radiologie. Ik ben Marije, 
Cindy en Suzan derhalve ook enorm dankbaar voor jullie 
vermogen om altijd mee te denken, zelfs als ik één dag 
van tevoren vroeg of we het half uur scantijd tussen de 
middag nog op mochten vullen.  
 
Dan uiteraard Tessa, je hebt me heel wat werk uit handen 
genomen! Ik kon op je bouwen en durfde mijn werk echt 
uit handen te geven (en ik weet dat dat niet mijn sterkste 
kant is). Je hebt vele donderdagavonden met me 
doorgebracht bij de MRI, waarbij je een erg prettige 
omgang met de proefpersonen had. We hadden een fijne  
klik en konden lekker kletsen over het volleyballen of ons privé leven. Daarnaast was je de 
eerste student die ik tijdens mijn PhD tijd heb mogen begeleiden en ik kon me geen fijnere 
student bedenken! Dit heeft ook nog eens geleid tot een prachtig manuscript, welke 
onderdeel is van deze thesis. Dankjewel voor de fijne tijd en flinke ondersteuning die je me 
tijdens mijn PhD tijd hebt gegeven.  
 
Collega’s van de afdeling fysiologie, daar waar het allemaal begonnen is :). Allereerst veel dank 
aan Dick Thijssen, ongelofelijk wat voor organisatorisch vermogen jij hebt om alle projecten 
te overzien, iedereen enthousiast te maken, en te houden, en daarnaast snel nieuwe 
experimenten op te zetten. Veel respect hoe jij alles weet te combineren: Liverpool, Nijmegen 
en je eigen gezin. Ook na mijn vertrek naar de afdeling Interne Geneeskunde bleef je 
geïnteresseerd en kon ik altijd terecht voor goed advies. Het is gewoon wachten tot je 
hoogleraar wordt en dat verdien je volkomen. Ik bewonder je en wens je alle goeds toe samen 
met je gezin! 
Thijs Eijsvogels, wat ben ik blij dat jullie ingingen op mijn mailtje in 2009 om mee te willen 
draaien bij wetenschappelijk onderzoek. Je hebt me onder jouw vleugels genomen tijdens 
meerdere Vierdaagse onderzoeken. Wat heb je daarna een vlucht gemaakt in jouw 
succesvolle carrière. Je pakt alle kansen en werkt ze perfect uit. Je bent een inspiratiebron 
voor vele jonge wetenschappers! 
Maria Hopman, dank voor het vertrouwen dat ik kreeg om mee te mogen draaien in allerlei 




Hiermee is een mooie basis gelegd voor mijn wetenschappelijke carrière. Dank daarnaast voor 
je persoonlijke interesse en bereidheid om mee te kijken hoe ik me verder kon ontwikkelen. 
PhD studenten van de afdeling Fysiologie, dank voor de fijne samenwerking de afgelopen 
dikke tien jaar. Initieel uiteraard in het begeleiden, daarna in het samen sparren over de beste 
onderzoekmethodes en het interpreteren van onze resultaten. Een speciaal dankwoord aan 
Rebecca Verheggen voor je inspiratie en tips ten aanzien van het onderzoek, maar vooral ook 
ten aanzien van de opleiding tot internist. Daarnaast ook dank aan Matthijs Veltmeijer, wat 
hebben we een fijne tijd samen op de afdeling gehad. Beide veel succes en geluk in de 
toekomst gewenst. 
 
Prof. Dr. Green, dear Danny, I would like to thank you sincerely for the great internship that 
I’ve had in Australia. You taught me important lessons in vascular research, and more 
important, about life. I still appreciate it very much that you were so kind to take care of me, 
together with your lovely wife Stephanie and great kids Abbey and Daniel. My time in 
Australia gave me insights into my own life and future career, and look where I am now. 
Thanks a lot again. I wish you all the best! 
 
Collega’s van de radiologie, allereerst Marinette, jij hebt vooral enorm geholpen bij de MRI 
protocollen en het opstarten met alle praktische problemen waar we tegenaan liepen. Jouw 
sterke technische achtergrond heeft ervoor gezorgd dat we in deze soms iets lastigere 
onderzoekspopulatie evengoed duidelijke MRI beelden wisten te verkrijgen. 
Chris, dank voor de interesse die je elke keer had, ook al zagen we elkaar maar sporadisch. 
Knap hoe jij het overzicht kan houden over de vele projecten die je had. 
Rik, jouw expertise op het gebied van de elastografie is bewonderingswaardig. Ik ben blij dat 
je mij als a-technicus zo goed hebt weten te begeleiden. Hopelijk kunnen we ons paper snel 
afronden ;). 
Gert, door jouw jarenlange kennis op het wetenschappelijke gebied van leverecho’s, wist jij 
precies waar ik op moest letten en hoe we deze data moesten interpreteren. Dank dat je elke 
keer open stond voor vragen en meedacht hoe we alle data geanalyseerd kregen. 
Sjaak, tsja.., daar belde die onderzoeker van de Interne weer. Of het nu ging om een bepaald 
software of een ander ‘simpel computerprobleem’ (waar ik echt geen verstand van had/heb), 
je wist me elke keer enorm te helpen.  
Heleen Dekker, dank voor het beoordelen van toevalsbevindingen. Gelukkig hebben we geen 
ernstige ziekten geconstateerd. Anton Meijer, jouw expertise hadden we hard nodig bij de 
analyses van de carotis MRI’s, fijn dat je hier tijd voor vrij wilde maken. 
 
Jos op ’t Roodt, wat was het fijn dat ik op je terug kon vallen bij alle technische problemen die 
we ervoeren bij onze echo apparaten. De praktische tips die je hier elke keer in wist te geven 
waren ook erg welkom. Dank daarnaast voor je interesse in de persoon achter de zoveelste 





Anne, Eveline, Daphne, Martijn, Bart, Angela, ieder van jullie heeft een fantastische stage 
gedaan, waarmee weer nieuwe inzichten ten aanzien van de MRI, echo lever en vaatmetingen 
zijn verkregen. Sorry dat de afspraken soms wat langer duurden door alle telefoontjes die ik 
kreeg vanuit de afdeling. Dank voor jullie samenwerking.  
 
Daarnaast wil ik uiteraard ook alle coauteurs 
bedanken. Door de vele samenwerkingen zijn het er 
teveel om op te noemen, dank voor de fijne 
samenwerking! Daarnaast alle CVON consortium 
genootjes: we hebben iets fantastisch neergezet de 
afgelopen jaren, ik hoop dat het microbioom nog 
verder op de kaart wordt gezet! In het bijzonder dank 
aan Alexander, Sasha en Jing voor de 
microbioomanalyses welke hebben geresulteerd in 
meerdere prachtige manuscripten. Daarnaast een  
speciaal woord van dank aan Loek voor de hulp bij de analyse van onze carotis MRI’s. Ik ben 
ervan overtuigd dat je een geweldige internist en wetenschapper wordt/bent.  
 
En dan komen uiteraard ook mijn directe collega’s van de (Experimentele) Interne 
Geneeskunde aan bod. Door de afwisseling van onderzoek en opleiding, ben ik veel van kamer 
geswitcht. Elke samenstelling bracht weer iets unieks en moois met zich mee. Het laatste jaar 
heb ik met name met Charlotte en Marvin doorgebracht: dank voor de fijne gesprekken, of 
deze nu op wetenschappelijk gebied, op het interne vlak of privé lagen, jullie waren een prettig 
luisterend oor en ik vond de verhalen uit de kliniek heerlijk! Daarnaast uiteraard ook dank aan 
alle vasculair geneeskundigen en fellows voor de welkome ontvangst en de vele vragen 
waarmee ik ook bij jullie terecht kon. 
 
Collega’s van het lab Experimentele Geneeskunde. Een speciaal woord van dank aan Heidi en 
Helga, jullie hebben enorm veel werk verricht voor het CVON project en altijd met erg veel 
enthousiasme en expertise. Ik zou niet weten hoe we het hadden moeten doen zonder jullie 
hulp, heel veel dank hiervoor! Cor, of hoe ik je de eerste keer noemde, dhr. Jacobs, dank voor 
je prachtige vermogen om alle touwtjes in handen te houden op het lab en elke paar weken 
een nieuwe PhD student in te werken. Heerlijk, de manier waarop jij in het leven staat. Rinke, 
dank voor je expertise op het gebied van muizenstudies en vetweefselanalyses, die hadden 
we meer dan nodig bij het interpreteren van onze onderzoeksdata. Ik vind het knap hoe je 
elke keer meteen weer de vervolgstappen helder had. Je was altijd in voor advies, ook al zat 
je in Wageningen. 
Hanne, bedankt voor je tips op wetenschappelijk gebied, maar ook de gezellige lunches en 
uiteraard je persoonlijke interesse. Ik heb bewondering hoe je zo positief blijft en alles op een 
fijn niveau weet te combineren. Ik ben blij dat we nog steeds collega’s zijn in het CWZ en 




Rob, ik kan me onze eerste ontmoeting nog goed herinneren. Je zag eruit als een hippie, maar 
ik was tegelijkertijd direct onder de indruk van je statistische expertise. Dank voor de fijne 
samenwerking de afgelopen tijd in ons CVON onderzoek. Veel succes en plezier me je carrière 
in Wenen.  
Harsh en Daniela, een dik jaar geleden zijn jullie aangesteld op het CVON-2 onderzoek. Echt 
heerlijk om zulke opvolgers te mogen hebben, aan jullie durf ik het met een gerust hart over 
te dragen. Veel succes en blijf goed zorgen voor onze proefpersonen :). 
Charles, thank you for your knowledge on IL-18BP and especially IL-1β. 
Siroon, ik heb enorme bewondering voor jouw 
talentvolle wetenschappelijk vermogen, je hebt niet 
voor niets de beurs van de Nederlandse 
Hartstichting gekregen en onlangs de prijs voor 
beste postdoc van 2019! Maartje en Michelle, dank 
voor de gezelligheid binnen en buiten het 
Radboudumc! Q-roomies, dankjewel dat ik altijd 
even binnen mocht vallen om wat verhalen uit de 
kliniek te horen of om jullie adviezen te krijgen t.a.v. 
analyses. 
Daarnaast mijn overige collega’s van het lab EIG: 
ondanks dat ik weinig op het lab te vinden was, waren jullie altijd in om mee te denken en 
bereid om me wederom wat uit te leggen of om gezellig een drankje te doen zoals tijdens onze  
Lowlands ervaring: Janna, Marije, Sanne, 
Martin, Sam, Mark, Thalijn, Charlotte en 
Charlotte, Duby, Hanne, Ekta, Hedwig, 
Jacqueline, Lisa, Mariska, Anouk, Simone, 
Arjan, Floor, Stephan, Andreea, Lily, Inge, 
Jelmer, Katharina, Kathrin en Kathryn, Marlies, 
Yvette, Rob en Rob, Wouter, Ruud, Valerie, 
Jessica, Berenica en Viola. Ik hoop heel erg dat 
ik niemand vergeten ben.  
 
Collega assistenten en internisten uit het CWZ, 
dank voor het warme bad waarin ik terecht ben gekomen. Dank ook voor het vertrouwen dat 
jullie me gegeven hebben waardoor ik mezelf heb kunnen ontwikkelen. Ik kijk met veel plezier 
uit naar mijn laatste jaar als assistent bij jullie. 
 
Naast collega’s zijn vrienden en familie net zo belangrijk geweest in het helpen ontspannen 
de afgelopen jaren. Ik zal jullie niet allemaal bij naam noemen. 
Allereerst dank aan dames 1 en 4, helaas is mijn volleybalcarrière abrupt geëindigd en ben ik 
bang dat ik ook in de toekomst niet meer actief deel kan nemen, maar wat heb ik een super 




fijn dat ik op deze manier toch nog onderdeel blijf van jullie gezellige team. John, dank voor je 
expertise en ondersteuning die ik (soms ook mentaal) nodig had tijdens mijn knierevalidatie. 
Dank daarnaast voor de mooie gesprekken die we konden voeren over de wetenschap en de 
voedingsindustrie. Het ga je goed!  
Eetclubje 3.0 dank voor de driewekelijks dinertjes die elke keer een groot succes zijn. Naast 
het heerlijke eten dat elke keer bereid wordt (waar ik als uiterst slechte kok super van kan 
genieten) uiteraard ook dank voor de diepgaande gesprekken, ik hoop dat we dit ondanks de 
kids nog lange tijd vol blijven houden :). 
Monique, Marjon, Franca, Carla en mannen van ons avondje samen, we kennen elkaar al 
sinds de basisschool, deels zelfs al vanuit de box vroeger (in de komkommerkas bij ons thuis). 
Onze band is alleen maar hechter geworden. Dank voor de ontelbare herinneringen, prachtige 
stapavonden, gezellige drankjes en hapjes, de buikpijnmomenten van het (schater)lachen, 
maar vooral dank voor alle momenten dat jullie er altijd zijn als het nodig is. 
Dames van Las Faranduleras, Linda, Ellen, Mariëlle, Kim en Helma, wat hebben we een 
heerlijke tijd samen doorgebracht op de middelbare school. Dank voor alle gekkigheid, onze 
avondjes bij the shuffle, maar uiteraard ook voor de vele middagen/avondjes onder genot van 
een heerlijk wijntje/biertje met nacho’s. Hopelijk mogen er nog vele weekendjes weg en 
samenzijn volgen.  
Anita en Thijs, we hebben altijd een erg bijzondere band gehad: van hele weekenden kermis 
vieren in Grashoek, tot vakanties in Amerika en zelfs 2 maanden inwonen (waar ik twee super 
lieve nieuwe broertjes had!): niks was te gek voor jullie. Dankjewel hiervoor! Truus & Suus, 
ook met jullie heb ik altijd een bijzondere band gehad, deze is door het overlijden van Frank 
nog sterker geworden, ik heb diep respect voor jullie: wederom een dikke knuffel voor jullie! 
Mieke, naast onze gezellige shopdagen met alle Heggertjes, hebben we ook de nodige 
carpooluurtjes doorgebracht. Dankjewel voor de gezellige tijd samen! 
 
Lieve oma, wat hebben wij een bijzondere band opgebouwd. Vanaf kinds af aan liep ik 
dagelijks bij je binnen. Na het samenwonen is dat wat minder frequent geworden, maar 
gelukkig zien we elkaar nog zeker wekelijks. Je hebt het niet altijd even gemakkelijk gehad, 
maar het is prachtig om te zien hoe jij van alles in het leven kunt genieten. Vooral ook van je 
achterkleinkinderen en ik weet zeker dat Saar hier ook enorm van geniet. Ik ben blij dat je me 
alles durft te vertellen en ik je meestal van advies kan voorzien. Dankjewel dat je zo’n heerlijke 
lieve oma bent!  
 
Lieve Ria en Joep, Maud, Pieter, Emma en Ties, met jullie heb ik ook al zo’n geluk gehad. 
Bedankt dat ik in jullie hechte familie word opgenomen. Dank daarnaast voor alle support, 








Lieve Eric, lief broertje, wat ben ik trots op jou. Je hebt het allemaal puik voor elkaar gekregen 
de afgelopen jaren: fijne vrienden, eigen huisje, fijne job, maar bovenal ben je een fijn 
persoon! Ik vind het gezellig dat je geregeld mee komt eten, met Saar komt spelen en mee op 
vakantie gaat. Daarnaast vind ik het natuurlijk fantastisch dat jij samen met Jeroen Kameraod 
Brouwers op hebt gezet.  
 
Lieve Mark, Krissie en Noud, dank dat we zo’n fijne band hebben en elkaar weten te vinden 
als het nodig is. Gelukkig heb je je nooit geïrriteerd dat je kleine zusje ook mee op stap ging. 
Ik geniet enorm van jouw droge humor, de etentjes samen bij pap en mam en de altijd zeer 
gezellige weekendjes weg. Daarnaast vind ik het prachtig om te zien hoe Saar en Noud samen 
opgroeien, dat zijn nu al dikke maatjes!  
 
Lieve pap en mam, bedankt voor de onvoorwaardelijke steun en het vertrouwen dat jullie me 
gegeven hebben. Ik ben blij dat jullie me altijd hebben gestimuleerd om te doen wat ik leuk 
vind. Dank daarnaast voor alle aanmoedigingen tijdens het sporten, de fijne wandelingen en 
onze onvergetelijke reizen. Jullie hebben een heerlijke veilige thuishaven gecreëerd en me 
altijd van goed advies voorzien. Ik houd zeer veel van jullie en ben enorm trots op jullie!  
 
Lieve lieve Jeroen, waar te  
beginnen. Bedankt dat je er elke  
keer opnieuw voor me bent! Dank  
ook voor je prachtige impulsieve  
ideeën, de overheerlijke gerechten  
die jij als geen ander kunt koken en 
voor onze wielrenritjes of 
wandelingen samen door het bos. 
Ik vind het heerlijk om zulke 
diepgaande gesprekken te kunnen 
voeren en jouw kijk op de wereld met jouw 
enthousiasme en passie te mogen delen. Ik kijk uit naar 
de toekomst waarin we samen kunnen genieten met 
Saar en ons tweede kindje straks. Ik houd van jou! 
Lieve kleine Saar, wat ben ik enorm trots op jou, ik houd 
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